Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 4437. Отображено 200.
23-03-2018 дата публикации

СПОСОБ ПОЛУЧЕНИЯ ИЗОБРАЖЕНИЯ КРОВОСНАБЖЕНИЯ МИОКАРДА

Номер: RU2648358C2

Изобретение относится к области медицины, а именно к контрастному агенту структурной формулы:где J представляет собой О; Y представляет собой углерод; K и L независимо выбраны из водорода и C-Салкила; М выбран из водорода, C-Салкилокси или C-Салкила, незамещенных или замещенныхF; Т и U вместе с атомами углерода, к которым они присоединены, образуют шестичленное ароматическое кольцо, которое незамещено или замещеноF; R, Rи Rнезависимо выбраны из водорода и фрагментаF; R, R, Rи Rявляются водородом; n=2; причем по меньшей мере одинF присутствует в структуре указанного контрастного агента и является фрагментом, обеспечивающим изображение. Изобретение также относится к применению указанного контрастного агента, композиции или диагностического набора на его основе для выявления, визуализации и/или мониторинга перфузии миокарда. Группа изобретений обеспечивает расширение арсенала диагностических маркеров для получения изображения кровоснабжения миокарда. 5 н. и 4 з.п. ф-лы, 55 пр.

Подробнее
26-12-2017 дата публикации

ПОЛУЧЕНИЕ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ МИКРОПУЗЫРЬКИ ГАЗА

Номер: RU2640078C2
Принадлежит: ДжиИ Хелткер АС (NO)

Изобретение относится к способу получения эхоконтрастных сред, в частности к композициям, содержащим микропузырьки газа, а более конкретно - к микропузырькам, инкапсулированным белком. Описан способ получения композиции, содержащей инкапсулированные микропузырьки газа, включающий последовательные стадии: i) обеспечения водного нагретого раствора денатурируемого под действием тепла белка при температуре, необходимой для достижения начальной денатурации, где указанная температура составляет в диапазоне от 50 до 100°С; ii) нагревания газа с использованием тепла от указанного нагретого раствора белка, при этом газ нагревают до температуры, которая не меньше, чем температура на 20°С ниже температуры указанного нагретого раствора белка; iii) смешивания нагретого газа со стадии (ii) и нагретого раствора белка со стадии (i) с получением нагретой смеси газ/жидкость; iv) диспергирования нагретого газа в растворе белка путем приложения механических усилий сдвига к нагретой смеси газ/жидкость со стадии ...

Подробнее
20-03-2008 дата публикации

КОНТРАСТНЫЕ АГЕНТЫ ДЛЯ ОТОБРАЖЕНИЯ ПЕРФУЗИИ МИОКАРДА

Номер: RU2006132814A
Принадлежит:

... 1. Способ получения изображения кровоснабжения миокарда, включающий введение пациенту контрастного агента, который содержит фрагмент, обеспечивающий изображение, и соединение, выбранное из дегелина, пиридабена, пиридимифена, тебуфенпирада, феназаквина, аналога дегелина, аналога пиридабена, аналога пиридимифена, аналога тебуфенпирада и аналога феназаквина, и сканирование пациента с применением диагностического изображения. 2. Способ по п.1, отличающийся тем, что фрагмент, обеспечивающий изображение, представляет собой радиоизотоп для ядерно-магнитной томографии, парамагнитные фрагменты для применения в MRI, эхогенную группу для ультразвукового исследования, флуоресцентную группу для применения при получении флуоресцентного изображения или светоактивную группу для применения при получении оптического изображения. 3. Контрастный агент, содержащий фрагмент, обеспечивающий изображение, и соединение, выбранное из дегелина, пиридабена, пиридимифена, тебуфенпирада, феназаквина, аналога дегелина ...

Подробнее
20-04-2016 дата публикации

СПОСОБ УЛУЧШЕНИЯ ФУНКЦИОНАЛЬНОЙ СИНАПТИЧЕСКОЙ СВЯЗИ

Номер: RU2014139834A
Принадлежит:

... 1. Применение композиции для производства продукта для улучшения или сохранения функциональной связи головного мозга, и/или функциональной синаптической активности, и/или сетевой организации головного мозга у нуждающегося в этом субъекта, и/или замедления возникновения, предотвращения или восстановления нарушенной функциональной связи головного мозга, и/или нарушенной функциональной синаптической активности, и/или нарушенной сетевой организации головного мозга у нуждающегося в этом субъекта, где указанная композиция содержит:i) одно или несколько из следующих веществ: уридин и цитидин или их соли, фосфаты, ацильные производные или сложные эфиры; иii) липидную фракцию, содержащую, по меньшей мере, одну из докозагексаеновой кислоты (22:6; ДГК), эйкозапентаеновой кислоты (20:5; ЭПК) и докозапентаеновой кислоты (22:5; ДПК), или их сложные эфиры.2. Применение композиции для производства продукта для лечения нуждающегося в этом субъекта, где указанная композиция содержит:i) одно или несколько ...

Подробнее
27-01-2009 дата публикации

ДИСПЕРСНЫЙ АКТИВАТОР ДЛЯ ВЫСОКОИНТЕНСИВНОЙ ФОКУСИРОВАННОЙ УЛЬТРАЗВУКОВОЙ ТЕРАПИИ И ЕГО ПРИМЕНЕНИЕ

Номер: RU2007127666A
Принадлежит:

... 1. Активатор для терапии высокоинтенсивным фокусированным ультразвуком (ВИФУЗ), где активатор включает дисперсную фазу, состоящую из вещества ядра, инкапсулированного мембранообразующим веществом, и дисперсионную среду, состоящую из водной среды; дисперсная фаза равномерно диспергирована в дисперсионной среде, и размер частиц дисперсной фазы находится в интервале 0,1-8 мкм; количество мембранообразующего вещества в активаторе составляет 0,1-100 г/л; вещество ядра состоит из жидкости, не претерпевающей перехода жидкость-газ в интервале 38-100°C, и количество вещества ядра в активаторе составляет 5-200 г/л. 2. Активатор по п.1, где дисперсная фаза содержит частицы размера от 0,5-5 мкм. 3. Активатор по п.2, где дисперсная фаза содержит частицы размера от 2,5-5 мкм. 4. Активатор по п.1, где мембранообразующее вещество является одним или более веществом, выбранным из группы, состоящей из фосфолипина, холестерина и гликолипида. 5. Активатор по п.4, где мембранообразующее вещество включает фосфолипин ...

Подробнее
20-08-2016 дата публикации

ПОЛУЧЕНИЕ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ МИКРОПУЗЫРЬКИ ГАЗА

Номер: RU2014150473A
Принадлежит:

... 1. Способ получения композиции, содержащей инкапсулированные микропузырьки газа, включающий последовательные стадии:i) обеспечения водного нагретого раствора денатурируемого под действием тепла белка при температуре, необходимой для достижения начальной денатурации, где указанная температура составляет в диапазоне от 50 до 100°C;ii) нагревания газа с использованием тепла от указанного нагретого раствора белка, при этом газ нагревают до температуры, которая не менее чем на 20°C ниже температуры указанного нагретого раствора белка;iii) смешивания нагретого газа со стадии (ii) и нагретого раствора белка со стадии (i) с получением нагретой смеси газ/жидкость;iv) диспергирования нагретого газа в растворе белка, путем приложения механических усилий сдвига к нагретой смеси газ/жидкость со стадии (iii) с получением композиции микропузырьков газа, инкапсулированных денатурированным белком.2. Способ по п. 1, в котором смешивание на стадии (iii) осуществляют или на входе в смешивающее устройство, ...

Подробнее
13-08-2014 дата публикации

Lipid sterilisation method

Номер: GB0201411423D0
Автор:
Принадлежит:

Подробнее
13-11-2000 дата публикации

"Gas-containing contrast agents of use in diagnostic imaging.

Номер: AP0000000890A
Принадлежит:

Microbubble dispersions stabilised by phospholipids predominantly comprising molecules which individually have an overall net charge exhibit advantageous stability, rendering them useful as efficacious contrast agents. An improved process for preparing microbubble-containing contrast agents is also disclosed, this comprising lyophilising an aqueous dispersion of gas microbubbles stabilised by one or more membrane-forming lipids to yield a dried product which may be reconstituted in an injectable carrier liquid to generate a microbubble-containing contrast agent.

Подробнее
30-09-1998 дата публикации

Impr vemen s in r rel ting o contrast agents

Номер: AP0009801319A0
Автор:
Принадлежит:

Подробнее
13-08-2001 дата публикации

Improvements in or relating to contrast agents

Номер: OA0000010839A
Принадлежит:

Подробнее
30-09-1998 дата публикации

Impr vemen s in r rel ting o contrast agents

Номер: AP0009801319D0
Автор:
Принадлежит:

Подробнее
27-06-2019 дата публикации

Preparation of composition comprising gas microbubbles

Номер: AU2017216553B2
Принадлежит: Davies Collison Cave Pty Ltd

... ll:\sxd\Interwoven\NRPortbl\DCC\SXD520799 l.docx-l8082017 The present invention relates to a process for preparation of ultrasound contrast media, particularly to compositions comprising gas microbubbles and more particularly to 5 microbubbles encapsulated by proteins. The microbubbles produced by the process of the invention will have a narrow size distribution. The invention further relates to apparatus useful in the process of the invention.

Подробнее
20-07-2000 дата публикации

Novel compositions of lipids and stabilizing materials

Номер: AU0000721923B2
Принадлежит:

Подробнее
02-09-1997 дата публикации

Improvements in or relating to contrast agents

Номер: AU0001884797A
Принадлежит:

Подробнее
02-10-1984 дата публикации

IMIDYL COMPOUNDS, POLYMERS THEREFROM, AND USE OF THE POLYMERS

Номер: CA1175439A
Принадлежит: CIBA GEIGY AG, CIBA-GEIGY AG

N-(Hydroxypolyoxaalkylene)-imidyl compounds, methacrylic acid esters thereof, of the formula (I) wherein R1 and R2 independently of one another are C1-C4-alkyl, or R1 and R2 together are tri- or tetramethylene which is unsubstituted or substituted by C1-C4-alkyl, R3 is a hydrogen atom or C1-C4-alkyl, n is a number from 2 to 30, and X is a hydrogen atom or CO-CR4=CH2, in which R4 is a hydrogen atom or methyl are described, together with processes for their preparation. The homopolymers and copolymers of these compounds are photosensitive, and are suitable as photographic recording materials. They are also useful as adhesives and surface coating materials. This combination of properties is of advantage in preparing printed circuit boards.

Подробнее
15-11-2012 дата публикации

ECHOGENICALLY ENHANCED DEVICE

Номер: CA0002836401A1
Принадлежит:

Devices with enhanced visualization in ultrasound imaging are provided.

Подробнее
01-09-2005 дата публикации

CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING

Номер: CA0002828128A1
Принадлежит:

... ²²The present disclosure is directed, in part, to compounds and methods for ²imaging mycardial ²perfusion, comprising administering to a patient a contrast agent such as of ²Formula III²(see above formula) ²which comprises a compound that binds MC-1 and an imaging moiety, and scanning ²the patient ²using diagnostic imaging, such as MRI, ultrasound imaging, fluorescence ²imaging and optical ²imaging.² ...

Подробнее
22-12-1994 дата публикации

METHODS OF PREPARING GAS-FILLED LIPOSOMES

Номер: CA0002164844A1
Принадлежит:

Methods of and apparatus for preparing gas-filled liposomes are described. Gas-filled liposomes prepared by these methods are particularly use ful, for example, in ultrasonic imaging application and in therapeutic drug delivery systems.

Подробнее
19-09-1996 дата публикации

A METHOD OF MAGNETIC RESONANCE FOCUSED SURGICAL AND THERAPEUTIC ULTRASOUND

Номер: CA0002214855A1
Принадлежит:

A novel method of magnetic resonance focused surgical ultrasound by administering to a patient a magnetic resonance imaging (MRI) contrast medium comprising gas filled vesicles, then scanning the patient with MRI techniques, and then applying ultrasound to effect surgery. These methods may also use an MRI contrast medium comprising gaseous precursor filled vesicles which undergo a phase transition from a liquid to gas in vivo after administration. Additionally, the MRI contrast medium may comprise a therapeutic compound.

Подробнее
21-03-1996 дата публикации

CONTAINER WITH MULTI-PHASE COMPOSITION FOR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS

Номер: CA0002200061A1
Принадлежит:

A container comprising an aqueous lipid suspension and a gaseous phase substantially separate from the aqueous stabilizing phase, useful in diagnostic imaging such as ultrasound and magnetic resonance imaging and in therapeutic applications, is disclosed.

Подробнее
25-02-1999 дата публикации

USTOVERShENSTVOVANIYa IN AREA OF CONTRASTING AGENTS

Номер: EA0199800745A1
Автор:
Принадлежит:

Подробнее
28-06-2019 дата публикации

METHODS AND DEVICES FOR PRODUCTION OF CONTRAST AGENTS FOR ULTRASONIC EXAMINATION

Номер: EA0201892520A1
Автор:
Принадлежит:

Подробнее
26-04-2019 дата публикации

Multimodal contrast agent and use thereof

Номер: CN0109675034A
Автор: RAN HAITAO, ZHANG WEI, CAO YANG
Принадлежит:

Подробнее
14-12-2011 дата публикации

Номер: CN0102274527A
Автор:
Принадлежит:

Подробнее
12-01-2012 дата публикации

OPACITY TECHNOLOGY

Номер: WO2012006231A2
Автор: MANGIARDI, Eric, K.
Принадлежит:

A catheter device comprising a chamber containing an opacity enhancing substance is disclosed. The opacity enhancing substance is in a dried or semi-dried form within the chamber of the device. Release of a liquid into the chamber suspends the substance and forms an opacity enhancing solution that is released into the lumen of the device in order to enhance the opacity of the device for imaging.

Подробнее
07-11-2000 дата публикации

Microporation of human skin for drug delivery and monitoring applications

Номер: US0006142939A
Автор:
Принадлежит:

A method of enhancing the permeability of the skin to an analyte for diagnostic purposes or to a drug for therapeutic purposes is described utilizing microporation and optionally sonic energy and a chemical enhancer. If selected, the sonic energy may be modulated by means of frequency modulation, amplitude modulation, phase modulation, and/or combinations thereof. Microporation is accomplished by (a) ablating the stratum corneum by localized rapid heating of water such that such water is vaporized, thus eroding the cells; (b) puncturing the stratum corneum with a micro-lancet calibrated to form a micropore of up to about 1000 mu m in diameter; (c) ablating the stratum corneum by focusing a tightly focused beam of sonic energy onto the stratum corneum; (d) hydraulically puncturing the stratum corneum with a high pressure jet of fluid to form a micropore of up to about 1000 mu m in diameter, or (e) puncturing the stratum corneum with short pulses of electricity to form a micropore of up to ...

Подробнее
12-11-2002 дата публикации

Method of preparing gas and gaseous precursor-filled microspheres

Номер: US0006479034B1

Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursor-filled liposomes prepared by these methods are particularly useful, for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.

Подробнее
07-10-2021 дата публикации

BIOCOMPATIBLE ULTRASONIC COUPLING AGENT FOR ENDOSCOPE AND USE THEREOF

Номер: US20210307724A1
Принадлежит:

Disclosed herein is a biocompatible ultrasonic coupling agent for endoscopes, comprising a biocompatible modified starch and a pharmaceutically acceptable carrier, or comprising an ingredient selected from the group consisting of cellulose, polyvinylpyrrolidone, polyoxyethylene, sodium alginate, glucan, hyaluronic acid, chitosan, light sensitive glue, ultrasonic sensitive glue, pH sensitive glue, gelatin and carbomer, and a pharmaceutically acceptable carrier; wherein the ultrasonic coupling agent produces an acoustic characteristic impedance matching the acoustic characteristic impedance of the human tissues during use for endoscopic ultrasound examination. Disclosed herein is also a kit for endoscopic ultrasound examination, comprising the said biocompatible ultrasonic coupling agent.

Подробнее
10-02-1997 дата публикации

Номер: JP0009501410A
Автор:
Принадлежит:

Подробнее
25-09-2018 дата публикации

СПОСОБ УЛУЧШЕНИЯ ФУНКЦИОНАЛЬНОЙ СИНАПТИЧЕСКОЙ СВЯЗИ

Номер: RU2667968C2
Принадлежит: Н.В. НЮТРИСИА (NL)

Группа изобретений относится к медицине. Описана композиция, включающая (i) одно или несколько из следующих веществ: уридин и цитидин или их соли, фосфаты, ацильные производные или сложные эфиры; и (ii) липидную фракцию, содержащую по меньшей мере одну из докозагексаеновой кислоты (22:6; ДГК), эйкозапентаеновой кислоты (20:5; ЭПК) и докозапентаеновой кислоты (22:5; ДПК) или их сложные эфиры, iii) холин или его соли или сложные эфиры, iv) меньшей мере два витамина В, для применения для сохранения или улучшения функциональной синаптической связи и/или сохранения сетевой организации головного мозга у нуждающегося в этом субъекта. Композиции применяются для улучшения или сохранения функциональной связи головного мозга и/или сетевой организации головного мозга у субъекта. 4 н. и 5 з.п. ф-лы, 4 ил., 2 табл., 2 пр.

Подробнее
30-08-2021 дата публикации

Гель для проведения ультразвуковых исследований

Номер: RU2754181C1

Изобретение относится к гелю для проведения ультразвуковых исследований. Гель содержит основу, глицерин и воду очищенную. В качестве основы используют карбоксиметилцеллюлозу, диэтиленгликоль и гидроксид натрия. Дополнительно гель содержит ароматизатор, консерванты и 75% спирт медицинский. Содержание компонентов готового геля составляет: карбоксиметилцеллюлоза 15,9-17,5 г; диэтиленгликоль 4,5-5,5 мл; гидроксид натрия 10-11 г; глицерин 5,8-6,5 мл; вода дистиллированная 50 мл; ароматизатор 4-4,5 мл; консерванты 5,4-6 мл; 75% спирт медицинский 0,28-0,59 мл. Технический результат - получение состава с высокими эксплуатационными характеристиками, расширение области применения и возможность многоразового использования. 4 з.п. ф-лы, 5 ил., 1 табл., 3 пр.

Подробнее
14-10-2019 дата публикации

Способ дифференциальной диагностики рецидивных плоскоклеточных опухолей полости рта с фиброзом и гиперкератозом

Номер: RU2702974C1

Изобретение относится к области медицины, а именно к онкологии. Способ дифференциальной диагностики рецидива плоскоклеточного рака полости рта и гиперкератозом или фиброзных изменений заключается в проведении ультразвукового исследования полости рта. Отличие предложенного способа в том, что ультразвуковое исследование проводят в В-режиме, дополнительно проводят режим контрастирования, используя 2,4 мл эхоконтрастного препарата (ЭКП). В течение 3 минут с момента болюсного внутривенного введения проводят мониторинг и записи фаз накопления и вымывания ЭКП из исследуемого образования. После окончания исследования посредством программного обеспечения выстраивают график изменения концентрации ЭКП в образовании относительно окружающих тканей с течением времени и анализируют время накопления ЭКП - wash-in. При одновременном мониторировании в двух режимах при контрастировании образования в обе фазы, времени накопления ЭКП 14-25с диагностируют рецидив плоскоклеточного рака полости рта. При отсутствии ...

Подробнее
15-08-2009 дата публикации

COMPOSITION AND PROCEDURE FOR THE MEDICAL IMAGE REPRESENTATION OF BODY CAVITIES

Номер: AT0000438412T
Принадлежит:

Подробнее
04-08-2011 дата публикации

Contrast agents for myocardial perfusion imaging

Номер: AU2005214898C1
Принадлежит:

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Подробнее
19-06-1995 дата публикации

Gas microspheres for topical and subcutaneous application

Номер: AU0002185095A
Принадлежит:

Подробнее
25-09-1995 дата публикации

Gas filled microspheres as magnetic resonance imaging contrast agents

Номер: AU0002157395A
Принадлежит:

Подробнее
30-04-2015 дата публикации

Device with echogenic coating

Номер: AU2012253737B2
Принадлежит:

Devices with enhanced visualization in ultrasound imaging are provided.

Подробнее
28-11-2013 дата публикации

Echogenically enhanced device

Номер: AU2012253742A1
Принадлежит:

Devices with enhanced visualization in ultrasound imaging are provided.

Подробнее
30-05-1995 дата публикации

FLUOROCARBON EMULSIONS HAVING SATURATED PHOSPHOLIPID EMULSIFIERS

Номер: CA0001335714C

A fluorocarbon emulsion having particle size stability comprising a continuous aqueous phase, a fluorocarbon in an amount from 25% to 125% weight per volume, and an effective amount of an emulsifying agent comprising a phospholipid with substantially saturated carbon bonds and having a particle size that is stable through heat sterilization, which can be used for delivering oxygen to body tissues or for imaging the human body.

Подробнее
05-01-2021 дата публикации

ULTRASOUND CONTACT FLUID

Номер: CA2872142C
Принадлежит: SINVENT AS

The present invention concerns an aqueous ultrasound contact fluid comprising a pharmaceutical grade triglyceride and a pharmaceutically acceptable emulsifier and the use of said ultrasound contact fluid in an intraoperative or interventional ultrasound imaging procedure.

Подробнее
03-01-2014 дата публикации

PREPARATION OF COMPOSITION COMPRISING GAS MICROBUBBLES

Номер: CA0002876950A1
Принадлежит:

The present invention relates to a process for preparation of ultrasound contrast media, particularly to compositions comprising gas microbubbles and more particularly to microbubbles encapsulated by proteins. The microbubbles produced by the process of the invention will have a narrow size distribution. The invention further relates to apparatus useful in the process of the invention.

Подробнее
22-11-2016 дата публикации

CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING

Номер: CA0002828128C

The invention is generally directed to contrast agents and their use for imaging myocardial perfusion. In some embodiments, the contrast agent comprises fenazaquin of a fenazaquin analog and an imaging moiety attached thereof. In some embodiments, the imaging agent comprises a formula such as: (see formula II), (see formula V), (see formula IV), or (see formula I).

Подробнее
08-06-1995 дата публикации

GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION

Номер: CA0002177713A1
Принадлежит:

Gas and gaseous precursor filled microspheres (1), and foams thereof, provide novel topical and subcutaneous delivery vehicles for various active ingredients, including drugs and cosmetics (2).

Подробнее
09-12-2008 дата публикации

MICROPARTICLES, MEDIA CONTAINING THE LATTER FOR ULTRASONIC DIAGNOSIS AS WELL AS PROCESS FOR THE PRODUCTION OF THE PARTICLES AND MEDIA

Номер: CA0002214737C

The invention relates to gaseous microparticles for ultrasonic diagnosis, whose wall material is built up from block copolymers of polyesters of .alpha.-, .beta.- or .gamma.-hydroxycarboxylic acids with linear or star-shaped polyethylene glycols and optionally liquid crystals or whose wall material is built up from polyesters of .alpha.-, .beta.- or .gamma.-hydroxycarboxylic acids and liqui d crystals, media that contain these particles for ultrasonic diagnosis, as well as a process for the production of the media and particles.

Подробнее
21-08-1997 дата публикации

IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS

Номер: CA0002246779A1
Принадлежит:

Microbubble dispersions stabilised by phospholipids predominantly comprising molecules which individually have an overall net charge exhibit advantageous stability, rendering them useful as efficacious contrast agents. An improved process for preparing microbubble-containing contrast agents is also disclosed, this comprising lyophilising an aqueous dispersion of gas microbubbles stabilised by one or more membrane-forming lipids to yield a dried product which may be reconstituted in an injectable carrier liquid to generate a microbubble-containing contrast agent.

Подробнее
19-09-1996 дата публикации

MICROPARTICLES, MEDIA CONTAINING THE LATTER FOR ULTRASONIC DIAGNOSIS AS WELL AS PROCESS FOR THE PRODUCTION OF THE PARTICLES AND MEDIA

Номер: CA0002214737A1
Принадлежит: BERESKIN & PARR

The invention concerns gas-containing microparticles for use in ultrasound diagnostics. The wall material of the microparticles is made either from block copolymers of .alpha.-, .beta.-, or .gamma.-hydroxycarboxylic acid polyesters with linear or stellate polyethylene glycols and, optionally, liquid crystals, or from .alpha.-, .beta.-, or .gamma.-hydroxycarboxylic acid polyesters with liquid crystals. The invention also concerns agents containing these particles for use in ultrasound diagnostics and processes for producing the said agents and particles.

Подробнее
27-06-2017 дата публикации

PREPARATION OF COMPOSITION COMPRISING GAS MICROBUBBLES

Номер: BR112014032254A2
Принадлежит:

Подробнее
22-12-1994 дата публикации

NOVEL THERAPEUTIC DELIVERY SYSTEMS

Номер: WO1994028874A1
Принадлежит:

Therapeutic delivery systems comprising gaseous precursor-filled microspheres comprising a therapeutic are described. Methods for employing such microspheres in therapeutic delivery applications are also provided. Therapeutic delivery systems comprising gaseous precursor-filled liposomes having encapsulated therein a contrast agent or drug are preferred. Methods of and apparatus for preparing such liposomes and methods for employing such liposomes in therapeutic delivery applications are also disclosed.

Подробнее
05-12-1996 дата публикации

ULTRASOUND CONTRAST AGENTS, CONTAINING PERFLUOROCARBON IN DEXTROSE-ALBUMIN MICROBUBBLES

Номер: WO1996038180A1
Автор: PORTER, Thomas, R.
Принадлежит:

A method for myocardial, renal or hepatic opacification comprising the steps of: (a) obtaining an echo contrast agent which comprises: (i) an aqueous albumin-dextrose solution containing between about a two-fold and about an eight-fold dilution of between about 5 % to about 50 % by weight dextose and between about 2 % to about 10 % by weight human serum albumin, and (ii) microbubbles, the gaseous content of which contains an amount of perfluorocarbon gas which is effective for visually detecting myocardial perfusion by echocardiogram following peripheral intravenous injection of said agent into a host; (b) introducing said echo contrast agent into a host by intravenous injection; and (c) performing an echo contrast study on said host using a suitable Doppler or ultrasound echo apparatus.

Подробнее
07-11-2000 дата публикации

Microporation of human skin for drug delivery and monitoring applications

Номер: US0006142939A1
Принадлежит: SpectRx, Inc., Altea Technologies, Inc.

A method of enhancing the permeability of the skin to an analyte for diagnostic purposes or to a drug for therapeutic purposes is described utilizing microporation and optionally sonic energy and a chemical enhancer. If selected, the sonic energy may be modulated by means of frequency modulation, amplitude modulation, phase modulation, and/or combinations thereof. Microporation is accomplished by (a) ablating the stratum corneum by localized rapid heating of water such that such water is vaporized, thus eroding the cells; (b) puncturing the stratum corneum with a micro-lancet calibrated to form a micropore of up to about 1000 μm in diameter; (c) ablating the stratum corneum by focusing a tightly focused beam of sonic energy onto the stratum corneum; (d) hydraulically puncturing the stratum corneum with a high pressure jet of fluid to form a micropore of up to about 1000 μm in diameter, or (e) puncturing the stratum corneum with short pulses of electricity to form a micropore of up to about ...

Подробнее
16-12-2004 дата публикации

Targeted polymerized liposome diagnostic and treatment agents

Номер: US20040253184A1
Принадлежит: Targesome, Inc.

Polymerized liposome particles which are linked to a targeting agent and may also be linked to a contrast enhancement agent and/or linked to or encapsulating a treatment agent. The targeting imaging enhancement polymerized liposome particles interact with biological targets holding the image enhancement agent to specific sites providing in vitro and in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. Targeting polymerized liposomes may be linked to or encapsulate a treatment agent, such as, proteins, drugs or hormones for directed delivery to specific biological sites for treatment.

Подробнее
16-12-1986 дата публикации

Imidylcompounds, polymers therefrom, and use of the polymers

Номер: US4629773A
Автор:
Принадлежит:

There are obtained from N-(hydroxypolyoxaalkylene)imidyl compounds and (meth)acrylic acid esters thereof homopolymers or copolymers with olefinically unsaturated comonomers. These polymers are photosensitive and are suitable as photographic recording material, as adhesives and as agents for surface coating.

Подробнее
06-09-2022 дата публикации

Cancer treatment methods using thermotherapy and/or enhanced immunotherapy

Номер: US0011433260B2
Автор: Gholam A. Peyman
Принадлежит: Gholam A. Peyman

Cancer treatment methods using thermotherapy and/or enhanced immunotherapy are disclosed herein. In one embodiment, the method comprising the steps of administering a plurality of nanoparticles to target a tumor in a patient, the nanoparticles being coated with an antitumor antibody, cell penetrating peptides (CPPs), and a polymer, and the nanoparticles containing medication and/or gene, and a dye or indicator in the polymer coating, at least some of the nanoparticles attaching to surface antigens of tumor cells so as to form a tumor cell/nanoparticle complex; exciting the nanoparticles using an ultrasound source generating an ultrasonic wave so as to peel off the polymer coating of the nanoparticles, thereby releasing the dye or indicator into the circulation of the patient and the medication and/or gene at the tumor site; and imaging a body region of the patient so as to detect the dye or indicator released into the circulation of the patient.

Подробнее
10-05-2002 дата публикации

НОВЫЕ КОМПОЗИЦИИ ЛИПИДОВ И СТАБИЛИЗИРУЮЩИХ МАТЕРИАЛОВ

Номер: RU2181998C2

Изобретение относится к диагностике. Описаны композиции, содержащие распределенные в водном носителе липид и вещество, способное стабилизировать композицию. Стабилизирующее вещество нековалентно связывается с липидом и присутствует в количестве, достаточном для покрытия липида, но недостаточном для увеличения вязкости композиции. Композиции особенно пригодны для использования при диагностике, включая ультразвуковую. Композиции могут представлять собой везикулярные композиции, такие как композиции, содержащие мицеллы и липосомы. Композиции проявляют повышенную стабильность. При их использовании уменьшается вероятность закупорки сосудов. 6 с. и 11 з.п.ф-лы, 3 табл.

Подробнее
10-05-2010 дата публикации

ФТОРУГЛЕРОДНЫЙ ЭМУЛЬСИОННЫЙ АКТИВАТОР ДЛЯ ВЫСОКОИНТЕНСИВНОЙ ФОКУСИРОВАННОЙ УЛЬТРАЗВУКОВОЙ ТЕРАПИИ И ЕГО ПРИМЕНЕНИЕ

Номер: RU2388492C2

Настоящее изобретение относится к области медицины и медицинской терапии, к области ультразвуковой терапии. Описан фторуглеродный эмульсионный активатор для терапии высокоинтенсивным фокусированным ультразвуком (ВИФУЗ терапия), который может повышать депонирование акустической энергии в расположении мишени в ходе ВИФУЗ терапии. Активатор включает дисперсную фазу, состоящую из вещества ядра, инкапсулированного мембранообразующим веществом, и дисперсионную фазу, состоящую из водной среды. Дисперсная фаза равномерно диспергирована в дисперсионной фазе, и размер частиц дисперсной фазы находится в интервале 0,1-1 мкм; количество мембранообразующего вещества в активаторе составляет 0,1-100 г/л; вещество ядра состоит из жидкости, претерпевающей переход жидкость-газ в интервале 38-100°С, и количество вещества ядра в активаторе составляет 5-200 мл/л. В результате существенно улучшаются возможности клинической ВИФУЗ терапии по удалению опухолевых клеток без поражения нормальных тканей на пути акустического ...

Подробнее
10-02-2009 дата публикации

УЛЬТРАЗВУКОВЫЕ КОНТРАСТНЫЕ ВЕЩЕСТВА И СПОСОБ ИХ ПОЛУЧЕНИЯ

Номер: RU2345793C2

Изобретение относится к способу получения лиофилизованной матрицы и, после ее восстановления, соответствующего пригодного для инъекций контрастного вещества, содержащего жидкую водную суспензию наполненных газом микропузырьков, стабилизированную преимущественно фосфолипидом. Способ включает приготовление эмульсии из водной среды, фосфолипида и не смешиваемого с водой органического растворителя. Затем эмульсию высушивают сублимацией, после чего восстанавливают в водную суспензию наполненных газом микропузырьков. Способ позволяет получить суспензии, содержащие микропузырьки с относительно малым диаметром и узким распределением по размерам. 5 н. и 31 з.п. ф-лы, 12 табл.

Подробнее
10-07-2015 дата публикации

УСТРОЙСТВО С ПОВЫШЕННОЙ ЭХОГЕННОСТЬЮ

Номер: RU2556569C1

Изобретение относится к медицинской технике, а именно к средствам с повышенной эхогенностью для получения ультразвуковых изображений. Интервенционное устройство содержит интервенционное устройство, для которого должно быть получено ультразвуковое изображение, имеющее внешнюю поверхность, содержащую одну или более топографических неровностей в других случаях гладкой внешней поверхности интервенционного устройства и полимерную пленку, которая находится в тесном контакте с внешней поверхностью и закрывает по меньшей мере участок одной или более топографических неровностей, при этом натяжение полимерной пленки и резонансная характеристика полимерной пленки являются регулируемыми. В способе повышения эхогенности формируют одну или более топографических неровностей в других случаях гладкой внешней поверхности интервенционного устройства и размещают полимерную пленку в тесном контакте с внешней поверхностью, причем натяжение полимерной пленки является регулируемым. Регулируют эхогенный отклик ...

Подробнее
20-10-2013 дата публикации

СПОСОБ ПОЛУЧЕНИЯ ИЗОБРАЖЕНИЯ КРОВОСНАБЖЕНИЯ МИОКАРДА

Номер: RU2012113613A
Принадлежит:

... 1. Контрастный агент, содержащий фрагмент, обеспечивающий изображение, и соединение, выбранное из дегелина, пиридабена, пиримидифена, тебуфенпирада, феназаквина, аналога дегелина, аналога пиридабена, аналога пиримидифена, аналога тебуфенпирада и аналога феназаквина.2. Контрастный агент по п.1, имеющий формулу (I),,гдекаждый А независимо выбран из О, CHR, S, и NR;В выбран из водорода и C-Салкила;С выбран из водорода, C-Салкила, и связи с В;D выбран из водорода и С-Салкила;Е выбран из водорода и C-Салкила; илиЕ и D, вместе с атомом углерода, к которому они присоединены, образуют двойную связь; илиЕ и D, вместе с атомом углерода, к которому они присоединены, образуют циклопропильное кольцо;обозначает простую или двойную связь;R, R, R, R, R, R, Rи Rкаждый независимо выбран из водорода и C-Салкила;Rи Rкаждый независимо выбран из водорода, C-Салкила, галоида, и гидроксильной группы;Rи R, если они содержатся, независимо выбраны из водорода, C-Салкила, галоида, и гидроксильной группы; илиRи Rвместе ...

Подробнее
18-12-1996 дата публикации

Ultrasound contrast agents, containing perfluorocarbon in de xtrose-albumin microbubbles

Номер: AU0005665496A
Автор: PORTER THOMAS R
Принадлежит:

Подробнее
11-02-2016 дата публикации

Modified variable domain molecules and methods for producing and using them b

Номер: AU2012245073B2
Принадлежит:

The present disclosure provides an isolated protein comprising an antibody light chain variable domain (V ...

Подробнее
14-06-2018 дата публикации

Ultrasound contact fluid

Номер: AU2013258028B2
Принадлежит: Phillips Ormonde Fitzpatrick

The present invention concerns an aqueous ultrasound contact fluid comprising a pharmaceutical grade triglyceride and a pharmaceutically acceptable emulsifier and the use of said ultrasound contact fluid in an intraoperative or interventional ultrasound imaging procedure.

Подробнее
04-03-1999 дата публикации

Gas microspheres for topical and subcutaneous application

Номер: AU0001004399A
Принадлежит:

Подробнее
01-09-2005 дата публикации

CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING

Номер: CA0002944947A1
Принадлежит:

... ²The present disclosure is directed, in part, to compounds and methods for ²imaging ²mycardial perfusion, comprising administering to a patient a contrast agent ²such as of ²Formula III (see formula III) which comprises a compound that binds MC-1 and ²an ²imaging moiety, and scanning the patient using diagnostic imaging, such as ²MRI, ²ultrasound imaging, fluorescence imaging and optical imaging.² ...

Подробнее
22-12-1994 дата публикации

METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES

Номер: CA0002164845A1
Принадлежит: SMART & BIGGAR

Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursorfilled liposomes prepared by these methods are particularly useful, for example, in ultrasonic imaging application and in therapeutic drug delivery systems.

Подробнее
05-12-2006 дата публикации

APPARATUS AND METHOD FOR MAKING GAS-FILLED VESICLES OF OPTIMAL SIZE

Номер: CA0002218860C

A method and apparatus for making vesicles suitable for use as contrast agents in which a container containing an aqueous suspension phase and a separate gas phase is shaken using reciprocating motion. The reciprocating motion is produced by a shaker arm that moves the container in two, substantially perpendicular directions, with the motion in the first direction being along an arcuate path. The overall path of the motion occurs in a figure-8 pattern. The frequency of shaking is at least approximately 2800 RPM, the length of the shaker arm is at least approximately 6 cm, and the angle through which the shaker arm rotates in the first direction is at least approximately 3.degree.. The total length of travel around the figure- 8 pattern is at least 0.7 cm.

Подробнее
29-04-2008 дата публикации

IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS

Номер: CA0002246779C

Microbubble dispersions stabilised by phospholipids predominantly comprising molecules which individually have an overall net charge exhibit advantageous stability, rendering them useful as efficacious contrast agents. An improved process for preparing microbubble--containing contrast agents is also disclosed, this comprising lyophilising an aqueous dispersion of gas microbubbles stabilised by one or more membrane-forming lipids to yield a dried product which may be reconstituted in an injectable carrier liquid to generate a microbubble--containing contrast agent.

Подробнее
06-11-2018 дата публикации

Stomach color doppler ultrasonography auxiliary developing agent

Номер: CN0108743979A
Принадлежит:

Подробнее
02-07-2019 дата публикации

would rather compound and use thereof

Номер: CN0109963839A
Автор:
Принадлежит:

Подробнее
29-04-2016 дата публикации

항균성 의료용 초음파 커플링제 및 이의 제조방법

Номер: KR1020160046907A
Принадлежит:

... 항균성 의료용 초음파 커플링제 및 이의 제조방법에 관한 것으로, 상기 커플링제를 이루는 원료의 중량 백분율에 있어서, 폴리에틸렌이민 사차 암모늄염은 1~2%이고, 폴리에틸렌 글리콜은 1~2%이며, 메틸렌 블루는 0.05~0.1%이고, 나머지는 증류수이다. 상기 항균성 의료용 초음파 커플링제의 제조방법은 비율에 따라 각종 원료와 물을 혼합시킨 다음, 원료가 용해되고 팽윤되도록 가열하면서 교반하고, 마지막으로 진공에서 감압을 진행하여 기포를 제거하면 담청색 겔상의 제품을 얻는다.

Подробнее
09-03-2018 дата публикации

집속초음파용 초음파 팬텀, 그 초음파 팬텀의 제조방법, 생체조직 모방 하이드로겔 팬텀, 그 제조방법 및 그 팬텀을 이용한 변색방법 및 약물전달방법

Номер: KR0101836634B1
Автор: 김세화, 김용태, 마동희
Принадлежит: 한국표준과학연구원

... 본 발명은 집속초음파용 초음파 팬텀에 대한 것이다. 보다 상세하게는, 생체 내에서의 음속과 대응되도록 생체 내를 모사한 초음파 팬텀에 있어서, 아가로오스와, 수크로오스와, 폴리디아세틸렌 소포체과, 증류수가 혼합되며, 집속초음파 변환기에 의해 초음파가 조사되어 가열된 특정부분이, 온도에 따라 점진적으로 변색되는 것을 특징으로 하는 집속초음파용 초음파 팬텀에 관한 것이다.

Подробнее
24-07-2014 дата публикации

APPLICATION OF SILVER AND PLATINUM NANO-CLUSTER IN TUMOR TARGETED IMAGING

Номер: WO2014110863A1
Принадлежит:

An application of a silver and platinum nano-cluster in tumor targeted imaging comprises the steps of: establishing a nude mouse tumor model; locally injecting an ultrasonically dispersed silver or platinum nano-cluster into a nude mouse, or directly injecting a silver or platinum containing solution of 0.1 to 100 μmol/L into a nude mouse; and in 24 hours after injection, performing medical imaging on the tumor part of the nude mouse by using a medical imaging method, and performing qualitative and quantitative analysis on the imaging result.

Подробнее
17-10-2000 дата публикации

Targeted polymerized liposome diagnostic and treatment agents

Номер: US0006132764A1
Принадлежит: Targesome, Inc.

Polymerized liposome particles which are linked to a targeting agent and may also be linked to a contrast enhancement agent and/or linked to or encapsulating a treatment agent. The targeting imaging enhancement polymerized liposome particles interact with biological targets holding the image enhancement agent to specific sites providing in vitro and in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. Targeting polymerized liposomes may be linked to or encapsulate a treatment agent, such as, proteins, drugs or hormones for directed delivery to specific biological sites for treatment.

Подробнее
23-06-1998 дата публикации

Therapeutic drug delivery systems

Номер: US0005770222A
Автор:
Принадлежит:

Therapeutic drug delivery systems comprising gas-filled microspheres comprising a therapeutic are described. Methods for employing such microspheres in therapeutic drug delivery applications are also provided. Drug delivery systems comprising gas-filled liposomes having encapsulated therein a drug are preferred. Methods of and apparatus for preparing such liposomes and methods for employing such liposomes in drug delivery applications are also disclosed.

Подробнее
27-02-2020 дата публикации

BIOREDUCIBLE N-OXIDE-BASED PROBES FOR IMAGING OF HYPOXIA

Номер: US20200062784A1

Hypoxia occurs when limited oxygen supply impairs physiological functions and is a pathological hallmark of many diseases including cancer and ischemia. Thus, detection of hypoxia can guide treatment planning and serve as a predictor of patient prognosis. Current methods suffer from invasiveness, poor resolution and low specificity. To address these limitations, various hypoxia-responsive probes (HyPs) for photoacoustic imaging are disclosed. The emerging modality converts safe, non-ionizing light to ultrasound waves, enabling acquisition of high-resolution 3D images in deep tissue. The HyPs feature an N-oxide trigger that is reduced in the absence of oxygen by haem proteins such as CYP450 enzymes. Reduction of HyPs produce a spectrally distinct product, facilitating identification via photoacoustic imaging. HyPs exhibit selectivity for hypoxic activation in vitro, in living cells and in multiple disease models in vivo. HyPs are also compatible with NIR fluorescence imaging, establishing ...

Подробнее
21-01-1998 дата публикации

NOVEL COMPOSITIONS OF LIPIDS AND STABILIZING MATERIALS

Номер: EP0000818989A1
Автор: UNGER, Evan, C.
Принадлежит:

Compositions comprising, in an aqueous carrier, a lipid and a material which is capable of stabilizing the composition. The stabilizing material is associated non-covalently with said lipid and is present in an amount sufficient to coat the lipid but insufficient to raise the viscosity of the composition. The compositions are particularly suitable for use in diagnostic applications, including ultrasound. The compositions can take the form of vesicular compositions, such as micelles and liposomes.

Подробнее
10-11-2015 дата публикации

УСТРОЙСТВО С ЭХОГЕННЫМ ПОКРЫТИЕМ

Номер: RU2567839C2

Группа изобретений относится к области медицины, а именно к интервенционному устройству с повышенной эхогенностью, содержащему устройство, имеющее внешнюю поверхность, и покрытие из расплавленных полимерных частиц, нанесенное, по меньшей мере, на участок внешней поверхности упомянутого устройства, при этом покрытие из расплавленных полимерных частиц содержит расплавленные частицы фторполимера, которые являются, по меньшей мере, частично связанными между собой, и обеспечивает нерегулярную топографию поверхности на внешней поверхности устройства; и способу повышения эхогенности интервенционного устройства. Группа изобретений обеспечивает достижение более высокого уровня эхогенности устройства и возможность визуализировать уникальный рисунок поверхности конкретного устройства. 2 н. и 8 з.п. ф-лы, 4 ил., 2 пр.

Подробнее
10-08-2012 дата публикации

КОНТРАСТНЫЕ АГЕНТЫ ДЛЯ ОТОБРАЖЕНИЯ ПЕРФУЗИИ МИОКАРДА

Номер: RU2457865C2

Данное изобретение относится к области фармацевтики и медицины и касается контрастного агента для получения изображения кровоснабжения миокарда, включающего пиридабен или его аналог, содержащий по крайней мере один фрагмент, представляющий собой 18F, способов получения, выявления, мониторинга кровоснабжения миокарда, соединения и диагностического набора для визуализации, выявления и мониторинга кровоснабжения миокарда. Изобретение обеспечивает простое и эффективное получение изображения. 8 н. и 5 з.п. ф-лы, 8 пр.

Подробнее
10-07-2009 дата публикации

ДИСПЕРСНЫЙ АКТИВАТОР ДЛЯ ВЫСОКОИНТЕНСИВНОЙ ФОКУСИРОВАННОЙ УЛЬТРАЗВУКОВОЙ ТЕРАПИИ И ЕГО ПРИМЕНЕНИЕ

Номер: RU2360700C2

Настоящее изобретение раскрывает дисперсный активатор для терапии высокоинтенсивным фокусированным ультразвуком (ВИФУЗ терапия). Активатор включает дисперсную фазу, состоящую из вещества ядра, инкапсулированного мембранообразующим веществом, и дисперсионную фазу, состоящую из водной среды. Дисперсная фаза равномерно диспергирована в дисперсионной фазе, и размер частиц дисперсной фазы находится в интервале 0,1-8 мкм; количество мембранообразующего вещества в активаторе составляет 0,1-100 г/л; вещество ядра состоит из жидкости, не претерпевающей перехода жидкость-газ в интервале 38-100°С, и количество вещества ядра в активаторе составляет 5-200 г/л. Дисперсный активатор для ВИФУЗ терапии по настоящему изобретению может значительно менять акустическую среду в расположении мишени, повышать депонирование акустической энергии в расположении мишени в ходе ВИФУЗ терапии. В результате существенно улучшаются возможности клинической ВИФУЗ терапии по удалению опухолевых клеток. Изобретение также раскрывает ...

Подробнее
02-02-2012 дата публикации

Contrast agent for photoacoustic imaging and photoacoustic imaging method using the same

Номер: US20120027679A1
Принадлежит: Canon Inc

It is intended to provide a novel contrast agent for photoacoustic imaging that is highly capable of binding to a target molecule and generates high photoacoustic signals. The present invention provides a contrast agent for photoacoustic imaging represented by Formula 1: MNP−((L) l −(P) m ) n   (Formula 1) (wherein MNP represents a particle containing an iron oxide particle; L represents a linker molecule; P represents a ligand molecule; l represents 0 or 1; and m and n represent an integer of 1 or larger), the contrast agent for photoacoustic imaging including: a particle containing an iron oxide particle that absorbs light in a near-infrared region; and at least one or more ligand molecule(s) immobilized on the particle containing an iron oxide particle, wherein the immobilization density of the ligand molecule is equal to or higher than the cell surface density of a target molecule.

Подробнее
22-03-2012 дата публикации

Complex and contrast agent for photoimaging using the same

Номер: US20120070375A1
Принадлежит: Canon Inc

There is provided a gelatin-ICG complex that can suppress leakage of ICG included therein. The complex has a gelatin derivative including at least one of a phospholipid covalently bonded to a gelatin or a cholesterol covalently bonded to a gelatin, and indocyanine green.

Подробнее
24-01-2013 дата публикации

Microbubble Compositions, Method of Making Same, and Method Using Same

Номер: US20130022550A1
Принадлежит: Individual

A method of forming a plurality of microbubbles, wherein the method disposes in a sealed container comprising a first volume at ambient pressure, a second volume of a mixture comprising one or more microbubble stabilizing materials. The first volume is greater than said second volume. The method further comprises sealing said container, introducing a gas into said sealed container, and shaking the container to form said plurality of microbubbles.

Подробнее
04-04-2013 дата публикации

COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS

Номер: US20130084247A1

The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer. 1. An isolated peptide that is a variant , derivative or structural equivalent of a cupredoxin; and that can inhibit the development of premalignant lesions in mammalian tissue.2. The isolated peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of azurin claim 1 , pseudoazurin claim 1 , plastocyanin claim 1 , rusticyanin claim 1 , Laz claim 1 , auracyanin claim 1 , stellacyanin and cucumber basic protein.3. The isolated peptide of claim 2 , wherein the cupredoxin is azurin.4Pseudomonas aeruginosa, Alcaligenes faecalis, Achromobacter xylosoxidan, Bordetella bronchiseptica, MethylomonasNeisseria meningitidis, Neisseria gonorrhea, Pseudomonas fluorescens, Pseudomonas chlororaphis, Xylella fastidiosaVibrio parahaemolyticus.. The isolated peptide of claim 1 , wherein the cupredoxin is from an organism selected from the group consisting of sp. claim 1 , and5Pseudomonas aeruginosa.. The isolated peptide of claim 4 , that is from6. The isolated peptide of claim 1 , which is part of a peptide selected from the group consisting of SEQ ID NOS: 1 claim 1 , 3-19.7. The isolated peptide of claim 1 , to which a sequence selected from the group consisting of SEQ ID NOS: 1 claim 1 , 3-19 has at least 80% amino acid sequence identity.8. The isolated peptide of claim 1 , which is a truncation of the cupredoxin.9. The isolated peptide of claim 8 , wherein the peptide is more than about 10 residues and not more than about 100 residues.10Pseudomonas aeruginosaPseudomonas aeruginosaPseudomonas aeruginosa. The isolated peptide of claim 8 , wherein the peptide comprises a ...

Подробнее
11-04-2013 дата публикации

SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE

Номер: US20130089505A1
Принадлежит: Valor Medical, Inc.

Alkyl cyanoacrylate compositions and methods for making those compositions, utilizing high purity monomeric starting materials, formed into more viscous oligomers, and combined with a plasticizer and inhibitor to provide a single-container, storage stable medical cyanoacrylate. 1. A medical grade composition suitable for application to or in the human body , comprising a mixture of:(a) a polymerizable alkyl cyanoacrylate oligomer, wherein said polymerizable alkyl cyanoacrylate oligomer has a viscosity of from 10 centipoise to 30 centipoise;(b) at least one polymerization inhibitor;(c) a contrast agent; and(d) a plasticizer,wherein said composition is sealed in a single container and is stable for more than one month at room temperature, and is adapted to polymerize in vivo.2. The composition of claim 1 , wherein the polymerizable alkyl cyanoacrylate oligomer is selected from the group consisting of 2-hexyl cyanoacrylate oligomer claim 1 , n-hexyl cyanoacrylate oligomer claim 1 , pentyl cyanoacrylate oligomer claim 1 , heptyl cyanoacrylate oligomer claim 1 , and octyl cyanoacrylate oligomer.3. The composition of claim 1 , wherein the polymerizable alkyl cyanoacrylate oligomer is n-hexyl cyanoacrylate oligomer.4. The composition of claim 1 , wherein the inhibitor is selected from the group consisting of 4-methoxyphenol claim 1 , 2 claim 1 ,6-di-tert-butyl-4-methylphenol claim 1 , hydroquinone claim 1 , phosphoric acid claim 1 , sulfur dioxide (SO) claim 1 , and any combination thereof.5. The composition of claim 4 , wherein the inhibitor is a mixture of 4-methoxyphenol claim 4 , 2 claim 4 ,6-di-tert-butyl-4-methylphenol claim 4 , and sulfur dioxide.6. The composition of claim 1 , wherein the plasticizer is tri-n-butyl O-acetylcitrate.7. The composition of claim 1 , wherein the contrast agent is selected from the group consisting of gold claim 1 , platinum claim 1 , tantalum claim 1 , titanium claim 1 , tungsten claim 1 , barium sulfate claim 1 , and combinations ...

Подробнее
25-04-2013 дата публикации

ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM

Номер: US20130101520A1
Принадлежит: BRACCO SUISSE S.A.

The invention is directed to injectable suspensions of gas-filled microvesicles, as well as methods of preparing and using the same, especially as ultrasound contrast agents. 153.-. (canceled)54. An ultrasound contrast agent comprising an aqueous suspension of gas filled microbubbles comprising a saturated phospholipid , a fatty acid , a hydrophilic stabilizer , and SF , wherein the amount of the saturated phospholipid in the suspension is less than about 0.01% by weight.55. The ultrasound contrast agent of claim 54 , wherein the fatty acid is present in an amount between 1% and 50% by weight of the amount of the saturated phospholipid.56. The ultrasound contrast agent of claim 54 , wherein the fatty acid is present in an amount between 10% and 15% by weight of the amount of the saturated phospholipid.57. The ultrasound contrast agent of claim 54 , wherein the fatty acid is a C-C.straight chain saturated fatty acid selected from the group consisting of lauric acid claim 54 , myristic acid claim 54 , palmitic acid claim 54 , stearic acid claim 54 , arachidic acid claim 54 , behenic acid claim 54 , lignoceric acid and mixtures thereof.58. The ultrasound contrast agent of claim 54 , wherein the fatty acid comprises palmitic acid in an amount between 10% and 15% by weight of the amount of the saturated phospholipid.59. The ultrasound contrast agent of claim 54 , wherein the saturated phospholipid is selected from the group consisting of dimyristoylphosphatidic acid claim 54 , dimyristoylphosphatidylglycerol claim 54 , dimyristoylphosphatidylserine claim 54 , dipalmitoylphosphatidic acid claim 54 , dipalmitoylphosphatidylglycerol claim 54 , dipalmitoylphosphatidylserine claim 54 , distearoylphosphatidic acid claim 54 , distearoylphosphatidylglycerol claim 54 , distearoylphosphatidylserine and mixtures thereof.60. The ultrasound contrast agent of claim 54 , wherein the saturated phospholipid comprises distearoylphosphatidylcholine (DSPC) and ...

Подробнее
23-05-2013 дата публикации

MULTIMODAL NANOPARTICLES FOR NON-INVASIVE BIO-IMAGING

Номер: US20130129633A1

Multimodal nanoparticles are nanoparticles containing contrast agents for PAT and one or more of luminescence imaging, x-ray imaging, and/or MRI. The multimodal nanoparticles can have a dielectric core comprising an oxide with a metal coating on the core. The particles can be metal speckled. The multimodal nanoparticles can be used for therapeutic purposes such as ablation of tumors or by neutron capture in addition to use as contrast agents for imaging. 1. A method for multimodal bio-imaging comprising:providing a multimodal nanoparticle comprising a dielectric core comprising at least one oxide, a speckled metal deposition on said core where said metal deposition and said dielectric core have an interface with interpenetrated gradient, and a plurality of at least one moiety that exhibits luminescence, magnetic or paramagnetic properties, x-ray opacity, or any combination thereof, wherein said multimodal nanoparticle is a contrast agent for photo acoustic tomography (PAT) imaging and at least one of luminescence imaging, magnetic resonance (MR) imaging and x-ray imaging;introducing said multimodal nanoparticle to a desired location; andimaging the desired location by photo acoustic tomography (PAT) and at least one of magnetic resonance, luminescence, and x-rays, wherein said multimodal nanoparticle enhances the contrast observed in said imaging wherein said imagings are performed simultaneously or sequentially.2. A method of therapy comprising:providing a multimodal nanoparticle comprising a dielectric core comprising at least one oxide, a speckled metal deposition on said core where said metal deposition and said dielectric core have an interface with interpenetrated gradient, and a plurality of at least one moiety that exhibits luminescence, magnetic or paramagnetic properties, x-ray opacity, or any combination thereof, wherein said multimodal nanoparticle is a contrast agent for photo acoustic tomography (PAT) imaging and at least one of luminescence imaging, ...

Подробнее
23-05-2013 дата публикации

POLYMERIZED SHELL LIPID MICROBUBBLES AND USES THEREOF

Номер: US20130129635A1
Принадлежит: Wilson Sonsini Goodrch & Rosati

The present invention relates to the fabrication and use of microbubbles. In some embodiments, the invention provides for the fabrication and use of polymerized shell lipid microbubbles (PSMs). The microbubbles of the invention can be used, for example, for diagnosis and treatment of a condition. 1. A microbubble comprising a polymerized lipid shell and a gas , wherein the gas is encased within the shell , and wherein the polymerized lipid shell comprises at least about 5% polymerizable lipid.2. (canceled)3. The microbubble of claim 1 , wherein the gas is a perfluorocarbon.4. The microbubble of claim 3 , wherein the perfluorocarbon is decafluorobutane.5. The microbubble of claim 1 , wherein the gas is a mixture of at least two perfluorocarbons.6. The microbubble of claim 1 , wherein the polymerized lipid shell comprises at least one polymerizable lipid and at least one non-polymerizable lipid and has a percentage of about 5-50% polymerizable lipid.7. The microbubble of claim 6 , wherein the at least one non-polymerizable lipid is L-α-phosphatidylcholine) claim 6 , PE-PEG2000 (1 claim 6 ,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 or PE-PEG2000-biotin.8. The microbubble of claim 6 , wherein the at least one polymerizable lipid is a diacetylenic lipid.9. The microbubble of claim 6 , wherein the microbubble is UV treated for about 2-5 minutes after fabrication to polymerize the lipid shell.10. (canceled)11. The microbubble of wherein the microbubble was prepared by a microfluidic flow focusing device.12. The microbubble of wherein the microbubble comprises a targeting agent.13. (canceled)14. (canceled)15. (canceled)16. The microbubble of claim 1 , wherein the microbubble is an ultrasound contrast agent further comprising an acceptable carrier for administration to an individual.17. (canceled)18. (canceled)19. A collection of microbubbles comprising gas-filled polymerized shell lipid microbubbles claim 1 , wherein the microbubbles ...

Подробнее
20-06-2013 дата публикации

TARGETED GAS-FILLED MICROVESICLES

Номер: US20130156706A1
Принадлежит: BRACCO SUISSE S.A.

Gas-filled microvesicles associated with a polypeptide comprising a sequence of amino acids, said sequence exhibiting binding affinity for selectins, particularly p-selectin. The gas-filled microvesicles can be used in ultrasound imaging. 1. An aqueous suspension comprising a gas-filled microvesicle , said microvesicle comprising a targeting construct comprising:a) an amphiphilic compound; andb) a polypeptide consisting of at most 200 amino acid residues and comprising at least amino acids 5-16 as set forth in SEQ ID NO:1; said polypeptide being in dimeric form and being covalently associated with said amphiphilic compound.2. An aqueous suspension according to wherein said polypeptide comprises at least amino acids 1-19 as set forth in SEQ ID NO: 1.3. An aqueous suspension according to wherein said polypeptide comprises at least amino acids 5-41 as set forth in SEQ ID NO: 1.4. An aqueous suspension according to wherein said polypeptide comprises at least amino acids 1-47 as set forth in SEQ ID NO: 1.5. An aqueous suspension according to wherein said polypeptide comprises at most 100 amino acid residues.6. An aqueous suspension according to wherein said polypeptide comprises at most 75 amino acid residues.7. An aqueous suspension according to wherein said polypeptide consists of the amino acid sequence as set forth in SEQ ID NO: 3.9. (canceled)10. An aqueous suspension according to wherein (X)comprises at least amino acids 1-19 as set forth in SEQ ID NO: 1.11. An aqueous suspension according to wherein (X)comprises at least amino acids 5-41 as set forth in SEQ ID NO: 1.12. An aqueous suspension according to wherein (X)comprises at least amino acids 1-47 as set forth in SEQ ID NO: 1.1314-. (canceled)15. An aqueous suspension according to wherein Y is Lysine.16. An aqueous suspension according to wherein n is an integer of from 12 to 99 and m+n is at most 99.17. An aqueous suspension according to wherein n is an integer of from 12 to 74 and m+n is at most 74.1819-. ( ...

Подробнее
11-07-2013 дата публикации

ANTI-DESPR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY

Номер: US20130177500A1
Принадлежит: Trustee of Boston University

Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anto-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments. 173-. (canceled)74. An isolated anti-DEspR antibody or antibody fragment thereof that specifically binds to human DEspR (dual endothelin/VEGF signal peptide receptor) expressed on a living cell , wherein the antibody , or antibody fragment thereof , is a composite fully human monoclonal antibody or antibody fragment thereof and wherein the antibody or antibody fragment thereof binds to a tumor cell.75. The anti-DEspR antibody or antibody fragment thereof of claim 74 , wherein the antibody or antibody fragment thereof specifically binds to residues 1-9 of SEQ ID NO:1.76. The anti-DEspR antibody or antibody fragment thereof of claim 74 , wherein the antibody or antibody fragment thereof comprises the complementarity determining regions (CDRs) of a variable heavy (V) chain amino acid sequence comprising a sequence of SEQ ID NO: 4 and the CDRs of a variable light (V) chain amino acid sequence comprising a sequence of SEQ ID NO: 9.77. A pharmaceutical composition comprising an isolated anti-DEspR antibody or antibody fragment thereof that specifically binds to human DEspR (dual endothelin/VEGF signal peptide receptor) expressed on a living cell claim 74 , wherein the antibody claim 74 , or antibody fragment thereof claim 74 , is a composite fully human monoclonal antibody or antibody fragment thereof and wherein the antibody or antibody fragment thereof binds to a tumor cell.78. A pharmaceutical ...

Подробнее
18-07-2013 дата публикации

Compositions Useful for Target, Detection, Imaging and Treatment, and Methods of Production and Use Thereof

Номер: US20130183234A1
Принадлежит:

Compositions useful for target detection, imaging and treatment, as well as methods of production and use thereof, are disclosed herein. 1. A complex of sequentially deliverable pharmaceutical reagents useful for detecting a target exposed in a lumen through imaging , wherein the complex is formed in the lumen , the complex comprising:at least one Stage I agent that binds to a target;a plurality of Stage II agents;a plurality of Stage III agents;wherein each of the plurality of Stage II agents binds to at least one Stage I agent, and wherein each of the plurality of Stage III agents binds to at least one Stage II agent, and wherein at least one of the Stage I, Stage II and Stage III agents is detectable by an imaging modality, thus allowing detection of the complex bound to the target.2. The complex of claim 1 , wherein two or more Stage III vesicles are bound to a single Stage II vesicle.3. The complex of claim 1 , wherein the Stage I claim 1 , Stage II and Stage III vesicles are each selected from the group consisting of liposomes claim 1 , echogenic liposomes claim 1 , multimodal echogenic liposomes claim 1 , microbubbles claim 1 , microballoons claim 1 , microspheres claim 1 , matrix particles claim 1 , micelles claim 1 , aggregation based constructs claim 1 , nanoparticles claim 1 , perfluorocarbon nanodroplets claim 1 , and combinations thereof.4. The complex of claim 1 , wherein at least one of the Stage I claim 1 , Stage II and Stage III agents comprises a gas.5. The complex of claim 1 , wherein at least one of the Stage I claim 1 , Stage II and Stage III agents further comprises a therapeutic composition incorporated/encapsulated therein.6. The complex of claim 4 , wherein the therapeutic composition is delivered claim 4 , released claim 4 , activated and/or excited upon targeting via the Stage I vesicle.7. The complex of claim 5 , wherein the release/activation/excitation is in response to exposure to at least one of heat claim 5 , ultrasound and chemical ...

Подробнее
15-08-2013 дата публикации

PARTICLE AND CONTRAST AGENT HAVING THE PARTICLE

Номер: US20130209367A1
Принадлежит: CANON KABUSHIKI KAISHA

There is provided an ICG-loaded polymer nanoparticle that is dynamically stable, prevents the leakage of contained ICG and the resulting discoloration, and has a high molar absorbance coefficient. The particle contains a hydrophilic dye having a sulfonate group and a hydrophobic polymer, and the particle further contains at least one of a lipid having a positively charged region, a nicotinic acid derivative and a thiamine derivative. 1. A particle comprising a hydrophilic dye having a sulfonate group and a hydrophobic polymer , wherein the particle further comprises at least one of a lipid having a positively charged region , a nicotinic acid derivative and a thiamine derivative.2. The particle according to claim 1 , wherein the hydrophilic dye having a sulfonate group is indocyanine green.5. The particle according to claim 1 , wherein the lipid having the positively charged region is at least one of dioleylphosphatidylethanolamine and distearoylphosphatidylcholine.6. The particle according to claim 1 , wherein the nicotinic acid derivative is nicotinamide.7. The particle according to claim 1 , wherein the thiamine derivative is at least one of fursultiamine claim 1 , prosultiamine and thiamin disulfide.8. The particle according to claim 1 , wherein the particle has a surfactant on a surface of the particle.9. The particle according to claim 8 , wherein the surfactant is a surfactant selected from at least one of a polyoxyethylene sorbitan fatty acid ester and a phospholipid.10. The particle according to claim 1 , wherein the particle further has a capture molecule that binds specifically to a target site.11. The particle according to claim 1 , wherein an average particle size of the particle is from 10 nm to 1 claim 1 ,000 nm.12. The particle according to claim 1 , wherein albumin is noncovalently bonded to a surface thereof.13. A contrast agent for optical imaging having a particle according to and a dispersion medium containing the particle dispersed therein. The ...

Подробнее
29-08-2013 дата публикации

PARTICLE CONTAINING HYDROPHOBIC DYE HAVING CYANINE STRUCTURE, AND CONTRAST AGENT CONTAINING THE PARTICLE

Номер: US20130224121A1
Принадлежит: CANON KABUSHIKI KAISHA

Provided is a particle which can stably hold a dye in itself even in an aqueous solution such as serum, in order to solve such a problem of a particle containing ICG, which has been conventionally used in a contrast agent or the like, that the ICG is a dye having a hydrophilic functional group and hence the ICG leaks out of the particle in an aqueous solution such as serum. More specifically, provided is a particle including a hydrophobic dye having a cyanine structure, in which the hydrophobic dye is represented by the following chemical formula (1). 3. A particle according to claim 1 , wherein the hydrophobic dye has an Rf value of 0.09 or more and 0.50 or less.5. A contrast agent claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the particle according to ; and'}a dispersion medium.6. A contrast agent according to claim 5 , wherein the contrast agent is used for photoacoustic imaging.9. A particle according to claim 7 , wherein the hydrophobic dye has an Rf value of 0.09 or more and 0.50 or less.11. A particle according to claim 7 , wherein the matrix material comprises a hydrophobic polymer.12. A particle according to claim 11 , wherein the hydrophobic polymer comprises any one of polylactic acid (PLA) and poly(lactide-co-glycolide) acid (PLGA).13. A contrast agent claim 11 , comprising:{'claim-ref': {'@idref': 'CLM-00007', 'claim 7'}, 'the particle according to ; and'}a dispersion medium.14. A contrast agent according to claim 13 , wherein the contrast agent is used for photoacoustic imaging. 1. Field of the InventionThe present invention relates to a particle containing a hydrophobic dye having a cyanine structure, and to a contrast agent containing the particle.2. Description of the Related ArtIn recent years, a fluorescence imaging method or a photoacoustic imaging method has attracted attention as an imaging method which allows non-invasive diagnosis.In the fluorescence imaging method, a fluorescent dye is irradiated with light and ...

Подробнее
05-09-2013 дата публикации

Therapeutic Angiogenesis for Treatment of the Spine and Other Tissues

Номер: US20130230454A1
Принадлежит: CARDIOVASCULAR BIOTHERAPEUTICS, INC.

Methods for the diagnosis and treatment of ischemic spinal conditions, degenerative disc disease, back pain and/or other tissue pathologies. Patients with ischemic spine disease can be categorized into subsets that are deemed to have potential to respond to therapy. In particular, therapies are disclosed which involve stimulation of neovascularization so as to increase perfusion of spinal and other anatomies. 1. A method of diagnosing a patient with an ischemic spinal disorder , comprisingobtaining electronic image data of one or more vertebral bodies of the patient;identifying one or more regions of interest in the electronic image data, the one or more regions of interest including electronic image data of at least a portion of an intravertebral microcirculation proximate to an intervertebral endplate;analyzing the one or more regions of interest to obtain one or more perfusion measurements within each region of interest;comparing the one or more perfusion measurements with a predetermined perfusion value; anddiagnosing said patient with said ischemic spinal disorder wherein said one or more perfusion measurements is below said predetermined perfusion value.2. A method of treating a patient having an ischemic spinal disorder comprising:obtaining one or more images of at least a portion of a spine of the patient;analyzing the one or more images with a computing system to quantify a localized perfusion of the intravertebral microcirculation proximate to one or more endplates of one or more intervertebral discs of the patient's spine;identifying at least one intravertebral location where the quantified localized perfusion of the intravertebral circulation indicates hypoperfusion of the intravertebral circulation; andtreating the patient by injecting an angiogenesis inducing compound proximate to the at least one intravertebral location where the quantified localized perfusion of the intravertebral circulation indicates hypoperfusion of the intravertebral circulation. ...

Подробнее
05-09-2013 дата публикации

Cyanine compounds

Номер: US20130230466A1
Принадлежит: Individual

Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

Подробнее
19-09-2013 дата публикации

Particles and contrast agent including the same for optical imaging

Номер: US20130243694A1
Принадлежит: Canon Inc

A particle includes a copolymer of lactic acid and glycolic acid, and at least one compound selected from silicon naphthalocyanine and derivatives of silicon naphthalocyanine, in which the particle has a particle size of 10 nm or more and less than 1000 nm.

Подробнее
26-09-2013 дата публикации

SYSTEMS, METHODS, AND DEVICES FOR ULTRASONIC ASSESSMENT OF CANCER AND RESPONSE TO THERAPY

Номер: US20130251633A1

Microbubbles can be injected into the bloodstream of a patient, for example, a cancer patient undergoing a treatment specifically targeting a biological process in a tumor. The injected microbubbles can act as vascular contrast agents, which can be detected in vivo using high-frequency ultrasound imaging. The microbubbles can have a surface chemistry that allows them to bind to molecular targets in the tumor vasculature. After injection, the microbubbles can selectively adhere to endothelia expressing a target receptor. The selective adhesion can be used to quantify the tumor vasculature in vivo. By imaging the adhered microbubbles with ultrasound, an indication of how tumor vasculature is affected by a specific cancer treatment can be obtained. Such techniques can be used in a clinical setting for rapid determination of anti-cancer treatment efficacy for individual patients. 1. A method for determining efficacy of treatment of a cancerous tumor in a patient , the method comprising:at a first time after administering the treatment to a patient, injecting a population of microbubbles into the patient, the population of microbubbles being size-selected so as to have diameters of 4-5 μm or 6-8 μm, each microbubble having a surface chemistry that targets receptor sites in said tumor;after the injecting, imaging a field of view using ultrasound so as to obtain a first image, the field of view including at least a portion of said tumor;after the imaging, sending an ultrasonic pulse to said field of view so as to destroy the microbubbles in said field of view, the ultrasonic pulse having a higher intensity than the ultrasound waves used for said imaging;re-imaging the field of view using ultrasound so as to obtain a second image; andcomparing the intensity of the first and second images so as to measure the number of microbubbles attached to the targeted receptor sites in said tumor.2. The method of claim 1 , further comprising:repeating the injecting, imaging, sending, re ...

Подробнее
26-09-2013 дата публикации

Marker or filler forming fluid

Номер: US20130253315A1
Принадлежит: SenoRx Inc

A system for at least partially filling and marking a cavity at a site within a patient's body includes a marker delivery device having a chamber configured to contain a marking substance and having a mechanism configured to expel the marking substance. A quantity of the marking substance is contained within the chamber of the marker delivery device. The marking substance is configured to at least partially fill the cavity and form therein a porous bioabsorbable body. A delivery tube is coupled in fluid communication with the chamber of the marker delivery device. The delivery tube has a distal end with a discharge port through which the marking substance is expelled. A marker is configured to be delivered to the cavity from the distal end of the delivery tube and is configured to remain with the porous bioabsorbable body within the cavity upon the formation thereof.

Подробнее
10-10-2013 дата публикации

Methods and Compositions for Using Bleomycin-Derivatized Microbubbles

Номер: US20130266518A1
Принадлежит:

Methods and compositions for using tumor targeting compounds bound to microbubbles to facilitate drug delivery and diagnostic imaging at tumor sites. 19-. (canceled)10. A method for selectively imaging a tumor in a patient , comprising (i) a microbubble comprising an outer shell, wherein the outer shell is derivatized with a first member of a binding pair; and', 'ii) bleomycin bound to the microbubble, wherein the bleomycin is derivatized with a second member of the binding pair, and wherein the first member of the binding pair and the second member of the binding pair are bound to each other,, '(a) administering a composition to a subject with a tumor selected from the group consisting of a breast carcinoma, a colon carcinoma, a prostate carcinoma, and a lung carcinoma, wherein the composition comprises'}under conditions suitable to promote binding of the bleomycin to the tumor; and(b) acquiring an ultrasound image of the composition in the subject.11. The method of claim 10 , wherein the method is carried out following a treatment to inhibit tumor growth claim 10 , wherein the method is used to monitor effects of the treatment.12. The method of claim 10 , wherein the tumor is selected from the group consisting of carcinomas of the breast claim 10 , lung claim 10 , and colon.13. The method of claim 10 , wherein the composition is administered intravenously claim 10 , percutaneously claim 10 , parenterally claim 10 , or intramuscularly.1418-. (canceled)19. The method of claim 10 , wherein the bleomycin is selected from the group consisting of bleomycin A2 claim 10 , bleomycin B2 claim 10 , bleomycin A6 and bleomycin A5.20. The method of claim 10 , wherein the first and second members of the binding pair comprise streptavidin and biotin.21. The method of claim 10 , wherein the microbubbles have a diameter of between about 0.1 micron to about 10 microns.22. The method of claim 10 , wherein the microbubbles have a diameter of between about 1 micron to about 4 microns. ...

Подробнее
10-10-2013 дата публикации

Targeting vector-phospholipid conjugates

Номер: US20130266519A1
Принадлежит: Bracco Suisse SA

Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.

Подробнее
24-10-2013 дата публикации

SONOSENSITIVE NANOPARTICLES

Номер: US20130281916A1
Принадлежит: lsis Innovation Limited

A method of delivering a therapeutic substance to tissue comprises delivering the therapeutic substance and nanoparticles to the tissue, the nanoparticles having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm, and insonating the tissue with pressure waves. Corresponding particles, and associated methods of controlling and imaging the treatment and delivery are also disclosed. 1. A nanoparticle for inducing cavitation in a medium under insonation , the nanoparticle having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm.2. A nanoparticle for the treatment of cancer in a body , the nanoparticle having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm , whereby the nanoparticle is arranged to enhance cavitation in the body when the body is insonated with pressure waves.3. A system for treating cancerous tissue , the system comprising a source of pressure waves and nanoparticles for delivery to the tissue , the nanoparticles having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm , whereby the nanoparticles are arranged to enhance cavitation in the tissue when the tissue is insonated with pressure waves from the source.4. A method of controlling cavitation in tissue , the method comprising delivering nanoparticles to the tissue , the nanoparticles having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm , and insonating the tissue with pressure waves.5. A method of imaging an object , the method comprising delivering nanoparticles to the object , the nanoparticles having a diameter in the range from 10 to 1000 nm and surface features having a depth in the range from 5 to 50 nm , and insonating the object with pressure waves such that the nanoparticles induce cavitation in the ...

Подробнее
31-10-2013 дата публикации

Medical imaging contrast devices, methods, and systems

Номер: US20130289398A1
Принадлежит: Columbia University of New York

Systems, methods, and devices for generating and using size-selected lanthanide-coated microbubbles for controlling an imaging signal via microbubble fragmentation and for magnetic resonance imaging guided focused ultrasound therapy.

Подробнее
21-11-2013 дата публикации

PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND

Номер: US20130309175A1
Принадлежит: Lantheus Medical Imaging, Inc.

The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent. 144-. (canceled)45. A process for preparing a lipid suspension for use with a perfluorocarbon gas as an ultrasound contrast agent , the method comprising:(a) contacting phospholipids with a first non-aqueous solvent which causes the phospholipids to dissolve and form a lipid solution, wherein the contacting comprises the sequential addition of individual phospholipids to the first non-aqueous solvent wherein the phospholipids are 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, mono sodium salt (DPPA) and N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt (MPEG5000-DPPE), or combining said phospholipids with each other prior to their addition to the first non-aqueous solvent;(b) contacting the non-aqueous lipid solution of (a) with a second non-aqueous solvent which causes the phospholipids to precipitate out as a solid lipid blend;(c) collecting the solid lipid blend;(d) contacting the solid lipid blend with a third non-aqueous solvent which causes the lipid blend to dissolve to form a lipid blend solution;(e) contacting the lipid blend solution with an aqueous solution to yield the lipid suspension; and(f) filtering the lipid suspension through one or two sterilizing filters to form a filtered lipid suspension.46. The process of claim 45 , wherein the one or two sterilizing filters are 0.2 micron filters.47. The process of claim 45 , further comprising dispensing the filtered lipid suspension into a vial.48. The process of claim 47 , further comprising exchanging the headspace gas of the vial with the perfluorocarbon gas.49. The process of claim 48 , wherein the perfluorocarbon gas is perfluoropropane.50. The process of claim 48 ...

Подробнее
28-11-2013 дата публикации

DYE-CONTAINING NANOPARTICLE FOR PHOTOACOUSTIC CONTRAST AGENT

Номер: US20130315837A1
Принадлежит: CANON KABUSHIKI KAISHA

An object of the present invention is to increase the dye content in nanoparticles and to improve the signal intensity per particle. According to the nanoparticle including at least a silicon naphthalocyanine or a derivative thereof and a surfactant, wherein the proportion of the silicon naphthalocyanine or the derivative thereof is 70% or more by weight in relation to the other component of the particle exclusive of the surfactant, the dye content in the nanoparticles can be increased and the signal intensity per particle can be improved without weakening the signal intensity per dye molecule (light absorptivity) 1. A nanoparticle comprising at least a silicon naphthalocyanine or a derivative thereof and a surfactant , wherein the proportion of the silicon naphthalocyanine or the derivative thereof in relation to the other components of the particle exclusive of the surfactant is 70% or more by weight.3. The nanoparticle according to claim 1 , wherein the silicon naphthalocyanine or the derivative thereof is any one of silicon 2 claim 1 ,3-naphthalocyanine dioctyloxide claim 1 , silicon 2 claim 1 ,3-naphthalocyanine dichloride claim 1 , bis(di-isobutyl octadecylsiloxy)silicon 2 claim 1 ,3-naphthalocyanine and silicon 2 claim 1 ,3-naphthalocyanine bis(trihexylsilyloxide).4. The nanoparticle according to claim 1 , wherein the average particle size thereof is 5 nm or more and 200 nm or less.5. The nanoparticle according to claim 1 , wherein the nanoparticle is used as a contrast agent.6. The nanoparticle according to claim 1 , wherein the nanoparticle is used as a contrast agent for a photoacoustic imaging method.8. The nanoparticle according to claim 1 , further comprising a capture molecule to be specifically bound to a target site. This application is a continuation of International Application No. PCT/JP2013/000995, filed Feb. 21, 2013, which claims the benefit of Japanese Patent Applications No. 2012-038036, filed Feb. 23, 2012 and No. 2012-263003, filed Nov. 30, ...

Подробнее
28-11-2013 дата публикации

COMPOUND

Номер: US20130315840A1
Принадлежит: CANON KABUSHIKI KAISHA

A compound including a polymer is represented by general formula (1): 1. A process for detecting a lesion marker , comprising administering to an individual a compound comprising a polymer represented by formula (1) to a single-chain antibody moiety of which a signal generating molecule is linked or adding such a compound to a sample obtained from an individual and detecting signals , thereby detecting presence or absence of lesion markers or presence or absence of lesion sites generating lesion markers in the individual or in the sample obtained from an individual , {'br': None, 'L-Y-A\u2003\u2003(1)'}, 'wherein the compound comprising the polymer represented by general formula (1) is as followswherein, A is a single-chain antibody moiety, which is a polypeptide comprising an antigen-binding site; L is a linker moiety, which is a polypeptide comprising a protease cleavage site; Y is a peptide moiety, which comprises 0 or more amino acids connecting the linker moiety L with the single-chain antibody moiety A; and the linker moiety L binds to an N terminus of the peptide moiety Y or an N terminus of the single-chain antibody moiety A.2. A process for producing a compound comprising a polymers represented by general formula (1) , comprising inserting to a plasmid a nucleic acid which has a base sequence encoding a single-chain antibody moiety A , a base sequence encoding a linker moiety L and a base sequence encoding a peptide moiety Y; introducing to bacteria the plasmid in which the nucleic acid is inserted; and collecting a compound expressed by the bacteria to which the plasmid is introduced:{'br': None, 'L-Y-A\u2003\u2003(1)'}wherein, A is single-chain antibody moiety, which is a polypeptide comprising an antigen-binding site; L is a linker moiety, which is a polypeptide comprising a protease cleavage site; Y is a peptide moiety, which comprises 0 or more amino acids connecting the linker moiety L with the single-chain antibody moiety A; and the linker moiety L ...

Подробнее
28-11-2013 дата публикации

Opacity technology

Номер: US20130317354A1
Автор: Eric K. Mangiardi
Принадлежит: QUALI MED GmbH

A catheter device comprising a chamber containing an opacity enhancing substance is disclosed. The opacity enhancing substance is in a dried or semi-dried form within the chamber of the device. Release of a liquid into the chamber suspends the substance and forms an opacity enhancing solution that is released into the lumen of the device in order to enhance the opacity of the device for imaging.

Подробнее
05-12-2013 дата публикации

TUMOR-TARGETING GAS-GENERATING NANOPARTICLE, METHOD FOR PREPARING THE SAME, AND TUMOR-TARGETING NANOPARTICLE FOR DRUG DELIVERY USING THE SAME

Номер: US20130323177A1
Принадлежит:

A tumor-targeting gas-generating nanoparticle, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same relate to a tumor-targeting gas-generating nanoparticle including a polycarbonate core and a amphiphilic coat, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same. Since a tumor-targeting gas-generating nanoparticle according to the present disclosure is accumulated in the tumor tissue in large quantity and generates strong ultrasound wave signals, it can be usefully used as a contrast agent for ultrasonic imaging. 1. A tumor-targeting gas-generating nanoparticle comprising a polycarbonate core and an amphiphilic coat.3. The tumor-targeting gas-generating nanoparticle according to claim 1 , wherein the amphiphilic coat is a polyethylene oxide-polypropylene oxide-polyethylene oxide triblock copolymer claim 1 , a polyethylene oxide-polyglycoliclactic acid copolymer or a polyethylene oxide-polylactic acid copolymer.4. The tumor-targeting gas-generating nanoparticle according to claim 1 , wherein the nanoparticle has a particle size distribution of 300±50 nm.5. A method for preparing a tumor-targeting gas-generating nanoparticle claim 1 , comprising:synthesizing a polycarbonate core through ring-opening polymerization; andencapsulating the polycarbonate core with an amphiphilic coat through oil-in-water emulsification.7. The method for preparing a tumor-targeting gas-generating nanoparticle according to claim 5 , wherein the amphiphilic coat is a polyethylene oxide-polypropylene oxide-polyethylene oxide triblock copolymer claim 5 , a polyethylene oxide-polyglycoliclactic acid copolymer or a polyethylene oxide-polylactic acid copolymer.8. A tumor-targeting nanoparticle for drug delivery comprising:a core comprising a drug to be delivered and a polycarbonate; andan amphiphilic coat.10. The tumor-targeting nanoparticle for drug delivery according to claim 8 , wherein the amphiphilic coat is a ...

Подробнее
05-12-2013 дата публикации

INDOCYANINE GREEN-CONTAINING PARTICLE AND CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING HAVING THE PARTICLE

Номер: US20130323178A1
Принадлежит: CANON KABUSHIKI KAISHA

Provided is the following indocyanine green (ICG)-containing particle to be used as, for example, a contrast agent for fluorescent imaging or photoacoustic imaging. The leakage of ICG from the particle in a serum is prevented and hence the particle can stably retain ICG. According to a particle characterized by having an aggregate of indocyanine green and a phospholipid, the leakage of ICG from the particle in a serum or the like is prevented and hence ICG can be stably retained in the particle. 1. A particle , comprising:a J-aggregate of indocyanine green (ICG); anda lipid having a positively charged region.2. The particle according to claim 1 , wherein a ratio of an absorbance for light having a wavelength of 895 nm to an absorbance for light having a wavelength of 780 nm is 0.1 or more.3. The particle according to claim 1 , further comprising claim 1 , on a surface thereof claim 1 , a surfactant.4. The particle according to claim 1 , further comprising a targeting molecule that specifically binds to a target site.5. The particle according to claim 1 , wherein the lipid forms a bilayer membrane.6. The particle according to claim 1 , wherein a ratio of the lipid to the particle is 30 wt % or more.7. The particle according to claim 1 , further comprising claim 1 , on a surface thereof claim 1 , a polyethylene glycol chain.8. A contrast agent for photoacoustic imaging claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the particle according to ; and'}a dispersion medium in which the particle is dispersed.9. A particle claim 1 , comprising:a phospholipid;cholesterol; andindocyanine green,wherein a ratio of an absorbance of the particle at 700 nm to an absorbance thereof at 780 nm is 1 or more.10. The particle according to claim 9 , further comprising a dextran.11. The particle according to claim 9 , wherein the phospholipid forms a bilayer membrane.12. The particle according to claim 9 , wherein the phospholipid comprises distearoyl ...

Подробнее
26-12-2013 дата публикации

INDOCYANINE GREEN-CONTAINING PARTICLES, PHOTOACOUSTIC-IMAGING CONTRAST AGENT INCLUDING THE SAME, AND METHOD FOR PRODUCING THE INDOCYANINE GREEN-CONTAINING PARTICLES

Номер: US20130344001A1
Принадлежит:

Indocyanine green-containing particles each include a metal oxide particle or a metal particle and an aggregate of indocyanine green. The aggregate of indocyanine green has a relative maximum absorbance at 880 nm or more and 910 nm or less. 1. Indocyanine green-containing particles each comprising:a metal oxide particle or a metal particle; andan aggregate of indocyanine green,the aggregate of indocyanine green having a relative maximum absorbance at 880 nm or more and 910 nm or less.2. The indocyanine green-containing particles according to claim 1 ,wherein the aggregate of indocyanine green is adsorbed on the metal oxide particle or the metal particle.3. The indocyanine green-containing particles according to claim 1 ,wherein the metal oxide particle is an iron oxide particle.4. The indocyanine green-containing particles according to claim 1 ,wherein the absorbance of the indocyanine green-containing particles at 895 nm is 2.0 times or more the absorbance at 780 nm.5. The indocyanine green-containing particles according to claim 1 ,wherein the indocyanine green-containing particles each include a dispersant on the surface thereof.6. The indocyanine green-containing particles according to claim 5 ,wherein the dispersant is dextran.7. A photoacoustic-imaging contrast agent comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the indocyanine green-containing particles according to ; and'}a dispersion medium.8. A method for producing the indocyanine green-containing particles according to claim 1 , the method comprising the steps of:heating an aqueous solution of indocyanine green;mixing the heated aqueous solution of indocyanine green with metal oxide particles or metal particles to prepare a liquid mixture; andheating the liquid mixture. 1. Field of the InventionThe present invention relates to indocyanine green-containing particles, a photoacoustic-imaging contrast agent including the indocyanine green-containing particles, and a method for producing the ...

Подробнее
09-01-2014 дата публикации

Multi-encapsulated formulations made with oxidized cellulose

Номер: US20140010755A1
Принадлежит: Confluent Surgical Inc

A microsphere and method for forming the same are disclosed. The microsphere includes modified cellulose and at least one of a visualization agent, a magnetic material, or a radioactive material.

Подробнее
23-01-2014 дата публикации

CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING AND PHOTOACOUSTIC IMAGING METHOD USING THE SAME

Номер: US20140023584A1
Принадлежит:

It is intended to provide a novel contrast agent for photoacoustic imaging that is highly capable of binding to a target molecule and generates high photoacoustic signals. The present invention provides a contrast agent for photoacoustic imaging represented by Formula 1: 122-. (canceled)23. A photoacoustic imaging method for detecting a target molecule , the method comprising steps of:irradiating with pulsed light a sample to which a contrast agent for photoacoustic imaging has been administered; andmeasuring a photoacoustic signal derived from the contrast agent bound to the target molecule present in the sample, {'br': None, 'sub': l', 'm', 'n, 'MNP-((L)-(P))\u2003\u2003(1),'}, 'wherein the contrast agent is represented by formula (1)wherein MNP represents a particle containing an iron oxide particle, L represents a linker molecule, P represents a ligand molecule, l represents zero or one, and m and n each represent an integer of one or larger, andwherein the particle containing the iron oxide particle absorbs light in a near-infrared region, at least one ligand molecule is immobilized on the particle, and an immobilization density of the ligand molecule is equal to or higher than a cell surface density of the target molecule.24. The photoacoustic imaging method according to claim 23 , further comprising a step of administering the contrast agent to a cell claim 23 , tissue claim 23 , animal claim 23 , or human.25. The photoacoustic imaging method according to claim 23 , wherein a number of ligand molecules is three or more per the particle containing the iron oxide particle.26. The photoacoustic imaging method according to claim 23 , wherein the ligand molecule is selected from the group consisting of a monoclonal antibody claim 23 , Fab claim 23 , Fab′ claim 23 , F(ab′) claim 23 , a single-chain antibody claim 23 , a peptide containing an antibody complementarity determining region claim 23 , and an antibody or a peptide that binds to epidermal growth factor ...

Подробнее
06-02-2014 дата публикации

CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF

Номер: US20140037554A1

The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. 1. A peptide , consisting of a sequence that has at least about 90% amino acid sequence identity to less than a full-length wild-type cupredoxin or H.8 outer membrane protein , and which facilitates the entry of a linked molecule into a mammalian cancer cell.2. The peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of azurin claim 1 , plastocyanin claim 1 , rusticyanin claim 1 , pseudoazurin claim 1 , auracyanin and azurin-like protein.3Pseudomonas aeruginosa, Phormidium laminosum, Thiobacillus ferrooxidans, Achromobacter cycloclastes, Pseudomonas syringa, Neisseria meningitidis, Vibrio parahaemolyticus, Bordetella bronchiseptica, Bordetella pertussis, Chloroflexus aurantiacusNeisseria gonorrhoeae.. The peptide of claim 1 , wherein the peptide is derived from a organism selected from the group consisting of and4. The peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of SEQ ID NO: 1 claim 1 , SEQ ID NO: 2 claim 1 , SEQ ID NO: 3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID NO: 29 claim 1 , SEQ ID NO: 30 claim 1 , SEQ ID NO: 31 claim 1 , SEQ ID NO: 32 claim 1 , SEQ ID NO: 33 claim 1 , SEQ ID NO: 34 claim 1 , SEQ ID NO: 36 and SEQ ID NO: 43.5. The peptide of claim 1 , which is at least about 10 residues and not more than about 50 residues in length.6. The peptide of claim 1 , comprising a sequence which has at least about 90% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID NO: 5 claim 1 , SEQ ID NO: 6 claim 1 , SEQ ID NO: 7 claim 1 , SEQ ID NO: 9 claim 1 , SEQ ID NO: 37 claim 1 , SEQ ID NO: 38 claim 1 , SEQ ID NO: 39 claim 1 , SEQ ID NO: 40 claim 1 , SEQ ID NO: 41 claim 1 , ...

Подробнее
27-02-2014 дата публикации

TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN AND INTO BRAIN CANCER CELLS AND METHODS OF USE THEREOF

Номер: US20140056820A1

The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer. 1Neisseria. An isolated transit peptide which is a variant , derivative or structural equivalent of Laz , Lip or Pan 1 from , and which facilitates the entry of a linked molecule into a mammalian brain cancer cell or across the blood-brain barrier.2. The transit peptide of claim 1 , to which the H.8 region of Laz (SEQ ID NO: 24) has at least 90% amino acid identity.3. The transit peptide of claim 1 , wherein the peptide is SEQ ID NO: 24.4. The transit peptide of claim 1 , wherein the transit peptide is modified to extend or optimize the half life of the peptide in the bloodstream.5. A transit peptide comprising a region consisting of at least 4 imperfect or perfect repeats of Ala-Ala-Glu-Ala-Pro (SEQ ID NO: 25) claim 1 , and which has at least about 50% AAEAP (SEQ ID NO: 25) pentapeptide repeats per total length.6. A transit peptide of claim 5 , wherein the region of repeats is at least about 90% identical to a peptide comprising an equal number of repeats of Ala-Ala-Glu-Ala-Pro (SEQ ID NO: 25).7. The transit peptide of claim 5 , which is synthetic.8. The transit peptide of claim 5 , wherein the transit peptide is modified to extend or optimize the half life of the peptide in the bloodstream.9. A complex comprising at least one cargo compound and a transit peptide claim 5 , wherein the transit peptide is the peptide of and the transit peptide is linked to the ...

Подробнее
06-03-2014 дата публикации

Optoacoustic-Ultrasonic Contrast Agents with Enhanced Efficiency

Номер: US20140066761A1
Принадлежит:

Provided herein are dual contrast agents or nanocomposite particles designed to enhance optoacoustic-ultrasonic imaging. The contrast agents or particles have a core designed to enhance response to incident transient ultrasonic pressure waves and at least two layers disposed around the core. The inner first layer is designed to effectively absorb incident transient optical waves, convert absorbed optical energy into heat and demonstrates significant thermal expansion and/or conversion of thermal energy into acoustic pressure. The outer second layer thermally insulates the inner layer from the surrounding aqueous environment and enhances the generation of transient ultrasonic pressure waves during optoacoustic-ultrasonic imaging and sensing. Also provided are methods of enhancing contrast in a tissue optoacoustic-ultrasonic imaging and producing enhanced optoacoustic images by contacting the tissue with the dual contrast agent or nanocomposite particles. 1. A dual contrast agent designed to enhance optoacoustic-ultrasonic imaging , comprising:a nanocomposite particle having a core effective to enhance response to incident transient ultrasonic pressure waves and at least two layers disposed around the core, said two layers comprising:a first inner layer comprising at least one compound effective to absorb incident transient optical energy, convert absorbed optical energy into heat, wherein said compound significantly thermally expands or converts thermal energy into acoustic pressure or both; anda second thermally insulating outer layer comprising at least one compound effective to insulate the inner layer from a surrounding aqueous environment, wherein the design of the nanocomposite particle enhances generation of transient ultrasonic pressure waves during optoacoustic-ultrasonic imaging.2. The dual contrast agent of claim 1 , wherein the nanocomposite particle comprises at least two layers claim 1 , the contrast agent further comprising a thin bonding layer ...

Подробнее
20-03-2014 дата публикации

CARBON NANOTUBES FOR IMAGING AND DRUG DELIVERY

Номер: US20140079630A1

The invention provides compositions and methods for visualizing particular tissues and delivering one or more therapeutics to that tissue using single-walled carbon nanotubes (SWNTs), which are taken up and delivered to target tissues by specific monocytes in the body. The delivery of SWNT to target tissues allows the visualization of the affected tissue for diagnostics and therapy in diseases where the specific monocyte is implicated in the disease pathogenesis. These nanotubes can be conjugated to a peptide, such as RGD, which helps direct the SWNT-containing monocytes to the vascular endothelium. 1. A composition for locating one or more tumors in a mammalian subject including a human subject , wherein the mammalian subject comprises monocytes selected from Ly-6Cmonocytes or CD14 monocytes , and wherein the composition comprises single walled carbon nanotubes (SWNTs) for delivery to the mammalian subject.2. The composition of claim 1 , wherein the SWNTs comprise one or more peptides.3. The composition of claim 1 , wherein the SWNTs comprise PEG and wherein the one or more peptides are attached to said PEG.4. The composition of claim 1 , wherein the SWNTs comprise one or more labels for detection.5. The composition of claim 1 , wherein locating one or more tumors utilizes one or more from the group consisting of fluorescence-based intravital imaging claim 1 , Raman imaging claim 1 , photoacoustic imaging claim 1 , near-infrared imaging claim 1 , radiation imaging claim 1 , positron emission tomography imaging claim 1 , computer axial tomography imaging and X-ray imaging.6. A composition for delivering a therapeutic to one or more tumors in a mammalian subject including a human subject claim 1 , wherein the mammalian subject comprises monocytes selected from Ly-6Cmonocytes or CD14 monocytes claim 1 , and wherein the composition comprises SWNTs claim 1 , and the SWNTs comprise one or more therapeutics for delivery to the tumor.7. The composition of claim 6 , wherein ...

Подробнее
07-01-2021 дата публикации

COMPOSITION AND METHODS FOR SENSITIVE MOLECULAR ANALYSIS

Номер: US20210000448A1
Принадлежит:

A method for ascertaining the presence of target-bound microbubbles in the context of ultrasound molecular imaging is taught. This method, referred to herein as dynamic scaling ultrasound molecular imaging, relies upon the time-varying behavior contrast agents within a region expressing a molecular imaging target and that within a reference region. Ultrasound contrast agents compositions that enable use of the method are also taught. The method is useful for the use of ultrasound molecular imaging in diagnosing and monitoring treatment. 128.-. (canceled)29. A method for quantifying magnitude of a contrast signal within a region of interest (ROI) , the method comprises administering to a target tissue of a subject a targeted contrast agent to image presence of one or more targeted molecular markers of disease; selecting a reference region representative of the amount of contrast agent circulating within the blood pool in a dynamic , time-varying manner; imaging said target tissue including the selected reference region; determining the magnitude quantitatively of an area of disease by said dynamic scaling , time-varying manner procedure wherein said targeted contrast agent is configured to be bound to said one or more molecular markers of disease expressed within the diseased region.30. The method of claim 29 , wherein said dynamic scaling claim 29 , time-varying manner procedure comprisesa. providing a time series of images depicting a single field of view,b. selecting one or more regions of interest and one or more corresponding reference regions,c. forming a reference-scaled image, and/or a reference-scaled signal magnitude in which the region of interest and reference region are obtained at the same instant in the time series,d. performing the scaling operation of (c) on two or more images in the time series to determine the time-intensity relationship of the reference-scaled signal magnitude quantitatively; wherein the reference-scaled signal increases in the ...

Подробнее
07-01-2021 дата публикации

PREPARATION OF SIZE-CONTROLLED MICROVESICLES

Номер: US20210000984A1
Принадлежит: Bracco Suisse SA

A method for preparing a suspension of “size-controlled” gas-filled microvesicles by microfluidic manufacturing techniques, which comprises using a gaseous flow comprising a first gas having high solubility in water and a second gas having low 5 solubility in water. 1. A method for preparing a suspension of gas-filled microvesicles which comprises:providing (i) a gaseous flow and (ii) an aqueous liquid flow comprising an amphiphilic microvesicle-stabilizing material;directing said gaseous flow and said liquid flow through respective inlet channels towards a contact zone;directing said gaseous flow and said liquid flow from the contact zone through a calibrated orifice to obtain an aqueous suspension comprising said gas-filled microvesicles; and 'wherein said gaseous flow comprises a first gas and a second gas, said first gas having high solubility in water and said second gas being a biocompatible fluorinated gas having low solubility in water, the volume percentage of said second gas in said gaseous flow being of from 18% to 2%.', 'directing said suspension comprising said microvesicles towards an outlet channel;'}2. The method according to wherein claim 1 , the volume percentage of said first gas in said gaseous flow is of 15% or lower.3. The method according to wherein claim 1 , the volume percentage of said first gas in said gaseous flow is of 13% or lower.4. The method according to wherein the volume percentage of said second gas is of at least 5%.5. The method according to wherein said first gas has a solubility in water (defined as Bunsen Coefficient “α”) higher than 0.01.6. The method according to wherein said first gas has a solubility in water higher than 0.5.7. The method according to wherein said second gas has a solubility in water (defined as Bunsen Coefficient “α”) of 0.008 or lower.8. The method according to wherein said second gas has a solubility in water of 0.001 or lower.9. The method according to wherein said second gas is a perfluorinated gas. ...

Подробнее
07-01-2021 дата публикации

Gel for Acoustic Coupler, Method for Producing the Same, and Ultrasonic Imaging Method

Номер: US20210000985A1
Принадлежит:

To provide an acoustic coupler capable of achieving both acoustic characteristics and mechanical characteristics required for ultrasonic imaging. The invention provides a hydrogel preparation method in which a plurality of kinds of polymerizations are performed under reduced pressure, and a gel for an acoustic coupler obtained by the preparation method. For example, a gel for an acoustic coupler includes polyacrylamide having a matrix structure and alginic acid, and the alginic acid is retained in a matrix of the matrix structure of the polyacrylamide. 1. A gel for an acoustic coupler to be disposed between a subject and a probe that transmits an ultrasonic wave , the gel for an acoustic coupler comprising:polyacrylamide having a matrix structure; andalginic acid, whereinthe alginic acid is retained in a matrix of the matrix structure of the polyacrylamide.2. The gel for an acoustic coupler according to claim 1 , whereinthe alginic acid retained in the matrix is crosslinked via an ion to form matrix-shaped alginic acid.3. The gel for an acoustic coupler according to claim 1 , whereina total concentration of the polyacrylamide and the alginic acid in the gel (hereinafter, a concentration (%) in the gel is expressed as a percentage of weight (unit: g)/volume (unit: ml) of the gel) is more than 3% and less than 5%.4. The gel for an acoustic coupler according to claim 3 , whereinthe total concentration of the polyacrylamide and the alginic acid in the gel is 3.5% or more and 4.5% or less.5. The gel for an acoustic coupler according to claim 3 , whereina relative concentration of the polyacrylamide to the total concentration of the polyacrylamide and the alginic acid in the gel is more than 60% and less than 100%.6. The gel for an acoustic coupler according to claim 5 , whereinthe relative concentration of the polyacrylamide to the total concentration of the polyacrylamide and the alginic acid in the gel is 65% or more and 90% or less.7. The gel for an acoustic coupler ...

Подробнее
07-01-2021 дата публикации

INCLUSION COMPLEXES SUITABLE FOR USE AS A HISTOTRIPSY AGENT

Номер: US20210000986A1
Принадлежит:

Disclosed are inclusion complexes suitable for use as histotripsy agents, the methods used in the preparation of the inclusion complexes, and the use of the complexes as histotripsy agents or for drug delivery. 1. Host-guest inclusion complexes comprising beta-cyclodextrin or methylated beta-cyclodextrin as a host molecule and perfluorohexane or perfluoropentane as a guest molecule.2. Inclusion complex according to claim 1 , characterized in that the host molecule is beta-cyclodextrin.3. (canceled)4. The inclusion complex according to claim 1 , characterized in that the guest molecule is perfluorohexane.5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. An inclusion complex according to claim 1 , characterized in that said complex is a methylated beta-cyclodextrin and a perfluorohexane host-guest inclusion complex.10. An inclusion complex according to claim 1 , characterized in that it is modified with a targeting agent.11. An inclusion complex according to claim 10 , wherein the targeting agent is selected from a group comprising antibodies claim 10 , antibody fragments claim 10 , or various peptides.12. A method for preparing an inclusion complex according to claim 1 , characterized in that said method comprises the steps of:a. dissolving the host molecule in a suitable solvent;b. cooling of the obtained solution to a certain temperature;c. addition of perfluorohexane or perfluoropentane into the cooled solution;d. obtaining an host molecule perfluorohexane or perfluoropentane inclusion complex by separating the solid and liquid parts of the formed precipitate and drying the solid portion.13. A method for preparing an inclusion complex according to claim 12 , characterized in that said method comprises the steps of:a. dissolution of beta-cyclodextrin in a suitable solvent;b. cooling of the obtained solution to a certain temperature;c. adding perfluorohexane to the cooled solution;d. obtaining a betacyclodextrin-perfluorohexane inclusion complex by separating ...

Подробнее
07-01-2016 дата публикации

PHOSPHOLIPID COMPOSITION AND MICROBUBBLES AND EMULSIONS FORMED USING SAME

Номер: US20160000943A1
Принадлежит:

A composition for stabilizing a fluorocarbon emulsion. That composition includes phosphatidylcholine, phosphatidylethanolamine-PEG, and a cone-shaped lipid. 1. A composition for stabilizing a fluorocarbon emulsion , comprising:phosphatidylcholine;phosphatidylethanolamine-PEG; anda cone-shaped lipid.2. The composition of claim 1 , wherein said cone shaped lipid is selected from the group consisting of monogalactosyldiacylglycerol (MGDG) claim 1 , monoglucosyldiacylglycerol (MGDG) claim 1 , diphosphatidylglycerol (DPG) claim 1 , phosphatidylethanolamine (PE) and diacylglycerol.3. The composition of claim 2 , wherein said neutral cone-shaped lipid comprises phosphatidylethanolamine.4. The composition of claim 3 , wherein said phosphatidylethanolamine comprises between about 5 and about 20 mole percent of the formulation.5. The composition of claim 3 , where in said phosphatidylethanolamine comprises about 10 mole percent of the formulation.6. The composition of claim 2 , comprising:between about 75 to about 85 mole percent phosphatidylcholine;between about 5 to about 15 mole percent phosphatidylethanolamine-PEG; andbetween about 5 and about 15 mole percent phosphatidylethanolamine.7. The composition of claim 2 , comprising:about 82 mole percent phosphatidylcholine;about 8 mole percent phosphatidylethanolamine-PEG; andabout 10 mole percent phosphatidylethanolamine.8. The composition of claim 7 , comprising:about 82 mole percent DPPC;about 8 mole percent DPPE-PEG(5,000); andabout 10 mole percent DPPE.9. The composition of claim 1 , wherein said phosphatidylcholine claim 1 , said phosphatidylethanolamine-PEG claim 1 , and said cone-shaped lipid comprise an aggregate concentration from about 0.1 mg/ml to about 100 mg/ml.10. The composition of claim 1 , wherein said phosphatidylcholine claim 1 , said phosphatidylethanolamine-PEG claim 1 , and said cone-shaped lipid claim 1 , comprise an aggregate concentration from about 0.75 mg/ml to about 5 mg/ml.11. The composition of ...

Подробнее
02-01-2020 дата публикации

PER-ORAL NEGATIVE CONTRAST AGENT FOR ABDOMINAL CT

Номер: US20200000942A1
Принадлежит:

An edible negative contrast agent for CT imaging of the gastrointestinal tract intended for oral intake. The contrast agent is a fluid, aqueous foam displaying a CT density contrast value in the range −300 to −800 HU and having a consistency of 7 to 12 cm as measured with Bostwick consistometer. The contrast agent comprises an aqueous continuous liquid phase having a pH of 6.5 to 8.0 and gas bubbles dispersed in the continuous aqueous liquid phase. The aqueous continuous liquid phase comprises a surfactant, the surfactant being a protein, a hydrocolloid acting as foam stabilizer, a buffering agent, and water. 1. An edible negative contrast agent for CT imaging of the gastrointestinal tract intended for oral intake , the contrast agent being a fluid , aqueous foam displaying a CT density contrast value in the range −300 to −800 HU , wherein the contrast agent comprises an aqueous continuous liquid phase having a pH of 6.5 to 8.0 , the aqueous continuous liquid phase comprising:a surfactant, the surfactant being a protein;a hydrocolloid acting as foam stabilizer;a buffering agent; andwater;and gas bubbles dispersed in the continuous aqueous liquid phase, the contrast agent having a consistency of 7 to 12 cm as measured with Bostwick consistometer over 30 seconds at 23±1° C.2. The edible negative contrast agent according to claim 1 , wherein the gas bubbles dispersed in the continuous aqueous liquid phase are air bubbles.3. The edible negative contrast agent according to or claim 1 , wherein the surfactant comprises ovalbumin.4. The edible negative contrast agent according to any one of the to claim 1 , wherein the contrast agent comprises at least 35 vol % dispersed air bubbles claim 1 , such as more than 50 vol % dispersed air bubbles.5. The edible negative contrast agent according to any one of the to claim 1 , wherein the contrast agent comprises 30 to 70 vol % dispersed air bubbles at 25° C. claim 1 , such as between 35 and 55 vol % dispersed air bubbles at 25° C. ...

Подробнее
02-01-2020 дата публикации

METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS

Номер: US20200000943A1
Принадлежит: Lantheus Medical Imaging, Inc.

Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use. 1128-. (canceled)129. A method of using lipid-encapsulated gas microspheres for ultrasound imaging comprising:placing a vial comprising an ultrasound contrast agent (UCA) lipid formulation in a shaking device comprising a holder, a detector and a processor;determining identity of the UCA lipid formulation as either a non-aqueous UCA lipid formulation or an aqueous UCA lipid formulation based on an indicator on the vial that is read by the detector;selecting a shaking rate and duration from pre-set options for non-aqueous and aqueous formulations using the processor;activating the identified UCA lipid formulation to form lipid-encapsulated gas microspheres, by imparting a shaking pattern at the selected shaking rate and for the selected duration, using the shaking device;administering the lipid-encapsulated gas microspheres to a subject; andobtaining an ultrasound image of the subject;wherein the aqueous UCA lipid formulation comprises DPPA, DPPC and MPEG5000-DPPE in an aqueous solvent, and a gas,wherein the non-aqueous UCA lipid formulation comprises DPPA, DPPC and MPEG5000-DPPE in a non-aqueous solvent comprising propylene glycol and glycerol, and a gas, and having less than 5% water (w/w),wherein the detector is an RFID reader, a barcode scanner, a color scanner, or a microchip reader, andwherein the pre-set options comprise a shaking duration of at least 30 seconds.130. The method of claim 129 , wherein one pre-set option comprises a shaking duration of about 45 seconds and a shaking rate of at least 4000 shaking motions per minute.131. The method of claim 129 , wherein the shaking device comprises two or more holders.132. A method of using lipid-encapsulated gas microspheres for ultrasound imaging comprising:placing a vial comprising an ultrasound contrast agent (UCA) lipid ...

Подробнее
02-01-2020 дата публикации

MOLECULAR IMAGING CONTRAST AGENTS AND USES THEREOF

Номер: US20200000944A1
Принадлежит: Trust-Biosonics, Inc.

Compositions and methods for molecular imaging of selectins are disclosed. Specifically, compositions comprising medical imaging contrast-producing agents associated with the extracellular domain of TIM-1 as a targeting ligand for use in molecular imaging of selectins are disclosed. Also, methods of using the extracellular domain of TIM-1 as a ligand for achieving specific targeting to selectins as therapeutic drug delivery vehicles is also disclosed. 133.-. (canceled)34. A method of imaging a living subject comprising:a. administering to a subject a composition comprising a contrast-producing agent associated with a targeting ligand, wherein said targeting ligand comprises the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 3 in a physiologically acceptable carrier;b. allowing sufficient time for said composition to accumulate at a target site in the subject; andc. imaging the subject using a diagnostic imaging modality.35. The method of wherein the diagnostic imaging modality is ultrasound.36. The method of wherein the time allowed for the composition to accumulate at the target site is between 1-60 minutes.37. The method of claim 34 , wherein the sequence further comprises a fusion protein comprising a terminal cysteine.38. The method of claim 34 , wherein the contrast-producing agent is an ultrasound contrast agent.39. The method of claim 34 , wherein the sequence further comprises a fusion protein comprising human Fc.40. The method of claim 34 , wherein the contrast-producing agent is an ultrasound contrast agent.41. The method of claim 40 , wherein the ultrasound contrast-producing agent comprises gas-filled microbubbles and the targeting ligand is attached to said microbubbles by means of a covalent chemical bond.42. The method of claim 34 , wherein the contrast-producing agent is an Mill contrast agent claim 34 , a SPECT contrast agent claim 34 , a PET contrast agent claim 34 , or an optical imaging contrast agent.43. The method of wherein the ...

Подробнее
02-01-2020 дата публикации

Gas-Encapsulated Acoustically Responsive Stabilized Microbubbles and Methods for Treating Cardiovascular Disease

Номер: US20200000945A1
Принадлежит:

Acoustically responsive stabilized microbubbles formulated with a phospholipid monolayer shell, an encapsulated bioactive gas, and an encapsulated perfluorocarbon gas of the formula CFin a volume ratio of from about 10:1 to about 1:10, wherein X is greater than or equal to 3, are disclosed. Also provided are methods for promoting localized vasodilation in a patient in need thereof by delivering a microbubble comprising a phospholipid monolayer shell and an encapsulated bioactive gas locally to a target diseased section of the patient's vasculature; and releasing the bioactive gas at the target diseased section, wherein the microbubble comprises the bioactive gas in a ratio of from about 10:1 to about 1:10 by volume with a perfluorocarbon gas. 2. The method according to claim 1 , wherein the ratio is about 10:1.3. The method according to claim 1 , wherein the bioactive gas is selected from the group consisting of nitric oxide claim 1 , xenon claim 1 , and hydrogen sulfide.4. The method according to claim 1 , wherein delivering locally comprises administering the microbubble comprising the bioactive gas to the patient at a site remote from the target diseased section; and administering acoustic energy to the target diseased section claim 1 , thereby releasing a therapeutically effective amount of the bioactive gas from the microbubble to the target diseased section for a clinically relevant time frame.5. The method according to claim 4 , further comprising monitoring for presence of the administered microbubble at the target diseased section prior to administering acoustic energy to the target diseased section claim 4 , wherein acoustic energy is administered upon detection of presence of the administered microbubble.6. The method according to claim 1 , wherein the perfluorocarbon has the formula CFand X is greater than or equal to three.7. The method according to claim 6 , wherein X=3 and Y=8.8. The method according to claim 1 , wherein the phospholipid monolayer ...

Подробнее
04-01-2018 дата публикации

APPARATUS FOR MASS PRODUCING A MONODISPERSE MICROBUBBLE AGENT

Номер: US20180001282A1
Принадлежит:

An apparatus for mass producing monodisperse microbubbles includes a microfluidic flow focusing device, which includes a dispersed phase fluid supply channel having an outlet that discharges into a flow focusing junction, a continuous phase fluid supply channel having an outlet that discharges into the flow focusing junction, and a bubble formation channel having an inlet disposed at the flow focusing junction. The configuration of the flow focusing junction is such that, in operation, a flow of dispersed phase fluid discharging from the outlet of the dispersed phase fluid supply channel is engageable in co-flow by a focusing flow of continuous phase fluid discharging from the outlet of the at least one continuous phase fluid supply channel under formation of a gradually thinning jet of dispersed phase fluid that extends into the inlet of the bubble formation channel. 1. An apparatus for mass producing monodisperse microbubbles , comprising: a dispersed phase fluid supply channel having an outlet that discharges into a flow focusing junction;', 'at least one continuous phase fluid supply channel having an outlet that discharges into the flow focusing junction; and', 'a bubble formation channel having an inlet disposed at the flow focusing junction,, 'at least one microfluidic flow focusing device including 'wherein said bubble formation channel has a length that is much greater than its hydraulic diameter by a factor of at least ten.', 'the configuration of the flow focusing junction being such that, in operation, a flow of dispersed phase fluid discharging from the outlet of the dispersed phase fluid supply channel is engageable in co-flow by a focusing flow of continuous phase fluid discharging from the outlet of the at least one continuous phase fluid supply channel under formation of a gradually thinning jet of dispersed phase fluid that extends into the inlet of the bubble formation channel,'}2. The apparatus according to claim 1 , further comprising:a source ...

Подробнее
01-01-2015 дата публикации

Methods and Systems for Coupling and Focusing Acoustic Energy Using a Coupler Member

Номер: US20150005638A1
Принадлежит: GUIDED THERAPY SYSTEMS, LLC

An exemplary system for coupling acoustic energy using an encapsulated coupler member comprises a display or indicator, a control system, a probe, and a coupler member. This invention provides a coupler member adjustably configured to perform at least one of (i) providing a standoff, (ii) focusing or defocusing energy, and (iii) coupling energy. An exemplary gel coupler member is configured to hold the shape of a lens geometry. In one aspect of the present invention, gel coupler member comprises water, glycerol, and polyvinyl alcohol, and exhibits an increased desiccation time and shelf life when compared to the prior art. The probe can comprise various probe and/or transducer configurations. In an exemplary embodiment, the probe delivers focused, unfocused, and/or defocused ultrasound energy to the region of interest. Imaging and/or monitoring may alternatively be coupled and/or co-housed with an ultrasound system contemplated by the present invention. 1. A system for coupling acoustic energy to a region of interest comprising:a substantially acoustically transparent gel coupler member comprising a shape of a lens geometry and said gel coupler member is a solid;a control system configured for control of said system;a probe configured for attachment to said gel coupler member and comprising a transducer configured to emit acoustic energy through said shape of said lens geometry; anda display system in communication with said control system and said probe.2. The system according to claim 1 , wherein said gel coupler member is further configured to provide a standoff.3. The system according to claim 1 , wherein said gel coupler member is comprised of:water in an amount of from about 30% to about 50% percent mass, an organic solvent in an amount of from about 40% to about 60% percent mass, and polyvinyl alcohol in an amount of from about 2% to about 20% percent mass.4. The system according to claim 3 , wherein said organic solvent is glycerol.5. The system according to ...

Подробнее
11-01-2018 дата публикации

TARGETED GAS-FILLED MICROVESICLES FORMULATION

Номер: US20180008731A1
Принадлежит: BRACCO SUISSE S.A.

Suspension of gas-filled microvesicles comprising a targeting ligand for binding to KDR or VEGF/KDR complex. The suspension is obtained by reconstituting a freeze-dried residue with a carbohydrate-containing solution in the presence of a physiologically acceptable gas and is stabilized by the presence of histidine. 1. An aqueous suspension of gas-filled microvesicles , said gas-filled microvesicles comprising a phospholipid and a targeting ligand comprising a peptide having an amino acid sequence selected from AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO: 01) , VCWEDSWGGEVCFRYDPGGGK (SEQ ID NO: 02) or a combination thereof , said aqueous suspension further comprising a carbohydrate and a histidine.2. The aqueous suspension according to wherein said targeting ligand is in a form of a dimeric peptide comprising a combination of SEQ ID NO: 01 and SEQ ID NO: 02.3. The aqueous suspension according to claim 1 , wherein said carbohydrate is a glucose.4. The aqueous suspension according to claim 1 , wherein said phospholipid is selected from the group consisting of dilauroyl-phosphatidyl-choline (DLPC) claim 1 , dimyristoyl-phosphatidylcholine (DMPC) claim 1 , dipalmitoyl-phosphatidyl-choline (DPPC) claim 1 , diarachidoyl-phosphatidylcholine (DAPC) claim 1 , distearoyl-phosphatidyl-choline (DSPC) claim 1 , dioleoyl-phosphatidylcholine (DOPC) claim 1 , 1 claim 1 ,2 Distearoyl-sn-glycero-3-ethylphosphocholine (Ethyl-DSPC) claim 1 , dipentadecanoyl-phosphatidylcholine (DPDPC) claim 1 , 1-myristoyl-2-palmitoyl-phosphatidylcholine (MPPC) claim 1 , 1-palmitoyl-2-myristoyl-phosphatidylcholine (PMPC) claim 1 , 1-palmitoyl-2-stearoyl-phosphatidylcholine (PSPC) claim 1 , 1-stearoyl-2-palmitoyl-phosphatidylcholine (SPPC) claim 1 , 1-palmitoyl-2-oleyl-phosphatidyl-choline (POPC) claim 1 , 1-oleyl-2-palmitoyl-phosphatidylcholine (OPPC) claim 1 , dilauroyl-phosphatidylglycerol (DLPG) and its alkali metal salts claim 1 , diarachidoylphosphatidyl-glycerol (DAPG) and its alkali metal salts claim 1 , ...

Подробнее
11-01-2018 дата публикации

METHODS FOR MAKING ULTRASOUND CONTRAST AGENTS

Номер: US20180008732A1
Принадлежит:

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations. 116-. (canceled)17. A method for preparing lipid-encapsulated gas microspheres comprisingcombining DPPA, DPPC and MPEG5000-DPPE, in propylene glycol to form a phospholipid solution, the MPEG5000-DPPE selected as having a calcium concentration of less than 115 parts per million (ppm),combining the phospholipid solution with an aqueous solution to form a phospholipid suspension, andactivating the phospholipid suspension with a perfluorocarbon gas to form lipid-encapsulated gas microspheres.1819-. (canceled)20. The method of claim 17 , wherein DPPA claim 17 , DPPC and MPEG-5000-DPPE are present in a mole % ratio of 10 to 82 to 8 (10:82:8).21. The method of claim 17 , wherein calcium concentration of DPPA is less than 780 ppm claim 17 , calcium concentration of DPPC is less than 90 ppm claim 17 , and calcium concentration of propylene glycol is less than 0.7 ppm.2224-. (canceled)25. A method for preparing lipid-encapsulated gas microspheres comprisingcombining DPPA, DPPC and MPEG5000-DPPE in propylene glycol, in a methanol and toluene free and methyl t-butyl ether free condition, to form a phospholipid solution, wherein MPEG5000-DPPC has a calcium concentration of less than 115 parts per million (ppm),combining the phospholipid solution with an aqueous solution to form a phospholipid suspension, andactivating the phospholipid suspension with a perfluorocarbon gas, to form lipid-encapsulated gas microspheres.26. The method of claim 25 , wherein DPPA claim 25 , DPPC and MPEG-5000-DPPE are present in a mole % ratio of 10 to 82 to 8 (10:82:8).27. The method of claim 25 , wherein calcium concentration of DPPA is less than 780 ppm claim 25 , calcium concentration of DPPC is less than 90 ppm claim 25 , and calcium concentration of propylene glycol is less than 0.7 ppm.2830-. (canceled)31. The method of claim 17 , wherein the phospholipid solution has a calcium ...

Подробнее
14-01-2021 дата публикации

TARGETED PHOTOACOUSTIC AGENTS AND USES THEREOF

Номер: US20210008229A1
Принадлежит:

The present application relates to photoacoustic agents, to kits comprising such photoacoustic agents and to uses thereof such as in methods for detecting a presence of a target in a subject. The photoacoustic agents comprise a photoacoustically active moiety (for example, a near infrared dye) that is coupled to a first bioorthogonal reactive group and optionally a targeting entity for a target that is coupled to a second bioorthogonal reactive group. 1. A photoacoustic agent comprising a photoacoustically active moiety coupled to a first bioorthogonal reactive group.2. The photoacoustic agent of claim 1 , wherein the photoacoustically active moiety is selected from a gold nanoparticle claim 1 , a carbon nanomaterial claim 1 , a polymer nanoparticle claim 1 , a genetically encoded chromophore and a near infrared (NIR) dye.3. The photoacoustic agent of claim 2 , wherein the photoacoustically active moiety is a NIR dye.4. The photoacoustic agent of claim 3 , wherein the NIR dye is capable of binding a blood protein.7. The photoacoustic agent of claim 1 , wherein the photoacoustic agent further comprises a targeting entity for a target.8. The photoacoustic agent of claim 7 , wherein the targeting entity is coupled to a second bioorthogonal reactive group that is complementary to the first bioorthogonal reactive group and the first bioorthogonal reactive group and the second bioorthogonal reactive group form a bioorthogonal complex.9. The photoacoustic agent of claim 8 , wherein the first bioorthogonal reactive group and the second bioorthogonal reactive group claim 8 , in either order claim 8 , are inverse electron demand Diels Alder reaction pairs claim 8 , or an azide and a functionalized phosphine claim 8 , or an azide and a strained alkyne.10. The photoacoustic agent of claim 9 , wherein the first bioorthogonal reactive group and the second bioorthogonal reactive group claim 9 , in either order claim 9 , are tetrazine and transcyclooctene.11. The photoacoustic ...

Подробнее
14-01-2021 дата публикации

TARGETED MICROBUBBLE, PREPARATION METHOD THEREOF, AND USE THEREOF

Номер: US20210008230A1
Автор: Sun Qiquan
Принадлежит:

The invention provides a targeted microbubble comprising a microbubble composed of a shell and a gas encapsulated in the shell, the shell is conjugated with a C4d antibody or a C3d antibody. The targeted microbubble of the present invention is employed as contrast agent for the ultrasonic imaging of C4d or C3d deposited in renal and cardiac allografts. The occurrence of antibody-mediated rejection (AMR) can be accurately diagnosed via qualitative and quantitative analysis. 1. A targeted microbubble , characterized in that the targeted microbubble comprises a microbubble composed of a shell and a gas encapsulated in the shell , the shell is conjugated with a C4d antibody or a C3d antibody.2. The targeted microbubble according to claim 1 , characterized in that the shell is coated with streptavidin claim 1 , the C4d antibody is a biotin-labeled antibody.3. The targeted microbubble according to claim 1 , characterized in that a surface of the shell is coated with streptavidin claim 1 , the C3d antibody is a biotin-labeled antibody.4. The targeted microbubbles according to claim 1 , characterized in that the C4d antibody or the C3d antibody is a fluorescence-labeled antibody.5. The targeted microbubble according to claim 1 , characterized in that a diameter of the targeted microbubble is 1 μm to 10 μm.6. The targeted microbubble according to claim 1 , characterized in that the shell comprises at least one selected from the group consisting of a phospholipid claim 1 , a protein claim 1 , a lipid claim 1 , and a polymers; the gas comprises at least one selected from the group consisting of perfluorocarbon claim 1 , nitrogen claim 1 , octafluoropropane claim 1 , and sulfur hexafluoride.7. A method for preparing the targeted microbubble according to claim 2 , characterized in that the method comprises mixing and incubating a microbubble with a biotin-labeled C4d antibody or a biotin-labeled C3d antibody to obtain the targeted microbubble; the microbubble comprises a shell ...

Подробнее
27-01-2022 дата публикации

FIBRIN-TARGETED POLYMERIZED SHELL LIPID MICROBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS

Номер: US20220023447A1
Принадлежит:

Fibrin-targeted microbubbles and their use in ultrasound-based diagnostic and therapeutic applications are disclosed. In particular, the invention relates to the use of fibrin-targeted polymerized shell lipid microbubbles and methods of fabricating and using such fibrin-targeted microbubbles for ultrasound imaging of fibrin deposition in tissue, including adhesions and atherosclerotic plaques. The invention further relates to the use of such fibrin-targeted microbubbles as carriers for drug delivery and in ultrasound-based methods of treatment. 1. A fibrin-targeted microbubble comprising:a) a polymerized lipid shell;b) a fibrin-targeting agent, wherein the fibrin-targeting agent is conjugated to the polymerized lipid shell; andc) a gas core comprising at least one gas, wherein the gas core is encased within the polymerized lipid shell.2. The fibrin-targeted microbubble of claim 1 , wherein the polymerized lipid shell comprises at least one polymerizable lipid and at least one non-polymerizable lipid.3. The fibrin-targeted microbubble of claim 2 , wherein the polymerized lipid shell comprises at least about 5% polymerizable lipid.4. The fibrin-targeted microbubble of claim 3 , wherein the polymerizable lipid ranges from about 5 to 50% of the total lipid in the polymerized lipid shell.5. The fibrin-targeted microbubble of claim 1 , wherein at least one non-polymerizable or at least one polymerizable lipid is PEGylated.6. The fibrin-targeted microbubble of claim 5 , wherein PEGylated lipid ranges from about 5% to about 50% of the total lipid in the polymerized lipid shell.7. The fibrin-targeted microbubble of claim 2 , wherein the non-polymerizable lipid is 1 claim 2 ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) claim 2 , 1 claim 2 ,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DSPE-PEG2000) claim 2 , or DSPE-PEG2000-biotin.8. The fibrin-targeted microbubble of claim 2 , wherein the polymerizable lipid is a diacetylenic lipid.9. ...

Подробнее
11-01-2018 дата публикации

System and Method for Controlled Manufacturing of Mono-Disperse Microbubbles

Номер: US20180008951A1
Принадлежит:

The present invention is related to a system and method for controlled manufacturing of mono-disperse microbubbles. According to the invention, the mono-disperse nature of the collection of generated microbubbles can be improved by releasing the pressurized gaseous medium used in the system using release valve units. This further allows the system to be embodied as a portable system. In turn, the operator of an ultrasound imaging apparatus may use the system according to the invention to generate microbubbles on a patient-by-patient basis. 1. A system for controlled manufacturing of microbubbles , comprising:a microbubble generation unit having a first inlet for receiving a dispersed phase fluid, a second inlet for receiving a continuous phase fluid, and a bubble formation channel in which microbubbles are generated using the received dispersed phase fluid and the received continuous phase fluid, wherein the bubble formation channel has a width in the range of 15-35 micrometer, and a height in the range of 10-30 micrometer;a liquid pressurization unit having an inlet for receiving a second pressure regulated gaseous medium from a source of said second pressure regulated gaseous medium and being configured for outputting a flow of a pressurized liquid to the second inlet of the microbubble generation unit in dependence of a flow and/or pressure of the received second pressure regulated gaseous medium, wherein the first inlet of the microbubble generation unit is connected to a source of a first pressure regulated gaseous medium;a first release valve unit arranged in between the source of the first pressure regulated gaseous medium and the first inlet of the microbubble generation unit and being configured for releasing the first pressure regulated gaseous medium;a second release valve unit arranged in between the source of the second pressure regulated gaseous medium and the inlet of the liquid pressurization unit and being configured for releasing the second ...

Подробнее
10-01-2019 дата публикации

Voltage-Activated Therapeutic, Diagnostic, And/Or Theranostic Constructs

Номер: US20190008987A1
Принадлежит:

The present invention provides constructs that can be used for delivering therapeutic and/or diagnostic agents to a subject's tissue or organ. In certain embodiments, the invention provides a doubly ultrasound-voltage-activated imaging agent. In other embodiments, the invention provides methods of selectively imaging a portion of a subject's body. 1. A construct comprising a liposome comprising a nesting shell , wherein the nesting shell encloses an inner compartment comprising an inner core liquid and at least one liquid droplet , wherein the at least one liquid droplet is insoluble in the inner core liquid.2. The construct of claim 1 , which is more acoustically active in the presence of an electric field than in the absence of an electric field.3. The construct of claim 2 , wherein the at least one liquid droplet comprises an echogenic agent claim 2 , which (a) is devoid of acoustic activity when the construct is subjected to ultrasound in the absence of an electric field claim 2 , and which has acoustic activity when the construct is subjected to ultrasound in the presence of an electric field claim 2 , or (b) has higher acoustic activity when the construct is subjected to ultrasound in the presence of an electric field as compared to in the absence of an electric field.4. The construct of claim 1 , wherein the inner compartment further comprises a therapeutic claim 1 , diagnostic claim 1 , or theranostic agent claim 1 , which crosses the nesting shell at a higher rate in the presence of an electric field than in the absence of an electric field.5. The construct of claim 1 , wherein the at least one liquid droplet comprises a perfluorocarbon.6. The construct of claim 5 , wherein the at least one liquid droplet is selected from the group consisting of perfluoropropane claim 5 , perfluorobutane claim 5 , perfluoropentane claim 5 , perfluorohexane claim 5 , and any mixtures thereof7. The construct of claim 1 , wherein the at least one liquid droplet is coated with ...

Подробнее
09-01-2020 дата публикации

Inverting Device for Liposome Preparation by Centrifugation

Номер: US20200009052A1
Принадлежит:

Methods and devices for producing a population of liposomes are provided. Aspects of the methods include applying a centrifugal force to a suspension of liposomes in a manner sufficient to pass the liposomes through a porous membrane to produce a population of liposomes. Aspects of the invention further include devices, systems and kits useful for performing the methods. 1. A liposome extrusion device comprising:a porous membrane; anda component configured to position the membrane between a first liquid container and a second liquid container, wherein, when the component is attached to the first liquid container and the second liquid container, an interior of the component is sealed from the surrounding atmosphere.2. The device according to claim 1 , further comprising the first liquid container.3. The device according to claim 2 , wherein the first liquid container comprises a centrifuge tube.4. The device according to claim 1 , further comprising the second liquid container.5. The device according to claim 4 , wherein the second liquid container comprises a centrifuge tube.6. The device according to claim 1 , wherein the membrane is positioned between a first end of the component and a second end of the component.7. The device according to claim 1 , wherein the component comprises a first subcomponent and a second subcomponent removably attached to the first subcomponent.8. The device according to claim 7 , wherein the membrane is positioned at an interface between the first subcomponent and the second subcomponent.91000. The device according to claim 1 , wherein the membrane has a pore size of nm or less.10. The device according to claim 1 , wherein the membrane comprises two or more layers of a membrane material.11. A method for producing a uniform population of liposomes claim 1 , the method comprising: a first liquid container;', 'a second liquid container in fluid communication with the first liquid container;', 'a porous membrane; and', 'a component ...

Подробнее
09-01-2020 дата публикации

STIMULI-RESPONSIVE PARTICLES ENCAPSULATING A GAS AND METHODS OF USE

Номер: US20200009065A1
Принадлежит: CHILDREN'S MEDICAL CENTER CORPORATION

Provided herein are various gas-filled particles having a stimuli-responsive shell encapsulating the gas. The stimuli-responsive shell comprises one or more release triggers. Compositions for medical or non-medical applications, methods of use and treatment, and methods of preparation are also described. 1. A composition comprisinga stable particle having a shell surrounding a gas core, wherein the shell includes a release trigger.2. The composition of claim 1 , wherein the shell comprises nanoparticle aggregates.3. The composition of claim 2 , wherein the stable particle is formed by nanoprecipitation of an amphiphilic polymer comprising the release trigger at an air/liquid interface to form the shell.4. The composition of claim 3 , wherein the amphiphilic polymer comprises acetylated dextran (Dex-Ac).5. The composition of claim 1 , wherein the stable particle is a Pickering foam.6. The composition of any one of - claim 1 , wherein the release trigger is a pH-responsive trigger.7. The composition of any one of - claim 1 , wherein the release trigger is a salt-responsive trigger.8. The composition of any one of - claim 1 , wherein the release trigger is a pressure-responsive trigger.9. The composition of any one of - claim 1 , wherein the release trigger is a temperature-responsive trigger.10. The composition of any one of - claim 1 , wherein the release trigger is a light-responsive trigger.11. The composition of any one of - claim 1 , wherein the release trigger is an ultrasound-responsive trigger.12. The composition of any one of - claim 1 , wherein the release trigger is a magnetic field-responsive trigger.13. The composition of any one of - claim 1 , wherein the release trigger is partial pressure of a gas in a fluid.14. The composition of any one of - claim 1 , wherein the release trigger is stable in water.15. The composition of any one of - claim 1 , wherein the shell comprises a biocompatible polymer or monomer.16. The composition of claim 15 , wherein the ...

Подробнее
09-01-2020 дата публикации

HYDROPORPHYRINS FOR PHOTOACOUSTIC IMAGING

Номер: US20200009272A1
Принадлежит: NIRvana Sciences Inc.

Provided are photoacoustic imaging contrast agents that include at least one radiation-absorbing component comprising a bacteriochlorin, a metallobacteriochlorin, a derivative thereof, or a combination thereof. Also provided are methods for using the disclosed photoacoustic imaging contrast agents either singly or in combination for generating an image of a volume, optionally a subject or a body part, cell, tissue, or organ thereof. Further provided are compositions and methods for multiplex photoacoustic imaging of a volume, optionally a subject or a body part, cell, tissue, or organ thereof using photoacoustic imaging contrast agents that include a plurality of the presently disclosed bacteriochlorins, metallobacteriochlorins, and/or derivatives thereof simultaneously. 1. A photoacoustic imaging contrast agent comprising at least one radiation-absorbing component comprising a bacteriochlorin , a metallobacteriochlorin , a derivative thereof , or a combination thereof.2. The photoacoustic imaging contrast agent of claim 1 , comprising a plurality of different bacteriochlorins claim 1 , metallobacteriochlorins claim 1 , derivatives thereof claim 1 , or combinations thereof claim 1 , each bacteriochlorin claim 1 , metallobacteriochlorin claim 1 , or derivative having a different absorption spectrum in the range of 650-1070 nm.3. The photoacoustic imaging contrast agent of claim 2 , wherein:the photoacoustic imaging contrast agent comprises at least three different bacteriochlorins, metallobacteriochlorins, or derivatives thereof;(ii) each bacteriochlorin, metallobacteriochlorin, or derivative thereof has an absorption spectrum with a peak absorption value in the range of 700-950 nm; and(iii) the at least three absorption spectra are substantially non-overlapping in the range of 700-950 nm.4. The photoacoustic imaging contrast agent of claim 1 , wherein the metallobacteriochlorin comprises a metal selected from the group consisting of nickel claim 1 , iron claim 1 , ...

Подробнее
11-01-2018 дата публикации

CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING

Номер: US20180009763A1
Принадлежит: Lantheus Medical Imaging, Inc.

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging. 125-. (canceled)27. A composition , comprising:{'claim-ref': {'@idref': 'CLM-00026', 'claim 26'}, 'the compound of and a solvent.'}29. A composition comprising:{'claim-ref': {'@idref': 'CLM-00028', 'claim 28'}, 'the compound of and a solvent.'}31. The precursor compound of claim 30 , wherein the precursor compound is provided in a solution.32. The precursor compound of claim 30 , wherein the precursor compound is provided as a solid preparation.33. The precursor compound of claim 32 , wherein the solid preparation is a lyophilized solid. The present application claims the benefit of priority under 35 U.S.C. §119(e) from the provisional application 60/544,861 filed Feb. 13, 2004, the contents of which are herein incorporated by reference.The present disclosure relates to novel compounds comprising imaging moieties, and their use for diagnosing certain disorders in a patient.Mitochondria are membrane-enclosed organelles distributed through the cytosol of most eukaryotic cells. Mitochondria are especially concentrated in myocardium tissue.Complex 1 (“MC-1”) is a membrane-bound protein complex of 46 dissimilar subunits. This enzyme complex is one of three energy-transducing complexes that constitute the respiratory chain in mammalian mitochondria. This NADH-ubiquinone oxidoreductase is the point of entry for the majority of electrons that traverse the respiratory chain, eventually resulting in the reduction of oxygen to water (1992, 25, 253-324).Known inhibitors of MC-1 include deguelin, piericidin A, ubicidin-3, rolliniastatin-1, rolliniastatin-2 (bullatacin), capsaicin, pyridaben, fenpyroximate, amytal, MPP+, quinolines, and quinolones (1998, 1364, 222-235).The present disclosure is based, in ...

Подробнее
19-01-2017 дата публикации

IN-VIVO INTRAVASCULAR BLOOD REPLACING LIQUID, IN-VIVO INTRAVASCULAR BLOOD REPLACING LIQUID FORMULATION, AND PREFILLED SYRINGE

Номер: US20170014535A1
Принадлежит: TERUMO KABUSHIKI KAISHA

An in-vivo intravascular blood replacing liquid of the present invention is injected into a blood vessel to replace blood at an intravascular portion to be inspected therewith in making an in-vivo intravascular inspection. The blood replacing liquid comprises an aqueous medium unharmful for a living body and a gelling property imparting substance, unharmful for the living body, which is added to the aqueous medium to impart a gelling property to the blood replacing liquid. The blood replacing liquid has a viscosity of not more than 3 mPa·s when the blood replacing liquid is injected into the blood vessel. 1. An in-vivo intravascular blood replacing liquid injected into a blood vessel to replace blood at an in-vivo intravascular portion to be inspected therewith in making an in-vivo intravascular inspection ,wherein said blood replacing liquid comprises an aqueous medium unharmful for a living body and a gelling property imparting substance, unharmful for said living body, which is added to said aqueous medium to impart a gelling property to said blood replacing liquid; and said blood replacing liquid has a viscosity of not more than 3 mPa·s when said blood replacing liquid is injected into said blood vessel.2. An in-vivo intravascular blood replacing liquid according to claim 1 , wherein said aqueous medium is sterile water claim 1 , saline or a buffer solution.3. An in-vivo intravascular blood replacing liquid claim 1 , according to claim 1 , wherein said blood replacing liquid has a viscosity of not more than 3 mPa·s at not more than 30 degrees C. and displays a gelling property at not less than 25 degrees C.4. An in-vivo intravascular blood replacing liquid according to claim 1 , wherein said gelling property imparting substance is a mucoperiosteum claim 1 , a polysaccharide thickener claim 1 , or a compound having a phosphate group claim 1 , a carboxylic acid group or a sulfate group; and said gelling property imparting substance includes glycyrrhizin acid claim ...

Подробнее
21-01-2016 дата публикации

ASSEMBLY COMPRISING AN ABSORBER OF NEAR INFRARED (NIR) LIGHT COVALENTLY LINKED TO AN INHIBITOR OF CARBONIC ANHYDRASE

Номер: US20160015661A1
Принадлежит: CONSIGLIO NAZIONALE DELLE RICERCHE

An assembly comprising an absorber of near infrared (NIR) light having an optical absorption cross section not lower than 100 nm2 covalently linked to an inhibitor of carbonic anhydrase (CA), process for its preparation and its use to hyperthermally target tumours or for treating other conditions in which the CA activity is involved is disclosed.

Подробнее
17-01-2019 дата публикации

VISCOSITY AND STABILITY MODIFIED ULTRASOUND GEL

Номер: US20190015529A1
Принадлежит:

An ultrasound gel is provided for use with internal ultrasound imaging and/or therapy. The gel can have acoustic properties that can closely match a soft tissue to be imaged/treated and can be of a high viscosity that is maintained at body temperature. In some embodiments, the gel can act as a lubricant and, although water based, can be hydrophobic and not dissolve in bodily fluids. In some embodiments, the gel can be sterile, safe for ingestion, safe for application over mucous membranes, and include a preservative. In order to achieve sterility while maintaining a desired viscosity range, the gel can include a viscosity stabilising agent such as a viscosity protection agent for protection from radiation induced breakdown. In some embodiments, methods of altering or maintaining the viscosity of a gel is provided. 1. An internal gel comprising:water;a thickening agent for thickening the water into a gel;a neutralizer for setting the gel viscosity and adjusting a pH level of the gel;a viscosity agent for reducing changes of gel viscosity due to radiation exposure; anda preservative for preserving the gel;wherein the gel has an acoustic impedance similar to soft tissue and can be safely used internally or orally.2. The gel of wherein i claim 1 , the viscosity agent comprises nanoparticles.3. The gel of wherein in the viscosity agent comprises CNC.4. The gel of wherein the viscosity agent comprises glycerin.5. The gel of wherein the thickening agent comprises a carbomer.6. (canceled)7. The gel of wherein the carbomer comprises carbomer homopolymer Type B.8. The gel of wherein the neutralizer comprises a base selected from the group consisting of potassium hydroxide claim 1 , sodium hydroxide claim 1 , and triethanolamine.9. The gel of wherein the pH level of the gel is between 5.8 and 6.4.10. The gel of wherein the preservative comprises a food grade preservative.11. The gel of wherein the preservative comprises potassium sorbate.12. The gel of further comprising a ...

Подробнее
16-01-2020 дата публикации

Near infrared absorbing dye-based composite particles exhibiting photothermal effect, method for manufacturing the same, and use thereof

Номер: US20200016269A1

The present invention relates to near-infrared-absorbing dye-based composite particles which exhibit a photothermal effect and/or photoacoustic signal upon photoirradiation, a preparation method thereof, and a use thereof. The near-infrared-absorbing composite particles comprise: a water-insoluble salt of a near-infrared-absorbing dye, which comprises anions of the near-infrared-absorbing dye and metal cations capable of forming a precipitation product with the anions of the near-infrared-absorbing dye; and particles of a polymeric surfactant, in which a water-insoluble salt of the near-infrared-absorbing dye is supported in the hydrophobic part of the polymeric surfactant.

Подробнее
26-01-2017 дата публикации

System and method for image guided magnetic trap controlled delivery of a mixture of bacteria and non-bacteria linked nanoparticles

Номер: US20170021041A1
Принадлежит: Siemens Medical Solutions USA Inc

A computer-implemented method for image-guided delivery of a nanoparticle mixture to a target tumor located in a region of interest includes selecting a non-hypoxic delivery location within the region of interest for delivery of a non-bacteria-associated nanoparticle component included in the nanoparticle mixture and selecting a hypoxic delivery location within the region of interest for delivery of a bacteria-associated nanoparticle component included in the nanoparticle mixture. An image-guided delivery and monitoring process may then be performed. During this process intra-operative images of the region of interest are continually acquired and used to guide placement of a device into the non-hypoxic delivery location, monitor delivery of the non-bacteria-associated nanoparticle component included in the nanoparticle mixture at the non-hypoxic delivery location, guide placement of the device into the hypoxic delivery location, and monitor delivery of the bacteria-associated nanoparticle component included in the nanoparticle mixture at the hypoxic delivery location.

Подробнее
25-01-2018 дата публикации

ULTRASOUND AND MICROBUBBLES IN OCULAR DIAGNOSTICS AND THERAPIES

Номер: US20180021557A1
Принадлежит:

The present disclosure described methods, systems, and techniques for applying contrast-enhanced ultrasound to locate areas of blockage within retinal vessels and to break up clots that are causing damage. In addition to identifying the damaged area, the researchers anticipate that the initial image may serve as a baseline for monitoring the effect of treatment on the vessel, which may be achieved in multiple ways. The vibration effect of the ultrasound itself may suffice to dislodge clots. The microbubbles may also be coated or filled with medication, with ultrasonic shock waves activating the coating or causing mini explosions to release the medicine. Loading the microbubbles with a therapeutic agent, visualizing their presence at the diseased site using the ultrasound diagnostic mode, and then activating the microbubbles to release their contents at the targeted lesion could be a powerful and effective way to reverse occlusion without harming other areas of the eye or body. 1. A method of treating blood vessel blockage , comprising:applying ultrasound energy to locate one or more areas of blockage within one or more blood vessels;directing microbubbles to an area of blockage; andbreaking up clots that are causing damage within the one or more areas of blockage.238-. (canceled) This application is a continuation-in-part of related U.S. patent application Ser. No. 12/061,147 filed 2 Apr. 2008 and entitled “Preoperative and Intra-Operative Lens Hardness Measurement by Ultrasound,” which claims the benefit of U.S. Provisional Patent Application No. 60/909,496 filed 2 Apr. 2007; this application also is a continuation-in-part of U.S. patent application Ser. No. 12/061,120 filed 2 Apr. 2008 and entitled “Thrombolysis In Retinal Vessels with Ultrasound,” which claims the benefit of U.S. Provisional Patent Application No. 60/911,385 filed 12 Apr. 2007; this application is a continuation-in-part of U.S. patent application Ser. No. 12/102,293 filed 14 Apr. 2008 and ...

Подробнее
22-01-2015 дата публикации

PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND

Номер: US20150023880A1
Принадлежит: Lantheus Medical Imaging, Inc.

The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent. 144-. (canceled)45. A method comprisingusing an ultrasound contrast agent to enhance contrast in an echocardiographic ultrasound image of a subject, wherein the ultrasound contrast agent comprises1,2-dipalmitoyl-sn-glycero-3-phosphotidic acid, mono sodium salt (DPPA), 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), and N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt (MPEG5000-DPPE), present in a mole ratio of 10% to 82% to 8%, and in an amount of about 0.75 mg/mL;sodium chloride;glycerin, present in an amount of about 0.1 mL/mL;propylene glycol, present in an amount of about 0.1 mL/mL;water, andperfluoropropane. The present invention relates generally to processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.Manufacturing of a phospholipid contrast agent can be divided into the following steps: (1) preparation of lipid blend; (2) compounding the bulk solution, which involves the hydration and dispersion of the lipid blend in an essentially aqueous medium to produce a lipid suspension; (3) filtration of the bulk solution through a sterilizing filter(s) to render the suspension free of microbial contaminants; (4) dispensing the sterile suspension into individual vials in a controlled aseptic area; (5) loading the dispensed vials into a lyophilizer chamber to replace the vial headspace gas with perfluoropropane gas (PFP); (6) transferring the sealed vials after gas exchange to an autoclave for terminal sterilization. There are three major obstacles in this process: (1) uniformity of the lipid blend; (2) hydration of the lipid blend; (3) uniformity ...

Подробнее
22-01-2015 дата публикации

CONTRAST AGENT FOR COMBINED PHOTOACOUSTIC AND ULTRASOUND IMAGING

Номер: US20150023881A1
Принадлежит:

A microbubble is used as a multi-modality contrast agent for photoacoustic imaging and ultrasound imaging. A method of preparing improved microbubbles that are used as a multi-modality contrast agent for photoacoustic imaging and ultrasound imaging is provided. The microbubble includes a dye-colored lipid shell; and a filling gas filling the inside of the lipid shell. The method of preparing microbubbles includes agitating a dye-colored lipid-containing solution in the presence of filling gas. 1. A microbubble comprising:a lipid shell colored with dye; andfilling gas filling the inside of the lipid shell.2. The microbubble of claim 1 , wherein the dye absorbs incident light having a wavelength of about 500 nm to about 1 claim 1 ,300 nm.3. The microbubble of claim 1 , wherein the dye is azure blue claim 1 , evans blue claim 1 , indocyanine green claim 1 , brilliant blue claim 1 , nile blu claim 1 , methylene blu claim 1 , or a combination thereof.4. The microbubble of claim 1 , wherein a concentration of the dye in a dye solution used to hydrate the lipid shell is in a range of about 0.5 mM to about 20 mM.5. The microbubble of claim 1 , wherein a concentration of the dye in a dye solution used to hydrate the lipid shell is 15 mM.6. The microbubble of claim 1 , wherein the dye is methylene blue claim 1 , and a concentration of the dye in a dye solution used to hydrate the lipid shell is in a range of about 0.5 mM to about 20 mM.7. The microbubble of claim 1 , wherein the dye is methylene blue claim 1 , and a concentration of the dye in a dye solution used to hydrate the lipid shell is 15 mM.8. The microbubble of claim 1 , wherein the lipid shell comprises phospholipid.9. The microbubble of claim 8 , wherein the phospholipid comprises 1 claim 8 ,2-dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA); 1 claim 8 ,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC); 1 claim 8 ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); 1 claim 8 ,2-dimyristoyl-sn-glycero-3- ...

Подробнее
24-01-2019 дата публикации

GOLD NANOPARTICLES AND ECOLOGICAL METHOD OF PRODUCTION

Номер: US20190022234A1
Автор: Morel Anne-Laure
Принадлежит:

A method of preparing biocompatible and stable gold nanoparticles comprises preparing at least one flavonoid-rich plant extract, and mixing at least one of the plant extracts with an aqueous solution of at least one gold salt. The flavonoid-rich plant extract is an extract of or . The gold nanoparticles may be used for medical and/or cosmetic purposes. 1. A method of preparing biocompatible and stable gold nanoparticle , comprising:preparing at least one flavonoid-rich plant extract; andmixing at least one of the plant extracts with an aqueous solution of at least one gold salt,{'i': Hubertia ambavilla', 'Hypericum lanceolatum., 'wherein the flavonoid-rich plant extract is an extract of or'}2. The method according to claim 1 , wherein the flavonoid-rich plant extract is a total crude extract of the plant or the flavonoids of the plant.3. The method of claim 1 , wherein the plant extract comprises flavonoids selected from among rutin claim 1 , quercetin claim 1 , hyperoside and isoquercetin or a combination of at least two thereof.4. The method of claim 1 , wherein the nanoparticles have a diameter of between 5 and 100 nm.5. The method of claim 1 , wherein the nanoparticles are spherical claim 1 , and the nanoparticles are obtained by mixing plant flavonoids with an aqueous solution of at least one gold salt.6. The method of claim 1 , wherein the nanoparticles are anisotropic and flower-shaped claim 1 , and the flower-shaped gold nanoparticles are obtained by mixing a total crude plant extract with an aqueous solution of at least one gold salt.7Hubertia ambavillaHypericum lanceolatum.. An anisotropic flower-shaped gold nanoparticle comprising a mixture of gold and crude extract of or8. The nanoparticle of claim 7 , wherein the diameter of the nanoparticle is between 40 nm and 80 nm when measured by transmission electron microscopy.9. The nanoparticle of claim 7 , wherein the nanoparticle is functionalized by proteins.10. A medicinal product comprising a nanoparticle ...

Подробнее
24-01-2019 дата публикации

Systems, Methods, and Devices for Production of Gas-Filled Microbubbles

Номер: US20190022617A1

Gas-filled microbubbles can be synthesized using a continuous flow chamber and a sonicator. The resulting microbubble solution can be size-sorted for a particular application, such as injection into a patient for gas delivery thereto. The microbubble solution may be concentrated to have greater than 50% volume gas while maintaining microbubble sizes below 10 μm. Control of the microbubble generation process can yield highly stable microbubbles. The microbubbles may retain over half of their original gas payload for over three weeks while exhibiting minimal change in microbubble size. The systems, methods, and devices described herein thus allow for continuous or batch-wise continuous production of gas-filled microbubbles that readily release their gas payload when introduced into an under-saturated or de-saturated solution. 1. A method for generating microbubbles , comprising:flowing a lipid solution at a first flow rate into a reaction volume of a continuous flow chamber, the reaction volume having an end of a sonicator member located therein;flowing gas at a first pressure into the reaction volume at a same time as the flowing a lipid solution;ultrasonically agitating an interface between the lipid solution and the gas in the reaction volume using said sonicator member so as to generate a solution of gas-filled microbubbles; andduring the ultrasonically agitating, adjusting at least the first pressure based on a location of the interface in the reaction volume with respect to the end of the sonicator member,ensuring the lipid solution ultrasonically agitated is saturated with a core gas to a level between 50% and 90%, inclusive, during the ultrasonically agitating.2. The method of claim 1 , further comprising claim 1 , after the ultrasonically agitating claim 1 , sorting the generated microbubbles responsively to size.3. The method of claim 1 , further comprising claim 1 , after the ultrasonically agitating claim 1 , sorting the generated microbubbles responsively ...

Подробнее
22-01-2015 дата публикации

APPARATUS AND METHOD FOR COMBINED PHOTOACOUSTIC AND ULTRASOUND DIAGNOSIS

Номер: US20150025373A1
Принадлежит:

A microbubble used as a contrast agent for ultrasound imaging burst due to high intensity of ultrasound, and the burst microbubble effectively acts as a contrast agent for photoacoustic imaging. Based on this point, a new apparatus and method for combined photoacoustic and ultrasound diagnosis are provided. 1. A combined photoacoustic and ultrasound diagnosis method , comprising operations of:(a) transmitting a first ultrasound signal having a low mechanical index to a subject to which a contrast agent having microbubbles has been administered, detecting an echo signal generated due to reflection of the first ultrasound signal by the microbubbles, and displaying an ultrasound image produced based on the echo signal;(b) transmitting a second ultrasound signal having a high mechanical index to the subject to burst the microbubbles to form microbubble flakes; and(c) irradiating the subject with a laser signal, detecting a photoacoustic signal generated due to the microbubble flakes stimulated by the laser signal, and then, displaying a photoacoustic image produced based on the photoacoustic signal.2. The combined photoacoustic and ultrasound diagnosis method of claim 1 , wherein the first ultrasound signal has a low mechanical index of less than about 0.5.3. The combined photoacoustic and ultrasound diagnosis method of claim 1 , wherein the microbubbles contain a drug that is to be delivered to an organ in the subject.4. The combined photoacoustic and ultrasound diagnosis method of claim 1 , wherein the second ultrasound signal has a high mechanical index of about 0.5 to about 1.9.5. The combined photoacoustic and ultrasound diagnosis method of claim 1 , wherein the microbubbles contain a drug that is to be delivered to an organ in the subject claim 1 , and the operation (b) begins when arriving of the microbubbles at the organ is confirmed.6. The combined photoacoustic and ultrasound diagnosis method of claim 1 , wherein the operation (c) begins when or after the ...

Подробнее
28-01-2021 дата публикации

Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods ofpreparing and using the same

Номер: US20210023015A1

Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

Подробнее
04-02-2016 дата публикации

DETECTION OF ACUTE RENAL ALLOGRAFT REJECTION

Номер: US20160030603A1
Принадлежит:

The invention provides a method of detecting acute renal allograft rejection in a subject as well as a method of stratifying a subject received a renal allograft and undergoing immunosuppressive therapy for alteration of the therapy. These methods comprise administering to the subject a probe capable of specifically binding to T lymphocytes, the probe being detectable by ultrasound. An allotransplanted kidney of the subject is exposed to ultrasound. The level of T lymphocytes in the kidney is detected. An elevated level of T lymphocytes in the kidney indicates an increased risk of renal allograft rejection and/or that the subject is in need of an alteration of the immunosuppressive therapy. 2. The method of claim 1 , wherein the probe has a binding molecule coupled thereto claim 1 , wherein the binding molecule is specific for T lymphocytes.3. The method of claim 1 , wherein the probe is a nanoparticle or a microvesicle.4. The method of claim 2 , wherein the binding molecule is specific for a molecule or a moiety present on T lymphocytes.5. The method of claim 4 , wherein the molecule present on T lymphocytes is one of CD3 claim 4 , CD4 claim 4 , CD8 claim 4 , CD154 claim 4 , CTLA-4 and CD62L.6. The method of claim 4 , wherein the binding molecule is an immunoglobulin or a proteinaceous binding molecule with immunoglobulin-like functions specific for the molecule or the moiety present on T lymphocytes.7. The method of claim 1 , wherein detecting the level of T lymphocytes in the kidney is carried out by means of an imaging technique.8. The method of claim 1 , wherein detecting the level of T lymphocytes in the kidney comprises comparing the detected level of T lymphocytes to a threshold value.9. The method of claim 8 , wherein the threshold value is based on the level of T lymphocytes in a homologous kidney of the subject.10. The method of claim 8 , wherein the threshold value is based on the level of T lymphocytes in a homologous kidney of a control subject.11. The ...

Подробнее
01-02-2018 дата публикации

GAS-FILLED STRUCTURES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS TO IMAGE A TARGET SITE

Номер: US20180028693A1
Принадлежит:

Gas vesicles, protein variants and related compositions methods and systems for singleplexed and/or multiplexed ultrasound imaging of a target site in which a gas vesicle provides contrast for the imaging which is modifiable by application of a selectable acoustic collapse pressure value of the gas vesicle. 1. An ultrasound imaging method to be used on a target site contrasted with a gas vesicle protein structure (GVPS) type having a selectable acoustic collapse pressure value derived from an acoustic collapse pressure profile of the GVPS type and a hydrostatic collapse pressure profile , a midpoint of the acoustic collapse pressure profile higher than a midpoint of the hydrostatic collapse pressure profile , the method comprisingcollapsing the GVPS type by applying collapsing ultrasound to the target site, the collapsing ultrasound applied at a collapsing ultrasound pressure greater than the selectable acoustic collapse pressure value; andimaging the target site by applying imaging ultrasound to the target site, the imaging ultrasound applied at a first imaging ultrasound pressure selected to provide an uncontrasted image of the target site.2. The ultrasound imaging method of claim 1 , wherein the collapsing ultrasound pressure is higher than the midpoint of the hydrostatic collapse pressure profile.3. The ultrasound imaging method of claim 1 , wherein the collapsing ultrasound pressure is higher than the midpoint of the acoustic collapse pressure profile.4. The ultrasound imaging method of claim 1 , further comprisingfurther imaging the target site prior to the collapsing by applying imaging ultrasound to the target site, the imaging ultrasound applied at a second imaging ultrasound pressure lower than the selectable acoustic collapse pressure and selected to provide a visible image; andcomparing the visible image of the target site with the uncontrasted image.5. The ultrasound imaging method of claim 4 , wherein the first imaging ultrasound pressure is equal to ...

Подробнее
02-02-2017 дата публикации

ABSCOPAL EFFECT OF USPIO THERANOSIS AND IMMUNOTHERAPY FOR CANCER TREATMENT

Номер: US20170029491A1
Автор: Wolf Gerald Lee
Принадлежит:

The invention disclosed herein concerns abscopal effect of USPIO theranosis and immunotherapy using the same for cancer treatment. 1. An abscopal method of treating macrophage-dependent cancer in a subject in need thereof , the method comprising administering a cancer recognition agent (CRA) into a thermally ablated cancer of the subject , or an adjacent draining lymphatics thereof.2. The method of claim 1 , wherein the cancer recognition agent is a cytokine claim 1 , an adjuvant claim 1 , a vaccine claim 1 , a monoclonal antibody claim 1 , or a non-virulent infectious agent.36-. (canceled)7. The method of claim 1 , wherein the CRA is administered such that tumor debris resulting from thermal ablation and the CRA are substantially simultaneously presented to APCs (antigen presenting cells) and/or Dendritic cells locally claim 1 , or within the regional lymph node chain.8. The method of claim 1 , wherein the CRA is locally administered claim 1 , either intratumorally or in close proximity interstitially.9. The method of claim 2 , wherein the CRA is not heat sensitive claim 2 , and is administered intra- or peri-tumorally just before enhanced hyperthermia.10. The method of claim 2 , wherein the CRA is heat sensitive claim 2 , and is given in the appropriate location after the tumor has sufficiently cooled after thermal ablation.11. The method of claim 1 , wherein the CRA is administered before claim 1 , immediately after claim 1 , or repeatedly after thermal ablation.12. The method of claim 1 , wherein more than one CRAs is administered.13. The method of claim 12 , wherein different CRAs are administered simultaneously claim 12 , concurrently claim 12 , or sequentially claim 12 , or in rotation for repeated administration.14. The method of claim 1 , wherein an immunologic response is mounted in the subject against one or more cancers at locations other than the thermally ablated cancer.15. The method of claim 1 , wherein tumor burden is reduced in the subject after ...

Подробнее
04-02-2016 дата публикации

CUPREDOXIN DERIVED TRANSPORT AGENTS AND METHODS OF USE THEREOF

Номер: US20160031947A1
Принадлежит:

The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer. 1. A peptide , consisting of a sequence that has at least about 90% amino acid sequence identity to less than a fill-length wild-type cupredoxin or H.8 outer membrane protein , and which facilitates the entry of a linked molecule into a mammalian cancer cell.2. The peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of azurin claim 1 , plastocyanin claim 1 , rusticyanin claim 1 , pseudoazurin claim 1 , auracyanin and azurin-like protein.3Pseudomonas aeruginosa, Phormidium laminosum, Thiobacillus ferrooxidans, Achromobacter cycloclastes, Pseudomonas syringa, Neisseria meningitidis, Vibrio parahaemolyticus, Bordetella bronchiseptica, Bordetella pertussis, Chloroflexus aurantiacusNeisseria gonorrhoeae.. The peptide of claim 1 , wherein the peptide is derived from a organism selected from the group consisting of and4. The peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of SEQ ID NO: 1 claim 1 , SEQ ID NO: 2 claim 1 , SEQ ID NO: 3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID NO: 29 claim 1 , SEQ ID NO: 30 claim 1 , SEQ ID NO: 31 claim 1 , SEQ ID NO: 32 claim 1 , SEQ ID NO: 33 claim 1 , SEQ ID NO: 34 claim 1 , SEQ ID NO: 36 and SEQ ID NO: 43.5. The peptide of claim 1 , which is at least about 10 residues and not more than about 50 residues in length.6. The peptide of claim 1 , comprising a sequence which has at least about 90% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID NO: 5 claim 1 , SEQ ID NO: 6 claim 1 , SEQ ID NO: 7 claim 1 , SEQ ID NO: 9 claim 1 , SEQ ID NO: 37 claim 1 , SEQ ID NO: 38 claim 1 , SEQ ID NO: 39 claim 1 , SEQ ID NO: 40 claim 1 , SEQ ID NO: 41 claim 1 , ...

Подробнее
29-01-2015 дата публикации

SEMICONDUCTING POLYMER NANOPARTICLES AS PHOTOACOUSTIC MOLECULAR IMAGING PROBES

Номер: US20150031996A1
Принадлежит:

Provided are nanoparticles comprising an organic photovoltaic semiconductor polymer and a phospholipid, the semiconductor polymer being near-infra red absorbing and generating a detectable photoacoustic signal and a fluorescent emission when irradiated by an incident activation energy. Also provided are methods of molecular imaging, comprising delivering to a subject a plurality of said nanoparticles, irradiating the subject with a first incident energy to generate a first photoacoustic signal, irradiating the subject with a second incident energy to generate a second photoacoustic signal, determining a ratio of the intensities of the two photoacoustic signals, comparing this first ratio with a second ratio determined from the nanoparticles before delivery to the subject, whereby a difference in said first and second ratios indicates ROS degradation of the nanoparticles in the subject; and generating a ratiometric image indicating the difference in said first and second ratios relative to an image of the subject. 1. A nanoparticle comprising an organic photovoltaic semiconductor polymer and a phospholipid , wherein the semiconductor polymer is near-infra red absorbing and generates a detectable photoacoustic signal and a fluorescent emission when irradiated by an incident activation energy.2. The nanoparticle of claim 1 , wherein the organic photovoltaic semiconductor polymer is selected from the group consisting of: poly(cyclopentadithiophene-alt-benzothiadiazole) (PCPDTBT) claim 1 , poly(acenaphthothienopyrazine-alt-benzodithiophene) (PATPBDT) claim 1 , poly[4 claim 1 ,6-(dodecyl-thieno[3 claim 1 ,4-b]thiophene-2-carboxylate)-alt-2 claim 1 ,6-(4 claim 1 ,8-dioctoxylbenzo[1 claim 1 ,2-b:4 claim 1 ,5-b]dit claim 1 , poly[N-90-heptadecanyl-2 claim 1 ,7carbazole-alt-3 claim 1 ,6-bis(thiophen-5-yl)-2 claim 1 ,5-dioctyl-2 claim 1 ,5-dihydropyrrolo[3 claim 1 ,4]pyrrole-1 claim 1 ,4-dione] claim 1 , poly{4 claim 1 ,8-bis[(2-ethylhexyl)oxy]benzo[1 claim 1 ,2-b:4 claim 1 ,5 ...

Подробнее
31-01-2019 дата публикации

A WEARABLE SENSOR, AND METHOD, TO MONITOR ANTI-COAGULATION THERAPY

Номер: US20190029637A1
Принадлежит:

Systems and methods disclosed provide a device that effectively replaces the aPTT test. Chemical sensors are employed that bind to heparin and produce an acoustic signal. The acoustic signal is then used to monitor anti-coagulation therapy, instead of drawing blood, as in the aPTT test. Other quantities of interest can also be measured and monitored. 1. A device for noninvasively monitoring therapy , comprising:a. a source of photoacoustically active dye, the dye photoacoustically active at least when bonded to a quantity of interest;b. an ultrasound photoacoustic imager configured to detect the level of the quantity of interest, the quantity of interest having been bonded to the dye,c. such that the level of the quantity of interest in a patient undergoing therapy can be determined and maintained within a therapeutic range.2. The device of claim 1 , wherein the quantity of interest is heparin.3. The device of claim 2 , wherein the dye is a charged species that interacts with heparin.4. The device of claim 3 , wherein the charged species that interacts with heparin is a type of methylene blue.5. The device of claim 3 , wherein the dye is a phenothiazinium species selected from the group consisting of: toluidine blue claim 3 , phenothiazinium dye claim 3 , methyl methylene blue claim 3 , dimethyl methylene blue claim 3 , azure B claim 3 , azure C claim 3 , thionin claim 3 , methylene violet claim 3 , and combinations of the above.6. The device of claim 3 , further comprising a source of protamine sulfate claim 3 , such that if the level of heparin is determined to exceed the therapeutic range claim 3 , the source of protamine sulfate is controlled to deliver protamine sulfate to the patient in a controlled manner.7. The device of claim 1 , wherein the quantity of interest is digoxin or phenytoin.8. The device of claim 1 , wherein the source of dye is a localized region of dye on a catheter.9. The device of claim 8 , wherein the source of dye is localized by disposing ...

Подробнее
01-02-2018 дата публикации

GENETICALLY ENGINEERED GAS VESICLE GENE CLUSTERS, GENETIC CIRCUITS, VECTORS, PROKARYOTIC CELLS, COMPOSITIONS, METHODS AND SYSTEMS FOR CONTRAST-ENHANCED IMAGING

Номер: US20180030501A1
Принадлежит:

Hybrid gas vesicle gene cluster (GVGC) configured for expression in a prokaryotic host are described comprising gas vesicle assembly (GVA) genes native to a GVA prokaryotic species and capable of being expressed in a functional form in the prokaryotic host, and one or more gas vesicle structural (GVS) genes native to one or more GVS prokaryotic species, at least one of the one or more GVS prokaryotic species different from the GVA prokaryotic species, and related gas vesicle reporting (GVR) genetic circuits, genetic, vectors, engineered cells, and related compositions methods and systems to produce GVs, hybrid GVGC and/or image a target site. 2. The hybrid gas vesicle gene cluster (GVGC) of claim 1 , wherein the prokaryotic host is a prokaryote of a same prokaryotic species of the GVA prokaryotic species.3. The hybrid gas vesicle gene cluster (GVGC) of claim 1 , wherein the prokaryotic host is a prokaryote of a prokaryotic species different from the GVA prokaryotic species.4Bacillus Megaterium.. The hybrid gas vesicle gene cluster (GVGC) of claim 1 , wherein the GVA prokaryotic species is5B. megaterium. The hybrid gas vesicle gene cluster (GVGC) of claim 4 , wherein the hybrid GV gene clusters comprise GVA genes GvpR claim 4 , GvpN claim 4 , GvpF claim 4 , GvpG claim 4 , GvpL claim 4 , GvpS claim 4 , GvpK claim 4 , GvpJ claim 4 , GvpT and GvpU.6B. megaterium. The hybrid gas vesicle gene cluster (GVGC) of claim 4 , wherein the hybrid GV gene clusters comprise GVA genes GvpA claim 4 , GvpF claim 4 , GvpG claim 4 , GvpJ claim 4 , GvpL claim 4 , GvpK claim 4 , GvpS claim 4 , GvpU7. The hybrid gas vesicle gene cluster (GVGC) of claim 1 , wherein the prokaryotic host is a Gram-negative bacteria.8E. coliSalmonella.. The hybrid gas vesicle gene cluster (GVGC) of claim 7 , wherein the prokaryotic host is claim 7 , or9Halobacterium.. The hybrid gas vesicle gene cluster (GVGC) of claim 1 , wherein the prokaryotic host is10Anabaena flosaquae.. The hybrid gas vesicle gene ...

Подробнее
04-02-2021 дата публикации

Medical Device with Structured Echogenic Coating Application and Method for Preparing Same

Номер: US20210030397A1
Автор: Lee Sung, Sandven Curry B.
Принадлежит:

An echogenically enhanced medical device is provided. The echogenically enhanced medical device includes a body portion configured to be inserted within human or animal tissue, where the body portion has a first acoustic impedance. The body portion of the medical device further includes at least one structured echogenic portion having a second acoustic impedance. The at least one structured echogenic portion is configured to enhance ultrasonic imaging of the medical device when inserted into a patient. The at least one structured echogenic portion includes at least one of a structured shape and a discontinuous pattern. A method of preparing an echogenically enhanced medical device is further disclosed. 1. An echogenically enhanced medical device comprising:a body portion configured to be inserted within human or animal tissue, the body portion having a first acoustic impedance;wherein the body portion further comprises at least one structured echogenic portion having a second acoustic impedance configured to enhance ultrasonic imaging of the medical device when inserted into a patient,wherein the at least one structured echogenic portion comprises at least one of a structured shape and a discontinuous pattern.2. The echogenically enhanced medical device of claim 1 , wherein the body portion comprises one of: a needle; a catheter; a cannula; a guidewire; an electrical lead; an implantable device; a probe; an implantable fluid delivery port; a breathing tube.3. The echogenically enhanced medical device of claim 1 , wherein the body portion is formed from one or more of metal material claim 1 , plastic material claim 1 , ceramic material claim 1 , and resin-based material.4. The echogenically enhanced medical device of claim 1 , wherein the second acoustic impedance is different from the first acoustic impedance.5. The echogenically enhanced medical device of claim 1 , wherein the at least one echogenic portion is formed from a material that is different from a ...

Подробнее
04-02-2021 дата публикации

BILIRUBIN DERIVATIVE-BASED DIAGNOSTIC AND THERAPEUTIC ULTRASOUND CONTRAST AGENT

Номер: US20210030897A1
Принадлежит:

Provided is a bilirubin derivative-based ultrasound contrast agent for diagnosis and treatment. The fine particles including the bilirubin derivative are sensitive to reactive oxygen species (ROS), bind with hydrophobic drugs, and can effectively chelate metals such as iron oxide nanoparticles. Therefore, the fine particle of the present invention can be used as an ultrasound contrast agent for diagnosis, as a magnetic resonance imaging contrast agent, or as a carrier for hydrophobic drugs or platinum-based drugs. 1. A fine particle , comprising:a core containing a gas; anda shell comprising a bilirubin derivative and surrounding the core.2. The fine particle of claim 1 ,{'sub': 6', '1', '10, 'wherein the gas is selected from the group consisting of air, nitrogen, helium, argon, carbon dioxide, sulfur hexafluoride (SF), and Cto Cperfluorocarbons.'}3. The fine particle of claim 1 ,wherein the bilirubin derivative is a bilirubin conjugated with a hydrophilic molecule.4. The fine particle of claim 3 ,wherein the hydrophilic molecule is selected from the group consisting of dextran, carbodextran, polysaccharide, cyclodextran, pluronic, cellulose, starch, glycogen, carbohydrate, monosaccharide, disaccharide and oligosaccharide, polypeptide, polyphosphazene, polyethylene glycol, PEG, Methoxy polyethylene glycol (methoxy polyethylene glycol, mPEG), polypropylene glycol, polyethylenimine, poly-L-lysine, polyglycolide, polymethyl methacrylate, Polyvinylpyrrolidone, poly(acrylate), poly(acrylamide), poly(vinylester), poly(vinyl alcohol) (poly[vinyl alcohol]), polystyrene, polyoxide, polyelectrolyte, poly(N-vinylpyrrolidone), poly(N-vinyl pyrrolidone), polyvinylamine, poly(beta-hydroxyethyl methacrylate), polyethylene oxide, poly(ethylene oxide-b-propylene oxide), and polylysine.5. The fine particle of claim 1 , further comprising:a metal ion or a metal compound selected from the group consisting of Cu, Ga, Rb, Zr, Y, Tc, In, Ti, Gd, Mn, Fe, Au, Pt, Zn, Na, K, Mg, Ca, Sr, and ...

Подробнее
04-02-2021 дата публикации

Thermally-Modulated Ultrasound Contrast Agents

Номер: US20210030898A1
Принадлежит: PURDUE RESEARCH FOUNDATION

The present disclosure relates to a novel nano-droplet composition comprising a fluorocarbon core and a polymeric shell, and the method of using and making the novel nano-droplet composition. The fluorocarbon core and the polymeric shell of the novel nano-droplet form a micelle with a size range of 10-1000 nm. The fluorocarbon core comprises at least one fluorocarbon compound with a formula of CFand n is 5-10. The fluorocarbon compound is substantial in liquid form. And the nano-droplet composition has a temperature profile such that the nano-droplet composition has a temperature range of 20-60° C. throughout a temperature modulation process, and has a temperature of about 37° C. prior to administration to a human, animal, biological cell, or tissue subject. 1. A nano-droplet composition comprising a fluorocarbon core and a polymeric shell , wherein:the fluorocarbon core and the polymeric shell form a micelle with a size range of 10-1000 nm;{'sub': n', '2n+2, 'the fluorocarbon core comprises at least one fluorocarbon compound with a formula of CFand n is 5-10;'}the fluorocarbon compound is substantial in liquid form; andthe nano-droplet composition has a temperature profile such that the nano-droplet composition has a temperature range of 20-60° C. throughout a temperature modulation process, and has a temperature of about 37° C. prior to administration to a human, animal, biological cell, or tissue subject.2. The composition of claim 1 , wherein the fluorocarbon compound is perfluorohexane (CF).3. The composition of claim 1 , wherein the polymeric shell comprises a biocompatible polymeric material claim 1 , wherein the biocompatible polymeric material may be optionally modified by incorporating various ligands to turn the nano-droplet into a multi-functional agent suitable for targeted diagnostics and therapy.4. The composition of claim 1 , wherein the biocompatible polymeric material comprises synthetic polymers claim 1 , polysaccharides claim 1 , proteins claim 1 ...

Подробнее
05-02-2015 дата публикации

CONTRAST AGENT

Номер: US20150037250A1
Автор: Yamagata Hitoshi
Принадлежит:

According to one embodiment, a contrast agent includes a blood vessel contrast enhancement particles configured to enhance contrast of a blood vessel of an object and a diseased tissue contrast enhancement particles configured to enhance contrast of a diseased tissue of the object. The blood vessel contrast enhancement particles have a first particle size larger than a gap of vascular endothelial cells under an EPR effect. The diseased tissue contrast enhancement particles have a second particle size smaller than the gap. 1. A contrast agent comprising a blood vessel contrast enhancement particle configured to enhance contrast of a blood vessel of an object and a diseased tissue contrast enhancement particle configured to enhance contrast of a diseased tissue of the object , the blood vessel contrast enhancement particle having a first particle size larger than a gap of vascular endothelial cells under an EPR effect , and the diseased tissue contrast enhancement particle having a second particle size smaller than the gap.2. The agent of claim 1 , wherein the blood vessel contrast enhancement particle is chemically modified to be bonded to albumin in the blood vessel.3. The agent of claim 1 , wherein the diseased tissue contrast enhancement particle includes a ligand configured to be specifically bonded to the diseased tissue.4. The agent of claim 3 , wherein the diseased tissue is a cancer cell claim 3 , andthe ligand is configured to be specifically bonded to a protein existing on a surface of the cancer cell or inside the cancer cell.5. The agent of claim 1 , wherein the first particle size is larger than a standard value of a gap between vascular endothelial cells contained in an imaging target blood vessel in which an EPR effect is recognized.6. The agent of claim 1 , wherein the second particle size is smaller than a standard value of a gap between vascular endothelial cells contained in an imaging target blood vessel in which an EPR effect is recognized.7. The ...

Подробнее
05-02-2015 дата публикации

CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING

Номер: US20150037254A1
Принадлежит:

Provided is a particle having a large photoacoustic signal per unit dye, the particle including: one of a hydrophobic metal naphthalocyanine dye and a hydrophobic metal phthalocyanine dye; one of an oil, a fatty acid, and a fatty acid ester as a matrix material; and a surfactant, in which a ratio of the weight of the matrix material to the weight of the particle is 50% or more. 1. A particle comprising:one of a hydrophobic metal naphthalocyanine dye and a hydrophobic metal phthalocyanine dye;one of an oil, a fatty acid, and a fatty acid ester as a matrix material; anda surfactant,wherein a ratio of a weight of the matrix material to a weight of the particle is 50% or more.3. The particle according to claim 1 , wherein one of the hydrophobic metal naphthalocyanine dye and the hydrophobic metal phthalocyanine dye comprises one of silicon 2 claim 1 ,3-naphthalocyanine bis(trihexylsilyloxide) and zinc 2 claim 1 ,9 claim 1 ,16 claim 1 ,23-tetra-tert-butyl-29H claim 1 ,31H-phthalocyanine.4. The particle according to claim 1 , wherein the matrix material comprises one of oleic acid claim 1 , canola oil claim 1 , and cholesterol oleate.5. The particle according to claim 1 , wherein the surfactant comprises a nonionic surfactant.6. The particle according to claim 1 , wherein the surfactant comprises a polyoxyethylene sorbitan-based fatty acid ester.7. The particle according to claim 1 , wherein the surfactant comprises one of Tween 20 and Tween 80.8. A particle comprising:one of a hydrophobic metal naphthalocyanine dye and a hydrophobic metal phthalocyanine dye;a molecule having a higher coefficient of thermal expansion than that of water as a matrix material; anda surfactant,wherein a ratio of a weight of the matrix material to a weight of the particle is 50% or more.9. A particle comprising:one of a hydrophobic metal naphthalocyanine dye and a hydrophobic metal phthalocyanine dye;a molecule having a lower specific heat capacity than that of water as a matrix material; anda ...

Подробнее
05-02-2015 дата публикации

PHTHALOCYANINE DYE-CONTAINING CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING

Номер: US20150037255A1
Принадлежит:

To provide a particle promoting hydrophobic metal phthalocyanine aggregation, having absorption in a wavelength region suitable for a photoacoustic imaging method and having a high molar absorbance coefficient per particle by increasing the weight percentage of the dye in the particle. The particle of the present invention is a particle having a hydrophobic metal phthalocyanine and a surfactant, wherein the weight percentage of the hydrophobic metal phthalocyanine is 6% or more. 1. A contrast agent for photoacoustic imaging , the contrast agent being a particle comprising a hydrophobic metal phthalocyanine and a surfactant , wherein the weight percentage of the hydrophobic metal phthalocyanine in the particle is 6% or more.3. The contrast agent for photoacoustic imaging according to claim 1 , wherein the hydrophobic metal phthalocyanine is zinc 2 claim 1 ,9 claim 1 ,16 claim 1 ,23-tetra-tert-butyl-29H claim 1 ,31H-phthalocyanine.4. The contrast agent for photoacoustic imaging according to claim 1 , wherein the surfactant is a non-ionic surfactant.5. The contrast agent for photoacoustic imaging according to claim 1 , wherein the surfactant is a polyoxyethylene sorbitan fatty acid ester.6. The contrast agent for photoacoustic imaging according to claim 1 , wherein the surfactant is Tween 20 or Tween 80.7. The contrast agent for photoacoustic imaging according to claim 1 , wherein the particle further comprises a matrix material.8. The contrast agent for photoacoustic imaging according to claim 7 , wherein the matrix material is a hydrophobic polymer.9. The contrast agent for photoacoustic imaging according to claim 1 , wherein the particle has a particle diameter of 200 nm or less.10. A contrast agent for photoacoustic imaging claim 1 , comprising the particle according to and a dispersion medium.11. The contrast agent for photoacoustic imaging according to claim 10 , further comprising an additive. 1. Field of the InventionThe present invention relates to a contrast ...

Подробнее
11-02-2016 дата публикации

NANOPARTICLE FABRICATION METHODS, SYSTEMS, AND MATERIALS

Номер: US20160038418A1
Принадлежит:

Nano-particles are molded in nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The nano-particles can include pharmaceutical compositions, taggants, contrast agents, biologic drugs, drug compositions, organic materials, and the like. The molds can be virtually any shape and less than 10 micron in cross-sectional diameter. 1223.-. (canceled)224. A pharmaceutical composition , comprising: a pharmaceutically or therapeutically active agent, wherein said agent is present throughout the particle;', 'wherein each particle of the plurality has a substantially uniform three-dimensional engineered shape having parallel lateral surfaces and parallel top and bottom surfaces in cross-section, wherein;', 'the size of each particle of the plurality is less than about 100 micrometers in a broadest dimension; and', 'further comprising a predetermined negative zeta potential in solution., 'a plurality of particles in a liquid solution wherein each particle of the plurality comprises225. The pharmaceutical composition of claim 224 , further comprising a biocompatible material selected from the group consisting of a poly(ethylene glycol) claim 224 , a poly(lactic acid) claim 224 , a poly(lactic acid-co-glycolic acid) claim 224 , a lactose claim 224 , a phosphatidylcholine claim 224 , a polylactide claim 224 , a polyglycolide claim 224 , a hydroxypropylcellulose claim 224 , a wax claim 224 , a polyester claim 224 , a polyanhydride claim 224 , a polyamide claim 224 , a phosphorous-based polymer claim 224 , a poly(cyanoacrylate) claim 224 , a polyurethane claim 224 , a polyorthoester claim 224 , a polydihydropyran claim 224 , a polyacetal claim 224 , a biodegradable polymer claim 224 , a polypeptide claim 224 , a hydrogel claim 224 , a carbohydrate claim 224 , and combinations thereof.226. The pharmaceutical composition of claim 224 , wherein each of said particles further comprises a diagnostic agent claim 224 , or a linker.227. The pharmaceutical ...

Подробнее
11-02-2016 дата публикации

SACCHARIDE CONJUGATES

Номер: US20160038615A1
Принадлежит:

This invention relates to compounds comprising a saccharide conjugated to an imaging agent or a reporter group, compositions comprising them and methods of using them. Specifically BLM-disaccharide and BLM-monosaccharide conjugates containing different linker groups and an imaging agent or a reporter group are provided for the targeting and imaging of tumors. 3. (canceled)4. The compound according to claim 1 , wherein the first linker is X-(L-Y)-L-Z claim 1 ,{'sub': '2', 'wherein X is CHor O;'}{'sup': '1', 'sub': 2', '6, 'Lis C-Calkyl;'}{'sup': y', 'y, 'sub': 1', '6, 'Y is O, S, or NR, wherein Ris hydrogen or C-Calkyl;'}m is an integer selected from 1 to 10;{'sup': '2', 'sub': 1', '20', '2', '20', '2', '20', '3', '5, 'Lis C-Calkyl, C-Calkenyl, C-Calkynyl, aryl, heteroaryl, heterocyclyl, C-Ccycloalkyl; and'}{'sup': x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x, 'sub': 2', '2', '2', '2, 'Z is absent, O, NR, S, C(O), S(O), S(O), OC(O), N(R)C(O), N(R)S(O), N(R)S(O), C(O)O, C(O)N(R), S(O)N(R), S(O)N(R), OC(O)O, OC(O)N(R), N(R)C(O)O, N(R)C(O)N(R), or N(R)S(O)N(R), wherein'}{'sup': 'x', 'sub': 1', '6, 'each Ris independently hydrogen or C-Calkyl.'}5. (canceled)6. The compound of claim 4 , wherein the first linker is O—(CHCH—O)—CHCH—Z claim 4 , wherein Z is O claim 4 , N(H) claim 4 , or S and m is an integer selected from 1 to 20 or the first linker is O—(CHCH—O)—CHCH—Z claim 4 , wherein Z is C(O) or S(O)and m is an integer selected from 1 to 20.7. (canceled)8. The compound according to claim 1 , wherein the second linker is (B-L)-D-E-L-F claim 1 ,{'sup': x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x', 'x, 'sub': 2', '2', '2', '2, 'wherein B is bond, O, NR, S, C(O), S(O), S(O), OC(O), N(R)C(O), N(R)S(O), N(R)S(O), C(O)O, C(O)N(R), S(O)N(R), S(O)N(R), OC(O)O, OC(O)N(R), N(R)C(O)O, N(R)C(O)N(R), or N(R)S(O)N(R);'}{'sup': '3', 'sub': 2', '6, 'Lis C-Calkyl;'}p is 2 or 3;D is CH when p is 2 and D is C when p is 3;{'sup': x', 'x', 'x', 'x', 'x', 'x', '2 ...

Подробнее
08-02-2018 дата публикации

ULTRASOUND CONTRAST AGENT DECORRELATION-BASED SIGNAL SEPARATION

Номер: US20180035979A1
Принадлежит:

An apparatus can be used to generate acoustic imaging pulse sequences and receive corresponding echoes elicited by the acoustic imaging pulse sequences. An acoustic radiation force (ARF) pulse sequence can be generated to agitate a contrast medium in a tissue region between the acoustic imaging pulse sequences. A decorrelation between images corresponding to the received echoes can be determined. A weighting map can be applied to an image to weight a region of the image corresponding to a spatial location of the contrast medium using the determined decorrelation. In an example, the receiving of corresponding echoes elicited by the acoustic imaging pulse sequences can include receiving acoustic energy having a range of frequencies offset from a fundamental frequency associated with the acoustic imaging pulse sequences. An acoustic imaging pulse sequence can include a pulse having an inverted amplitude envelope with respect to another pulse included in the sequence. 1. A method , comprising:generating a first acoustic imaging pulse sequence to insonify a tissue region;receiving first echoes elicited by the first acoustic imaging pulse sequence;generating a second acoustic imaging pulse sequence to insonify the tissue region, the tissue region including a contrast medium agitated by insonation;receiving second echoes elicited by the second acoustic imaging pulse sequence;generating a weighting map using imaging information obtained by evaluation of a similarity metric between images corresponding to the received first echoes and the received second echoes; andapplying the weighting map to an image to weight at least a region of the image corresponding to a spatial location of the contrast medium.2. The method of claim 1 , comprising generating an acoustic radiation force (ARF) pulse sequence to agitate the contrast medium in the tissue region.3. The method of claim 1 , wherein at least one of the first or second acoustic imaging pulse sequences comprises a pulse having ...

Подробнее
08-02-2018 дата публикации

Gas-Encapsulated Acoustically Responsive Stabilized Microbubbles and Methods for Treating Cardiovascular Disease

Номер: US20180036437A1
Принадлежит: University of Cincinnati

Acoustically responsive stabilized microbubbles formulated with a phospholipid monolayer shell, an encapsulated bioactive gas, and an encapsulated perfluorocarbon gas of the formula C x F y in a volume ratio of from about 10:1 to about 1:10, wherein X is greater than or equal to 3, are disclosed. Also provided are methods for promoting localized vasodilation in a patient in need thereof by delivering a microbubble comprising a phospholipid monolayer shell and an encapsulated bioactive gas locally to a target diseased section of the patient's vasculature; and releasing the bioactive gas at the target diseased section, wherein the microbubble comprises the bioactive gas in a ratio of from about 10:1 to about 1:10 by volume with a perfluorocarbon gas.

Подробнее
08-02-2018 дата публикации

SHINY ULTRASOUND GEL

Номер: US20180036438A1
Принадлежит:

An improved ultrasound gel adapted to have a shiny effect by adding glitter to an ultrasound gel, using a silver, reflective label and using a silver, reflective dispenser closure. This improved ultrasound gel is adapted to a pink lavendula lavender color by using the preservatives as coloring agents. Lavender essential oil is used as a perfume and preservative. The reflective glitter, reflective label, and reflective dispenser closure allow the ultrasonographer to better see the ultrasound gel and bottle in a darkened ultrasound room. The ultrasound gel is improved to have an aesthetic effect for the patient and healthcare provider by providing the combination of both a pink lavendula lavender color and a lavender scent. 1. An ultrasound formulation , comprising:a carrier suitable for transmitting ultrasound waves;at least one preservative admixed with the carrier, wherein the preservative is not a paraben of formaldehyde donor;at least one essential oil with antimicrobial properties and admixed with the carrier; andreflective mica glitter having a particle size less than 151 microns, the glitter admixed with the carrier, wherein the glitter does not contain coal tar dyes.2. The ultrasound formulation of claim 1 , wherein the carrier includes a gel.3. The ultrasound formulation of claim 1 , wherein the preservative includes sodium hydroxymethylglycinate.4. The ultrasound formulation of claim 1 , wherein the essential oil includes lavender essential oil.5. The ultrasound formulation of claim 1 , further comprising elderberry extract.6. The ultrasound formulation of claim 1 , wherein the essential oil includes lemongrass essential oil.7. The ultrasound formulation of claim 1 , further comprising sodium gluconate.8. The ultrasound formulation of claim 1 , further comprising aloe vera powder.9. The ultrasound formulation of claim 1 , having a pink color.10. The ultrasound formulation of claim 1 , having a lavender scent.11. An ultrasound product claim 1 , comprising:an ...

Подробнее
12-02-2015 дата публикации

METHOD FOR IMPROVING FUNCTIONAL SYNAPTIC CONNECTIVITY

Номер: US20150044138A1
Принадлежит: N.V. NUTRICIA

The invention relates to a composition comprising: (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, for use in preserving or improving functional synaptic connectivity and/or preserving brain network organization in a subject in need thereof.

Подробнее
15-02-2018 дата публикации

Echogenic Vehicle for Clinical Delivery of Plasminogen Activator and Other Fibrin-Binding Therapeutics to Thrombi

Номер: US20180042841A1
Принадлежит:

We disclose a composition comprising an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and a thrombolytic compound trapped by the ELIP. We also disclose a method of treating a medical condition in a patient characterized by a thrombus in the patient's vasculature, comprising administering to the patient the composition in an amount effective to reduce the size of the thrombus. 1. A composition , comprising:an echogenic liposome (ELIP) having an exterior surface, an interior surface, and at least one bilayer comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, anda thrombolytic compound trapped by the ELIP; andtissue plasminogen activator (tPA) exposed on the exterior surface of the ELIP, wherein the tPA is the only active targeting molecule exposed on the exterior surface of the ELIP, and the enzymatic activity of the tPA exposed on the exterior surface of the ELIP is inhibited.2. The composition of claim 1 , wherein the at least one bilayer of the echogenic liposome comprises at least one lipid selected from the group consisting of dipalmitoylphosphatidylcholine (DPPC) claim 1 , dioleoylphosphatidylcholine (DOPC) claim 1 , dipalmitoylphosphatidylglycerol (DPPG) claim 1 , dipalmitoylphosphatidylethanolamine (DPPE) claim 1 , egg phosphatidylcholine (PC) claim 1 , and cholesterol.3. The composition of claim 2 , wherein the ELIP comprises from about 0 mole parts to about 90 mole parts DPPC claim 2 , from about 0 mole parts to about 50 mole parts DOPC claim 2 , from about 10 mole parts to about 50 mole parts DPPG claim 2 , from about 0 mole parts to about 20 mole parts DPPE claim 2 , from about 0 mole parts to about 90 mole parts egg PC claim 2 , and from ...

Подробнее
14-02-2019 дата публикации

Photoacoustic detection of psma

Номер: US20190046106A1
Принадлежит: Individual

An apparatus for use in a minimally invasive prostate cancer detection system, using a fluorophore peptide dye conjugate compound which has at least one absorption wavelength in a range of 380 to 1400 nm, wherein said compound attaches to a prostate-specific membrane antigen (PSMA) expressed by a prostate cancer cell. A photo-acoustic imaging probe to be inserted in at least one of a rectum, urethra, or placed proximal the prostate. The probe having an emitter to emit a first signal at the prostrate and a prostate cancer, excite the conjugate compound and a receiver to receive a second signal from said conjugate compound, thereby indicating a cancerous region of the prostrate. A processor unit connected to said probe, is configured and operable for receiving and processing said to produce a tomographic representation of the prostrate.

Подробнее
14-02-2019 дата публикации

Lipid microbubbles and process of making thereof

Номер: US20190046667A1
Принадлежит: Trust Biosonics Inc

Disclosed is a suspension of gas-filled microbubbles in a physiologically acceptable liquid carrier comprising a lipid mixture of a first lipid having transition temperature of about 41° C. such as DPPC or DPPG, a second lipid having transition temperature of about 55° C. such as DSPC or DSPG, and a PEGylated DSPE such as DSPE-PEG2000, DSPE-PEG3000, or DSPE-CPEG5000, and methods of preparation thereof.

Подробнее
13-02-2020 дата публикации

NON-INVASIVE METHOD FOR PRESSURE MEASUREMENT

Номер: US20200046313A1
Принадлежит:

The present invention relates to the use of contrast-enhanced ultrasound using microbubble-based ultrasound contrast agents to accomplish noninvasive subharmonic aided pressure estimation (SHAPE) in a region of interest (ROI) of a subject. The method of the invention provides a non-invasive, direct, and accurate method for pressure estimation. 1. A method for obtaining a pressure measurement in at least one region of interest (ROI) in a subject wherein said method comprises:administering a diagnostically effective amount of a microbubble ultrasound contrast agent (UCA) to said subject;allowing said UCA to accumulate in said subject;transmitting an ultrasonic wave to said ROI in said subject wherein said ultrasonic wave is a broadband wave;optimising the acoustic power for said ultrasonic wave;receiving an ultrasonic echo generated by reflecting the ultrasonic wave transmitted in step (iii) from said ROI thereby acquiring a detection signal;extracting a sub-harmonic component from the ultrasonic echo based on the detection signal; andusing the inverse linear relationship between the subharmonic signal amplitude and the ambient pressure to obtain said pressure measurement.2. The method as defined in wherein said subject is a mammal.3. The method as defined in wherein said mammal is a human.4. The method as defined in wherein said administering is intravenous.5. The method as defined in wherein said administering is an infusion.6. The method as defined in wherein said administering is a co-infusion with saline.7. The method as defined in wherein said UCA comprises microbubbles each of which comprises a gas enclosed by a stabilising shell.8. The method as defined in wherein said gas has a different compressibility compared to the blood of said subject.9. The method as defined in wherein said gas is a high-density claim 8 , high-molecular weight gas that exhibits low solubility.10. The method as defined in wherein said gas is selected from the group comprising perflutren ...

Подробнее
25-02-2021 дата публикации

ASEPTIC PROCESS FOR AZIDO-FUNCTIONALIZED LIGAND CONJUGATION TO SIZE-ISOLATED MICROBUBBLES VIA STRAIN-PROMOTED AZIDE-ALKYNE CYCLOADDITION

Номер: US20210052750A1
Принадлежит:

The current inventive technology includes system, methods and compositions for the generation of a cloaked microbubble having buried-ligand architecture (BLA) that may allow the cloaked microbubble to circumvent potentially deleterious immunogenic, or other unwanted chemical responses in a host. The current inventive technology may also includes systems and methods to isolate monodisperse size populations of microbubbles for enhanced therapeutic and diagnostic applications. 124-. (canceled)25. A conjugated microbubble comprising:a polymer tether coupled with the surface of a microbubble;at least one azido-functionalized ligand conjugated with said polymer tether through a click chemistry reaction to form a bioconjugate polymer.26. The conjugated microbubble of wherein said at least one azido-functionalized ligand conjugated with said polymer tether through a click chemistry reaction to form a bioconjugate polymer comprises at least one azido-functionalized ligand conjugated with said polymer tether through a process of strain-promoted [3+2] azide-alkyne cycloaddition (SPAAC).27. The conjugated microbubble of wherein said azido-functionalized ligand conjugated with said polymer tether through a click chemistry reaction to form a bioconjugate polymer comprises least one azido-functionalized ligand conjugated with said polymer tether through a strain-promoted [3+2] azide-alkyne cycloaddition (SPAAC) conjugation reaction between a polymer tether comprising PEGylated claim 25 , dibenzocyclooctyne-functionalized phosphatidylethanolamine (DSPE-PEG2000-DBCO) claim 25 , and said azido-functionalized peptide ligand to form 1 claim 25 ,2 claim 25 ,3-triazole linked bioconjugate claim 25 , wherein said SPAAC reaction is performed in the absence of a copper (Cu) catalyst.28. The conjugated microbubble of wherein said microbubble comprises a microbubble having buried-ligand architecture (BLA).29. The conjugated microbubble of wherein said microbubble having BLA comprises a ...

Подробнее
25-02-2021 дата публикации

Ultrasound Gel Composition

Номер: US20210052751A1
Автор: Treff Menachem
Принадлежит: MYT Enterprises LLC

A method for conducting an ultrasound session using an ultrasound probe system includes the steps of providing an ultrasound gel for use in combination with the ultrasound probe system, the ultrasound gel defining a composition including 1-10% by weight of Carbopol; 0.001-0.02% by weight of fungistat; 0.001-0.02% by weight of NaOH; 0.001-0.02% by weight of chlorhexidine; 1-5% by weight of glycerin up; 90-95% by weight of purified water; 0.001-0.02% by weight of curacao; 0.1-0.8% by weight of aloe vera leaf juice; 0.01-0.03% by weight of citric acid; 0.001-0.02% by weight of EDTA disodium; 0.001-0.02% by weight of phenoxyethanol; 0.001-0.02% by weight of ethylhexylglycerin; and 0.001-0.02% by weight of methylisothiazolinone; and selectively applying the ultrasound gel on an ultrasound site and operating the ultrasound probe system thereon. 1. A method for conducting an ultrasound session using an ultrasound probe system , said method comprising the steps of:providing an ultrasound gel for use in combination with the ultrasound probe system, the ultrasound gel defining a composition comprising:(a) 1-10% by weight of Carbopol;(b) 0.001-0.02% by weight of fungistat;(c) 0.001-0.02% by weight of NaOH;(d) 0.001-0.02% by weight of chlorhexidine;(e) 1-5% by weight of glycerin up;(f) 90-95% by weight of purified water;(g) 0.001-0.02% by weight of curacao;(h) 0.1-0.8% by weight of aloe vera leaf juice;(i) 0.01-0.03% by weight of citric acid;(j) 0.001-0.02% by weight of EDTA disodium;(k) 0.001-0.02% by weight of phenoxyethanol;(l) 0.001-0.02% by weight of ethylhexylglycerin; and(m) 0.001-0.02% by weight of methylisothiazolinone; andselectively applying said ultrasound gel on an ultrasound site and operating the ultrasound probe system thereon.2. The method as recited in wherein said ultrasound gel defines a composition comprising:(a) 5% by weight of Carbopol;(b) 0.01% by weight of fungistat;(c) 0.01% by weight of NaOH;(d) 0.01% by weight of chlorhexidine;(e) 3% by weight of ...

Подробнее
14-02-2019 дата публикации

A RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING

Номер: US20190048062A1
Принадлежит: Bracco Suisse SA

The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes. 1. A recombinant chimeric P-Selectin Glycoprotein Ligand-1 (PSGL-1) protein comprising at least: a selectin Binding domain comprising at least aa 5-16 of SEQ ID NO:11 (mature PSGL-1 sequence) , leucine zipper domain comprising an amino acid sequence at least 90% homologous or identical to aa 187-208 of SEQ ID NO:12 (Neural Retina-specific Leucine Zipper) and a disulfide bonds promoting region.2. The recombinant chimeric PSGL-1 protein according to wherein the selectin Binding domain comprises at least an 1-47 of SEQ ID NO:11 (PSGL-1 sequence).3. The recombinant chimeric PSGL-1 protein according to wherein said leucine Zipper comprises an amino acid sequence at least 90% homologous or identical to aa 181-215 of SEQ ID NO:12.4. The recombinant chimeric PSGL-1 protein according to wherein said disulfide bonds promoting region comprises an amino acid sequence defined by the following general formula:{'br': None, 'sub': 1', '2', '3, 'i': n', 'm, '(X)-C(X)-(X)'} [{'sub': 1', '2, 'X, ...

Подробнее
25-02-2021 дата публикации

DETECTION OF PANCREATIC CANCER WITH AN ENGINEERED ANTI-THY1 SINGLE-CHAIN ANTIBODY

Номер: US20210054068A1
Принадлежит:

Compositions and methods for detection and diagnosis of pancreatic cancer are disclosed. An engineered anti-thymocyte differentiation antigen 1 (Thy1) single-chain antibody and bioconjugates thereof can be used for detecting and diagnosing pancreatic adenocarcinoma. The anti-Thy1 single-chain antibody selectively binds to the Thy1 antigen, which is overexpressed on pancreatic tumor neovasculature and precancerous lesions, and is capable of detecting pancreatic cancer even at the earliest stages of the disease. Thy1-targeted diagnostic agents can be produced by conjugation of the anti-Thy1 single-chain antibody to various diagnostic agents, such as contrast agents, photoactive agents, or detectable labels that are useful for detection and medical imaging of pancreatic tumors. 1. A single chain antibody selected from the group consisting of:a single chain antibody comprising an amino acid sequence of SEQ ID NO:1;a single chain antibody comprising an amino acid sequence having at least 95% identity to the sequence of SEQ ID NO:1, wherein the single chain antibody specifically binds to a thymocyte differentiation antigen 1 (Thy1); anda single chain antibody comprising a Thy1-binding fragment of the single chain antibody of (a) or (b) that binds to the same epitope as or competes for binding to Thy1 with the single chain antibody of (a) or (b).2. The single chain antibody of comprising the sequence of SEQ ID NO:1.3. The single chain antibody of claim 1 , wherein the single chain antibody binds to human Thy1.4. The single chain antibody of claim 1 , wherein the single chain antibody binds to Thy1 with a dissociation constant (Kd) of less than or equal to 2 nM.5. A Thy1-targeted imaging agent comprising the single chain antibody of conjugated to a diagnostic agent.6. The Thy1-targeted imaging agent of claim 5 , wherein the diagnostic agent is a contrast agent or a photoactive agent.7. The Thy1-targeted imaging agent of claim 6 , wherein the contrast agent is an ultrasound ...

Подробнее
26-02-2015 дата публикации

CX3CR1-TARGETING IMAGING AGENTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF DISEASE

Номер: US20150056133A1
Принадлежит:

The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis. 1. An imaging agent comprising a CX3CR1-targeting polypeptide linked to a detection label.2. An imaging agent according to claim 1 , wherein the CX3CR1-targeting polypeptide is an immunoglobulin single variable domain.3. An imaging agent according to claim 1 , wherein the CX3CR1-targeting polypeptide is a VHH domain.4. An imaging agent according to claim 1 , wherein the CX3CR1-targeting polypeptide includes CDR1 claim 1 , CDR2 and CDR3 sequences selected from:SEQ ID No: 141, 162 and 186, respectively; orSEQ ID No: 141, 163 and 187, respectively; orSEQ ID No: 141, 164 and 186, respectively; orSEQ ID No: 141, 166 and 186, respectively; orSEQ ID No: 141, 167 and 186, respectively; orSEQ ID No: 141, 167 and 189, respectively; orSEQ ID No: 141, 168 and 186, respectively; orSEQ ID No: 141, 168 and 187, respectively; orSEQ ID No: 141, 169 and 190, respectively; orSEQ ID No: 141, 170 and 186, respectively; orSEQ ID No: 141, 171 and 186, respectively; orSEQ ID No: 141, 174 and 186, respectively; orSEQ ID No: 141, 175 and 187, respectively; orSEQ ID No: 142, 165 and 188, respectively; orSEQ ID No: 142, 173 and 188, respectively; orSEQ ID No: 143, 164 and 186, respectively; orSEQ ID No: 144, 172 and 187, respectively; orSEQ ID No: 145, 172 and 187, respectively; orSEQ ID No: 141, 214 and 186, respectively; orSEQ ID No: 141, 215 and 186, respectively; orSEQ ID No: 141, 216 and 186, respectively; orSEQ ID No: 141, 217 and 186, respectively; orSEQ ID No: 141, 218 and 186, respectively; orSEQ ID No: 141, 219 and 186, respectively; orSEQ ID No: 141, 220 and 186, respectively; orSEQ ID No: ...

Подробнее
26-02-2015 дата публикации

Composition used for contrast imaging

Номер: US20150056146A1
Автор: Kouichi Kato
Принадлежит: Canon Inc

There is provided a composition used for contrast imaging, the composition containing an aqueous solution containing a J-aggregate of indocyanine green and at least one storage stabilizer selected from the group consisting of alkali metal ions, alkaline earth metal ions, and an ammonium ion.

Подробнее
03-03-2016 дата публикации

MICROPARTICLE COMPOSITIONS

Номер: US20160058893A1
Автор: YEH James Shue-Min
Принадлежит:

There is provided a microparticle composition suitable for molecular imaging, the composition comprising microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and wherein the core microparticle structure comprises (i) a phosphatidylcholine lipid: (ii) a phosphatidylethanolamine lipid comprising at least one maleimide moiety; and (iii) an alkoxylated fatty acid. 1. A microparticle composition suitable for molecular imaging , the composition comprising microparticles , wherein the microparticles comprise: a core microparticle structure having a central area and a shell , and wherein the core microparticle structure comprises:(i) a phosphatidylcholine lipid;(ii) a phosphatidylethanolamine lipid comprising at least one maleimide moiety; and(iii) an alkoxylated fatty acid.2. A microparticle composition according to claim 1 , further comprising at least one molecular binding element claim 1 , wherein the at least one molecular binding element is covalently attached to the shell of the core microparticle structure.3. A microparticle composition according to claim 2 , wherein the at least one molecular binding element is covalently attached to the core microparticle structure via the at least one maleimide moiety.4. A microparticle composition according to claim 1 , wherein the core microparticle structure is micellar.5. A microparticle composition according to claim 1 , wherein the molar ratio of (i) to (iii) satisfies the following ranges:(iv) 70 to 80;(v) 5 to 15; and(vi) 10 to 20.6. A microparticle composition according to claim 1 , wherein the core microparticle structure further comprises a labelling moiety.7. A microparticle composition according to claim 6 , wherein the molar ratio of the labelling moiety in the composition is 0.2 to 50.8. A microparticle composition according to claim 7 , wherein the molar ratio of the labelling moiety in the composition is 0.5 to 5.9. A microparticle composition ...

Подробнее
15-05-2014 дата публикации

Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies

Номер: US20140134102A1

The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.

Подробнее